

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: SAN DIEGO MARRIOTT LA JOLLA
4240 LA JOLLA VILLAGE DRIVE
LA JOLLA, CALIFORNIA

DATE: MAY 29, 2014
9 A.M.

REPORTER: BETH C. DRAIN, CSR
CSR. NO. 7152

BRS FILE NO.: 95376

BARRISTERS' REPORTING SERVICE

I N D E X

ITEM DESCRIPTION	PAGE NO.
REPORTS & DISCUSSION ITEMS	
1. CALL TO ORDER.	4
2. PLEDGE OF ALLEGIANCE.	4
3. ROLL CALL.	4
4. CHAIRMAN'S REPORT.	6
5. PRESIDENT'S REPORT.	11
6. FINANCE UPDATE.	14
7. RESEARCH FUNDING UPDATE.	16
ACTION ITEMS	
8. CONSIDERATION OF APPLICATIONS FOR RFA 13-03A STRATEGIC PARTNERSHIP III AWARDS (TRACK A).	111
9. CONSIDERATION OF APPLICATIONS FOR RFA 09-04: CIRM RESEARCH LEADERSHIP AWARDS.	23
10. CONSIDERATION OF APPLICATION FOR PA 14-04 EXTRAORDINARY SUPPLEMENT AWARD (MAJOR) FROM EARLY TRANSLATION III AWARD TR3 -05501	121
11. CONSIDERATION OF APPOINTMENT OF NEW SCIENTIFIC MEMBERS OF GRANTS WORKING GROUP.	95
12. CONSIDERATION OF INITIATING RULEMAKING FOR AMENDMENTS TO THE GRANTS ADMINISTRATION POLICY.	139
13. CONSIDERATION OF RESOLUTION HONORING MARCY FEIT.	97

BARRISTERS' REPORTING SERVICE

I N D E X (CONT'D.)

14. CONSIDERATION OF RESOLUTION HONORING ALAN TROUNSON.	104
15. CONSIDERATION OF MINUTES FROM THE MARCH 2014 ICOC BOARD MEETING.	108
16. CONSIDERATION OF RENEWAL OF CONTRACT WITH REMCHO, JOHANSEN & PURCELL, LLP.	108
17. CLOSED SESSION	
DISCUSSION ITEMS	
18. SPOTLIGHT ON DISEASE.	NOT REPORTED
19. COMMUNICATIONS UPDATE.	143
20. PUBLIC COMMENT.	79, 149

BARRISTERS' REPORTING SERVICE

1 LA JOLLA, CALIFORNIA; THURSDAY, MAY 29, 2014

2 9 A.M.

3
4 CHAIRMAN THOMAS: GOOD MORNING, EVERYBODY.
5 WELCOME TO SAN DIEGO FOR THE MAY BOARD MEETING OF
6 THE ICOC. VERY HAPPY TO SEE EVERYBODY AS ALWAYS.
7 NOW CALLING THE MEETING TO ORDER, MARIA, WOULD YOU
8 PLEASE LEAD US IN THE PLEDGE OF ALLEGIANCE.

9 (THE PLEDGE OF ALLEGIANCE.)

10 CHAIRMAN THOMAS: MARIA, PLEASE CALL THE
11 ROLL.

12 MS. BONNEVILLE: DAVID BRENNER.

13 DR. BRENNER: HERE.

14 MS. BONNEVILLE: LINDA BOXER.

15 DR. BOXER: HERE.

16 MS. BONNEVILLE: SUE BRYANT.

17 DR. BRYANT: HERE.

18 MS. BONNEVILLE: KEN BURTIS.

19 DR. BURTIS: PRESENT.

20 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

21 DR. DULIEGE: HERE.

22 MS. BONNEVILLE: ELIZABETH FINI.

23 DR. FINI: HERE.

24 MS. BONNEVILLE: MICHAEL FRIEDMAN.

25 DR. FRIEDMAN: HERE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: JUDY GASSON. SAM
2 HAWGOOD. STEPHEN JUELSGAARD.
3 DR. JUELSGAARD: HERE.
4 MS. BONNEVILLE: SHERRY LANSING. BERT
5 LUBIN.
6 DR. LUBIN: HERE.
7 MS. BONNEVILLE: SHLOMO MELMED. LAUREN
8 MILLER. JOE PANETTA.
9 MR. PANETTA: HERE.
10 MS. BONNEVILLE: FRANCISCO PRIETO.
11 DR. PRIETO: HERE.
12 MS. BONNEVILLE: ROBERT QUINT. AL
13 ROWLETT. JEFF SHEEHY. OSWALD STEWARD.
14 DR. STEWARD: HERE.
15 MS. BONNEVILLE: JONATHAN THOMAS.
16 CHAIRMAN THOMAS: HERE.
17 MS. BONNEVILLE: ART TORRES. KRISTINA
18 VUORI.
19 DR. VUORI: HERE.
20 MS. BONNEVILLE: DONNA WESTON. DIANE
21 WINOKUR.
22 MS. WINOKUR: HERE.
23 MS. BONNEVILLE: IS SAM HAWGOOD ON THE
24 LINE?
25 DR. HAWGOOD: I'M HERE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: THANK YOU, SAM.

2 DR. HAWGOOD: MORNING, EVERYONE.

3 CHAIRMAN THOMAS: MORNING, SAM.

4 SO WHEN LAST WE MET, WE WERE IN THE FINAL
5 STAGES OF A MOST IMPORTANT UNDERTAKING WHICH WAS OUR
6 SEARCH FOR A NEW PRESIDENT. IN THE INTERVENING TIME
7 BETWEEN THE TWO BOARD MEETINGS, WE HAD A NUMBER OF
8 DIFFERENT MEETINGS AND INTERVIEWS AND MANY, MANY
9 HOURS OF DISCUSSION. WE WERE, AS YOU MAY RECALL,
10 LOOKING FOR SOMEBODY WHO WAS AT ONCE FAMILIAR WITH
11 THE STEM CELL SPACE, FAMILIAR WITH CIRM, SOMEBODY
12 WHO HAD HAD MANY YEARS OF CEO LEVEL EXPERIENCE,
13 SOMEONE WHO HAD A GREAT DEAL OF EXPERIENCE IN
14 GUIDING A STEM CELL PRODUCT OR PRODUCTS THROUGH THE
15 CLINICAL TRIALS PROCESS, SOMEBODY WHO HAD A GREAT
16 DEAL OF EXPERIENCE DEALING WITH REGULATORY AGENCIES,
17 SOMEONE WITH EXPERIENCE IN THE CAPITAL RAISING AREA,
18 AND LAST, BUT NOT LEAST, SOMEBODY WHO IS PASSIONATE
19 ABOUT PATIENTS AND HAD A SINGULAR GOAL OF
20 EXPEDITIOUSLY, BUT PRUDENTLY GETTING PRODUCTS
21 THROUGH TO PATIENTS TO TREAT THEM FOR WHATEVER
22 DISEASE IT MIGHT BE.

23 THE END OF WHAT WAS A SIX-MONTH PROCESS
24 AND AN INTERNATIONAL SEARCH, THE BOARD UNANIMOUSLY
25 VOTED TO ELECT OUR NEW PRESIDENT. AND TODAY BEGINS

BARRISTERS' REPORTING SERVICE

1 THE FIRST DAY OF THE NEW PRESIDENT'S ERA AT THE
2 BOARD. AND I'D LIKE TO INTRODUCE -- THE BOARD, OF
3 COURSE, HAS ALREADY MET, BUT TO THOSE IN THE
4 AUDIENCE AND ON THE PHONE -- DR. RANDY MILLS.

5 (APPLAUSE.)

6 CHAIRMAN THOMAS: RANDY, WE ARE DELIGHTED
7 TO HAVE YOU ON BOARD. AND AS YOU AND I AND YOU AND
8 THE BOARD AND YOU AND YOUR TEAM HAVE DISCUSSED, AS
9 WE HEAD INTO THIS ERA WITH INCREASED EMPHASIS ON
10 PRODUCT DEVELOPMENT, CLINICAL TRIALS, DEALING WITH
11 THE REGULATORS, ETC., WE ARE DELIGHTED TO HAVE YOU
12 SHEPHERDING THE PROCESS AND LEADING US INTO THIS
13 NEXT CRITICAL STAGE.

14 WE'LL HAVE A NUMBER OF COMMENTS FOR ALAN A
15 LITTLE BIT LATER IN THE AGENDA, BUT FOR NOW I JUST
16 WANTED TO INTRODUCE RANDY. THAT HAS BEEN SORT OF
17 THE OVERWHELMING AREA THAT WE HAVE SPENT TIME ON IN
18 THE LAST COUPLE OF MONTHS.

19 OTHER ITEMS TO DISCUSS IN THE CHAIRMAN'S
20 REPORT, IT WAS WITH SORT OF BITTERSWEET
21 UNDERSTANDING THAT I ACCEPTED THE RESIGNATION OF
22 LONGTIME BOARD MEMBER JOAN SAMUELSON. JAMES, MARIA,
23 AND I WENT TO VISIT WITH JOAN SEVERAL WEEKS AGO.
24 AND IN TALKING TO HER, IT WAS APPARENT THAT THE TIME
25 HAD COME FOR HER TO STEP DOWN AND TO YIELD THE SEAT

BARRISTERS' REPORTING SERVICE

1 TO A NEW PERSON WHO COULD BE AS PASSIONATE AS SHE
2 WAS IN THE AREA OF PARKINSON'S DISEASE. WE ARE VERY
3 HOPEFUL THAT JOAN WILL BE ABLE TO JOIN US VERY SOON
4 AT A SUBSEQUENT BOARD MEETING UP IN THE BAY AREA SO
5 THAT WE CAN GIVE HER THE PROPER APPRECIATION WHICH
6 SHE DESERVES FOR HER MANY, MANY YEARS OF LEADERSHIP
7 AND INPUT AND CARING.

8 NEXT, LIKE TO NOTE HAD A NUMBER OF
9 INTERESTING SPEECHES OVER THE LAST COUPLE MONTHS. I
10 SPOKE TO A COUPLE OF HIGH SCHOOLS, WHICH IS
11 SOMETHING I WOULD ENCOURAGE, TO THE EXTENT BOARD
12 MEMBERS AND MEMBERS OF THE CIRM TEAM HAVEN'T BEEN
13 ABLE TO DO TO DATE, WOULD STRONGLY ENCOURAGE YOU TO
14 GET OUT THERE. I SPOKE IN LOS ANGELES TO NEW
15 COMMUNITY JEWISH HIGH SCHOOL, WHICH IS IN THE WEST
16 VALLEY, AND TO OUR CHILDREN'S SCHOOL, HARVARD WEST
17 LAKE IN STUDIO CITY. NOT JUST SORT OF THE THEME OF
18 STEM CELL RESEARCH, BUT ON EXCITING DEVELOPMENTS IN
19 BIOLOGY OVER THE LAST 20 YEARS, SORT OF STARTING
20 WITH DOLLY AND MOVING FORWARD.

21 IT'S A REAL KICK, IT REALLY IS. THESE
22 KIDS, WHEN YOU SIT THERE AND YOU TALK ABOUT THE
23 THINGS THAT HAVE HAPPENED -- AND BY THE WAY, I
24 SHOULD TELL YOU THAT THERE WERE A NUMBER OF TEACHERS
25 IN THE AUDIENCE TOO. AND, INTERESTINGLY, THERE WERE

BARRISTERS' REPORTING SERVICE

1 SOME THINGS THAT WE CAME UP WITH AND TALKED ABOUT
2 THAT EVEN THE TEACHERS WEREN'T AWARE OF. BUT THE
3 KIDS WERE SO ENTHUSIASTIC AND REALLY ENERGIZED. AND
4 AS WE CONTINUE ALONG WITH THE UNDERSTANDING THAT WE
5 NEED TO HAVE THE FUTURE GENERATION JUST AS
6 ENTHUSIASTIC AS WE ALL ARE, THESE SORTS OF THINGS
7 ARE IMPORTANT BECAUSE YOU NEVER KNOW WHAT'S GOING TO
8 TRIGGER A CHILD'S ENTHUSIASM OR CHANGE THEIR
9 DIRECTION OR GET THEM TO GO INTO AN AREA THEY HADN'T
10 PERHAPS THOUGHT OF BEFORE.

11 AFTER BOTH SPEECHES, IN EACH INSTANCE
12 PROBABLY, KIDS WOULD COME UP AFTERWARDS AND TALK
13 ABOUT WHAT WE'D JUST DISCUSSED, ASKED ABOUT WHERE
14 THEY CAN DO INTERNSHIPS, HOW DO THEY ADVANCE
15 THEMSELVES. A GREAT DEAL OF ENTHUSIASM FOR TACKLING
16 BIOLOGY AND RELATED AREAS WHEN THEY GET INTO
17 COLLEGE. IT WAS JUST GREAT. SO I REALLY WOULD
18 ENCOURAGE ALL OF US TO TRY TO TALK TO -- TARGET A
19 COUPLE HIGH SCHOOLS IN THE AREA OVER THE COURSE OF
20 THE YEAR. I KNOW WE'RE ALL BUSY, BUT IT'S VERY
21 MEANINGFUL. AND WE NEED THESE GUYS IN THE PIPELINE.

22 SO A THIRD SPEECH THAT WAS JUST AS
23 INTERESTING, AS YOU KNOW, EVERY END OF APRIL AND
24 EARLY MAY THERE IS THE MILKEN GLOBAL CONFERENCE IN
25 LOS ANGELES. I'M SURE MANY OF HAVE BEEN TO IT FROM

BARRISTERS' REPORTING SERVICE

1 TIME TO TIME. IT'S A TRULY UNIQUE EVENT. MIKE
2 MILKEN HAS TREMENDOUS CONVENING CAPACITY; AND
3 BASICALLY WHEN HE ASKS PEOPLE TO COME DO A PANEL,
4 THEY COME. SO THE LIST OF EXTRAORDINARY SPEAKERS
5 AND PANELISTS AT THIS FOUR-DAY EVENT IS ALWAYS JUST
6 STRIKING.

7 I WAS FORTUNATE TO BE ASKED TO CONVENE AND
8 MODERATE A PANEL IN STEM CELL RESEARCH. AND SO WE
9 DID. WE HAD FOUR OF OUR GRANTEES JOIN ME AT THAT
10 MEETING, AND WE DID A PANEL WHICH, VERY
11 INTERESTINGLY, I THINK WAS VERY WELL RECEIVED. I
12 HAD OCCASION TO BUMP INTO THE STATE CONTROLLER, JOHN
13 CHIANG, LATER IN THE AFTERNOON. AND HE SAID, "YOU
14 KNOW, I REALLY WANTED TO HEAR YOUR PANEL, BUT THE
15 ROOM WAS PACKED. SO I WENT TO THE OVERFLOW ROOM
16 WITH CLOSED CIRCUIT TV AND THAT WAS PACKED, AND I
17 COULDN'T GET INTO EITHER ONE." AND I THOUGHT, YOU
18 KNOW, THAT'S PRETTY GOOD. IT'S NOT A REFLECTION ON
19 ANYBODY WHO WAS ON THE PANEL, BUT IT'S A REFLECTION
20 OF THE INTEREST LEVEL IN STEM CELL RESEARCH BECAUSE
21 THERE WERE A LOT OF PEOPLE IN BOTH ROOMS AND THERE
22 WERE MANY COMPETING PANELS GOING ON CONCURRENTLY.
23 SO THAT TO ME SAID WE'RE STRIKING A CHORD, AND THAT
24 WAS VERY GRATIFYING.

25 SO FOR ALL OF US, OUR ENTIRE TEAM PUT IN

BARRISTERS' REPORTING SERVICE

1 SO MUCH WORK AND HAVE HELPED TO POSITION CALIFORNIA
2 WHERE IT IS THAT IS RECOGNIZED CLEARLY BY THAT
3 EVENT.

4 SO LAST THING I WANT TO MENTION, HAD A
5 VERY NICE TOUR FOR OUR UCI FRIENDS HERE. LAUREN
6 MILLER, ONE OF OUR NEW BOARD MEMBERS, AND I DID A
7 TOUR AT UCI TO GET HER FAMILIAR WITH THAT PROGRAM
8 DOWN THERE. AND IS ALWAYS THE CASE WHENEVER YOU GO
9 ON SUCH A TOUR, YOU'RE SORT OF OVERWHELMED WITH THE
10 TREMENDOUS AMOUNT OF WORK AND JUST EXTRAORDINARY
11 HIGH CALIBER PROJECTS AND TALENT THAT YOU HAVE.

12 SO JUST TO OUR UCI, WE HAVE A NUMBER OF
13 UCI FOLK HERE BETWEEN OS AND SUE AND JACOB, THANK
14 YOU FOR THAT TOUR. AND THIS IS SOMETHING ELSE THAT
15 WE ALL HAVE OUR OR MANY OF US HAVE OUR OWN PROGRAMS
16 GOING ON AT OUR PARTICULAR PLACE, BUT I'D ENCOURAGE
17 YOU, IF YOU GET A CHANCE, TO GET OUT AND GO SEE
18 WHAT'S GOING ON AT OTHER CENTERS HERE BECAUSE WE'RE
19 JUST DOING FANTASTIC WORK EVERYWHERE.

20 SO THAT CONCLUDES THE CHAIRMAN'S REPORT.
21 AND NOW WE'LL TURN IT OVER, IN ALL OF HIS FIVE DAYS
22 ON THE JOB, WE'LL JUST TURN IT OVER TO RANDY FOR
23 SOME BRIEF COMMENTS AND THE PRESIDENT'S REPORT.

24 DR. MILLS: THANK YOU. I ONLY HAVE 139
25 SLIDES, SO THIS SHOULD GO FAIRLY QUICKLY. THANK YOU

BARRISTERS' REPORTING SERVICE

1 VERY MUCH, JONATHAN, FOR THAT INTRODUCTION AND KIND
2 COMMENTS. I WILL APPROPRIATELY KEEP MY COMMENTS
3 BRIEF AS I AM ONLY HERE FIVE DAYS, I AM MEETING
4 PEOPLE, AND I AM GETTING UP TO SPEED, AND I'M DONE
5 WITH NEITHER OF THOSE YET.

6 BUT WHAT I CAN TELL YOU, SO HAVING SPENT
7 FIVE YEARS ON THE GRANTS WORKING GROUP AND IN
8 VIEWING THAT SIDE, WHAT I'VE SEEN IN MY FIRST FIVE
9 DAYS ON THIS SIDE IS ACTUALLY QUITE EXCITING. AND I
10 AM THRILLED TO BE HERE, AND I'M VERY EXCITED TO
11 CONTINUE THE WORK THAT WE'VE STARTED.

12 THERE'S REALLY THREE ASPECTS OF THINGS
13 THAT I LIKE THAT I'VE SEEN SO FAR. ONE IS I THINK
14 WE HAVE AN EXCELLENT TEAM AT CIRM. TWO, I'VE SEEN
15 SOME REMARKABLY EXCITING TECHNOLOGIES THAT I JUST
16 DIDN'T GET A CHANCE TO SEE ON THE GRANTS WORKING
17 GROUP SIDE THAT I'M BEGINNING TO SEE AND UNDERSTAND
18 NOW THAT EXIST WITHIN OUR PORTFOLIO WHICH HAVE A
19 REAL DIFFERENCE TO IMPACT PATIENT'S LIVES GOING
20 FORWARD. AND THAT IS FOR ME WHAT THIS IS ABOUT.

21 THE THIRD THING, AND ALTHOUGH I HAVEN'T
22 GOTTEN AROUND TO EACH OF YOU YET, I DO PROMISE THAT
23 I WILL, IS THAT THE BOARD MEMBERS WHO I HAVE MET
24 WITH ARE AN INCREDIBLY ENGAGED GROUP. AND I THINK
25 WE HAVE A REAL OPPORTUNITY OUT OF THIS FOR US TO

BARRISTERS' REPORTING SERVICE

1 CREATE SOMETHING GREAT BY FOCUSING THAT ENGAGEMENT
2 AND THAT ENERGY. AND SO MY MISSION, AS I SEE IT
3 GOING FORWARD HERE, IS TO ENSURE THAT ALL OF THESE
4 ASSETS ARE FOCUSED AND ALIGNED ON A FEW THINGS.

5 ONE, SPEEDING THERAPIES TO THE PATIENTS
6 THAT NEED THEM; TWO, INCREASING THE LIKELIHOOD OF
7 SUCCESS OF STEM CELL THERAPIES MAKING IT TO
8 PATIENTS; AND THIRD IS MAKING SURE WE'RE DOING THAT
9 FOR ACTUAL UNMET MEDICAL DISEASES WHICH IF BUT NOT
10 FOR US WOULDN'T OTHERWISE HAPPEN.

11 IN DOING SO, I ALSO BELIEVE WE NEED TO BE
12 FINANCIALLY RESPONSIBLE IN THAT. AND WE ALWAYS NEED
13 TO MAKE SURE THAT WE ARE TREATING THE MONEY WE SPEND
14 WITH THE RESPECT THAT IT DESERVES. SO LOOKING
15 FORWARD, I HOPE I WILL -- ACTUALLY I DON'T HOPE. I
16 KNOW I'LL BE GETTING TO KNOW EACH OF YOU BETTER AND
17 I'M VERY EXCITED ABOUT THAT. I'M VERY EXCITED ABOUT
18 FORGING ACTUALLY VERY HONEST, REAL, PRODUCTIVE
19 RELATIONSHIPS WITH EACH OF THE BOARD MEMBERS AND
20 WORKING WITH YOU IN A WAY WHERE WE CAN SERVE THE
21 PATIENTS OF CALIFORNIA WHO REALLY DESERVE OUR BEST.
22 CALL ME, E-MAIL ME, DO WHATEVER YOU NEED TO GET A
23 HOLD OF ME, DISAGREE WITH ME, YELL AT ME. IN ANY
24 WAY THAT WE CAN FORM A GOOD, HONEST WORKING
25 RELATIONSHIP, I AM UP FOR IT. AND I WANT TO JUST

BARRISTERS' REPORTING SERVICE

1 END BY THANKING YOU ALL VERY, VERY MUCH FOR THE
2 OPPORTUNITY TO PARTICIPATE IN WHAT I THINK IS A
3 WONDERFUL PROGRAM AND ONE THAT I HOPE WILL CHANGE
4 THE WORLD GOING FORWARD. THANK YOU.

5 CHAIRMAN THOMAS: THANK YOU, RANDY. NEXT
6 WE'RE GOING TO GO TO THE FINANCE UPDATE. CHILA.

7 MS. SILVA-MARTIN: GOOD MORNING. GOOD
8 MORNING, MR. CHAIR, MEMBERS OF THE BOARD, MEMBERS OF
9 CIRM STAFF, AND THE PUBLIC. I WILL BE PROVIDING YOU
10 THIS MORNING WITH A VERY BRIEF FINANCIAL UPDATE.

11 FIRST, JUST SOME HIGHLIGHTS. I WANT TO
12 POINT OUT THAT OUR GRANT DISBURSEMENTS FOR THE
13 FISCAL YEAR HAVE TOTALED ABOUT \$163 MILLION, WHICH
14 IS ROUGHLY WHAT WE DISBURSED DURING THE '12-'13
15 FISCAL YEAR DURING THE SAME PERIOD.

16 I JUST WANT TO BRIEF YOU ON OUR CASH. WE
17 HAVE A VERY HEALTHY CASH RESERVE. AS YOU MAY
18 RECALL, BEGINNING WITH THE '12-'13 FISCAL YEAR, THE
19 STATE TREASURER'S OFFICE AND THE DEPARTMENT OF
20 FINANCE PUT US ON COMMERCIAL PAPER FUNDING. SO WE
21 WERE ROUGHLY RECEIVING COMMERCIAL FUNDING EVERY
22 MONTH. IN APRIL WE WERE NOTIFIED BY THOSE AGENCIES
23 THAT THEY WOULD BE MOVING FORWARD WITH A BOND SALE
24 ON BEHALF OF CIRM. SO ON MAY 1ST THEY DID ISSUE A
25 BOND SALE, AND WE RECEIVED \$80 MILLION. SO AS A

BARRISTERS' REPORTING SERVICE

1 RESULT AS OF MAY 1ST WE HAD JUST \$130 MILLION IN OUR
2 CASH RESERVE. SO THAT'S A VERY HEALTHY BALANCE.

3 SO NOW MOVING ON TO THE '13-'14 BUDGET, I
4 JUST WANT TO LET YOU KNOW THAT WE ARE ON TRACK WITH
5 OUR BUDGET. WE WERE ALLOCATED \$17.4 MILLION. WE
6 ARE CURRENTLY FORECASTING THAT WE WILL SPEND ABOUT
7 \$16.4 MILLION. SO WE WILL HAVE A SAVINGS OF ABOUT A
8 MILLION DOLLARS.

9 THE SAVINGS IS REALLY COMING IN IN TWO
10 AREAS. THE LARGEST SAVINGS ARE IN OUR EMPLOYEE
11 EXPENSES AND IN OUR REVIEWS, MEETINGS, AND
12 WORKSHOPS. THE SAVINGS IN EMPLOYEE EXPENSES ARE
13 REALLY A RESULT OF SCIENCE AND MEDICAL OFFICER
14 POSITIONS THAT WE HAD VACANT THROUGHOUT THE YEAR
15 THAT WE DID NOT FILL. AND THE SAVINGS IN OUR
16 REVIEWS, MEETINGS, AND WORKSHOPS IS A RESULT OF A
17 COUPLE OF THINGS. WE HAD A TOOLS AND TECHNOLOGIES
18 GRANT WORK REVIEW SCHEDULED FOR THE '13-'14 FISCAL
19 YEAR, AND THAT HAS ACTUALLY BEEN POSTPONED TILL NEXT
20 YEAR. AND THEN WE HAD A SERIES OF WORKSHOPS THAT WE
21 HAD BUDGETED THAT DID NOT MATERIALIZE.

22 THE LAST THING I JUST WANTED TO POINT OUT
23 BRIEFLY IS THE '14-'15 BUDGET. AS YOU MAY RECALL,
24 WE BEGAN THAT PROCESS IN JANUARY. WE DID FINALIZE
25 THE BUDGET AND SUBMIT IT TO A FINANCE SUBCOMMITTEE

BARRISTERS' REPORTING SERVICE

1 EARLIER THIS MONTH, ON MAY 12TH; BUT BECAUSE WE DID
2 HAVE THE APPOINTMENT OF OUR NEW PRESIDENT, THE
3 FINANCE SUBCOMMITTEE DETERMINED THAT WE SHOULD --
4 THEY WOULD HOLD OFF ON APPROVING THAT BUDGET UNTIL
5 OUR NEW PRESIDENT HAD AN OPPORTUNITY TO REVIEW THAT
6 BUDGET. SO WE ACTUALLY ARE NOW INTERNALLY GOING
7 THROUGH THAT BUDGET, AND WE WILL HAVE ANOTHER
8 FINANCE SUBCOMMITTEE EARLY IN JUNE, AND THEN HOPE TO
9 BRING IT TO THIS BOARD LATER ON IN THE MONTH FOR
10 FINAL APPROVAL.

11 AND THAT REALLY IS THE REPORT. I'M HAPPY
12 TO TAKE ANY QUESTIONS YOU MAY HAVE. THANK YOU.

13 CHAIRMAN THOMAS: THANK YOU, CHILA. WE'RE
14 GOING TO NOW MOVE ON AND SKIP OVER ITEM 8 FOR THE
15 MOMENT AND GO TO ITEM 9, WHICH IS CONSIDERATION OF
16 APPLICATIONS FOR THE RFA FOR THE CIRM RESEARCH
17 LEADERSHIP AWARDS. SORRY. SORRY. THANK YOU,
18 MARIA. DIDN'T SEE THAT ONE.

19 PAT, COULD YOU PLEASE COME UP -- I'D HATE
20 TO GIVE YOU SHORT SHRIFT, PAT, AT ANY TIME -- AND
21 GIVE US THE RESEARCH FUNDING UPDATE, WHICH IS
22 SETTING THE TABLE FOR THE NEXT COUPLE OF ITEMS.
23 THANK YOU.

24 DR. OLSON: CHAIRMAN THOMAS, MEMBERS OF
25 THE BOARD, MEMBERS OF THE PUBLIC, AND COLLEAGUES,

BARRISTERS' REPORTING SERVICE

1 I'D LIKE TO PROVIDE AN UPDATE FOR YOU ON OUR
2 RESEARCH PROGRAM FUNDING GIVEN THAT WE ARE, IN FACT,
3 BRINGING FOR YOUR CONSIDERATION FUNDING DECISIONS ON
4 APPLICATIONS FOR TWO OF OUR PROGRAMS.

5 SO I JUST WANT TO REMIND YOU ABOUT THE
6 CURRENT BREAKDOWN OF THE RESEARCH FUNDING, SO THE
7 2.75 BILLION. AND AS SHOWN IN THIS SLIDE, IT'S
8 BROKEN DOWN BETWEEN AWARDED, AND THIS IS WHAT HAS
9 ALREADY BEEN APPROVED BY THE BOARD. AND IN THIS
10 CASE IT DID ALSO ASSUME THAT THOSE FUNDING DECISIONS
11 COMING TO YOU TODAY, IT ASSUMES FUNDING AS
12 RECOMMENDED.

13 THERE'S A CONCEPT APPROVED CATEGORY WHERE
14 THE ICOC HAS AGREED TO ALLOCATE A CERTAIN AMOUNT OF
15 FUNDS TO BE AVAILABLE FOR A PROGRAM, AND THERE'S
16 WHERE WE GO THROUGH THE REQUEST FOR APPLICATION AND
17 REVIEW PROCESS, AND IT INCLUDES THE FUTURE FUNDING
18 FOR THOSE REMAINING FUNDS. AND IT'S CURRENTLY
19 ALLOCATED IN ACCORDANCE WITH THE SCENARIO THAT WAS
20 AGREED TO WITH THE BOARD IN DECEMBER 2013.

21 JUST A COUPLE OF KEY POINTS. THERE'S 877
22 MILLION YET TO BE AWARDED, WHICH OBVIOUSLY INCLUDES
23 THE CONCEPT APPROVED, THE \$491 MILLION IN THE
24 CONCEPT APPROVED CATEGORY THAT HAS NOT YET BEEN
25 AWARDED AND THE FUTURE FUNDING.

BARRISTERS' REPORTING SERVICE

1 I WOULD JUST NOTE FOR YOUR CONSIDERATION
2 THAT EVEN WITHIN THE AWARDED CATEGORY 500 MILLION IS
3 YET TO BE DISBURSED.

4 IN THE NEXT SLIDE I WANTED TO JUST
5 HIGHLIGHT THE AWARDED CATEGORY. AND I WANTED TO
6 HIGHLIGHT THE DISTRIBUTION OF THE CURRENTLY AWARDED
7 FUNDING NOW AND AS IT WOULD BE PROJECTED AT THE END
8 OF THIS FUNDING CYCLE; THAT IS, WHEN WE GO THROUGH
9 THE 2.75 BILLION SUBJECT TO THE ASSUMPTIONS THAT ARE
10 OUTLINED THERE.

11 THE CURRENTLY AWARDED FUNDING, IF YOU
12 NOTE, THAT ROUGHLY -- IT'S ROUGHLY ALLOCATED
13 SIMILARLY BETWEEN THE DIFFERENT CATEGORIES. SO 25
14 TO 44 PERCENT IS THE RANGE OF THE ALLOCATION, SO
15 IT'S ROUGHLY EQUIVALENT WITH THE LARGEST AMOUNT
16 BEING IN THE DEVELOPMENT AND CLINICAL TRIAL CATEGORY
17 SUBJECT TO THE ASSUMPTIONS OUTLINED THERE. THE KEY
18 ONES ARE, WHICH, AGAIN, THE DECEMBER 2013 SCENARIO
19 AND THAT THE CURRENT STRATEGIC RESERVE IS ALLOCATED
20 TO CLINICAL TRIALS AND DEVELOPMENT. YOU CAN SEE
21 WHAT IT WOULD LOOK LIKE WHEN THE BOARD HAS
22 ALLOCATED -- HAS AWARDED ALL THE MONEY IN THIS
23 CYCLE. AND WHAT YOU SEE IN THAT CIRCUMSTANCE IS
24 THAT THE LARGEST CATEGORY TO WHICH THE FUNDING GOES
25 IS ESSENTIALLY THE DEVELOPMENT AND CLINICAL TRIALS

BARRISTERS' REPORTING SERVICE

1 AND WOULD BE ROUGHLY 42 PERCENT.

2 AND SO THAT ACTUALLY REPRESENTS WHAT THE
3 SITUATION MIGHT LOOK LIKE GIVEN THE CONCEPT APPROVED
4 AND THE FUTURE FUNDING SET SCENARIO.

5 SO NOW I'LL GO INTO A LITTLE BIT MORE
6 DETAIL ON EACH OF THOSE. THIS IS THE CONCEPT
7 APPROVED CATEGORY. AS YOU CAN TELL BY LOOKING AT
8 THE GRAPH, MOST OF THE FUNDING IS GOING TO
9 DEVELOPMENT AND CLINICAL TRIALS. IT DIFFERS FROM
10 WHAT I BROUGHT TO YOU IN MARCH. NO NEW CONCEPTS ARE
11 BEING BROUGHT TO YOU TODAY; BUT OF THE TWO
12 PROGRAMS -- OF THE PROGRAMS THAT YOU'RE GOING TO
13 MAKE FUNDING DECISIONS ON TODAY, THEY HAVE BEEN
14 MOVED EITHER TO THE AWARDED CATEGORY OR, WHEN THERE
15 WERE LEFTOVER FUNDS, TO THE STRATEGIC RESERVE AND
16 FUTURE FUNDING CATEGORY.

17 I WILL JUST REMIND YOU THAT THERE ARE
18 CURRENTLY NO ACTIVE OR NEW CONCEPTS IN THE CATEGORY
19 OF THE FACILITIES OR CORE RESOURCES, NONE IN
20 TRAINING OR CAREER DEVELOPMENT, AND NONE IN BASIC
21 RESEARCH. THE OTHERS ARE AS INDICATED.

22 IF I GO TO THE NEXT SLIDE, THE FUTURE
23 FUNDING, AGAIN, THIS CURRENTLY ASSUMES THE DECEMBER
24 2013 ALLOCATIONS. AND, AGAIN, THE MOST NOTABLE
25 CHANGE SINCE I LAST SPOKE WITH YOU IN MARCH ABOUT

BARRISTERS' REPORTING SERVICE

1 THIS IS THE GROWTH IN THE STRATEGIC RESERVE
2 CATEGORY. IN MARCH IT WAS 30 MILLION. IT IS NOW, I
3 BELIEVE, 96 MILLION. AND THIS PRIMARILY IS DUE TO
4 THE FACT THAT, IF YOU WOULD LIKE, CALL IT LEFTOVER
5 CONCEPT APPROVED FUNDING NOT RECOMMENDED, HAS BEEN
6 PLACED IN THAT CATEGORY PENDING AN ACTUAL FUNDING
7 DECISION BY THE BOARD.

8 AND AS YOU CAN SEE, AGAIN, BY THE GRAPH,
9 CURRENTLY THERE'S A SIGNIFICANT AMOUNT, I THINK 43
10 PERCENT, OF THE FUTURE FUNDING GOING TO DEVELOPMENT
11 AND CLINICAL TRIALS. THE STRATEGIC RESERVE CATEGORY
12 IS 20 PERCENT. OBVIOUSLY THAT'S UP TO DECISIONS AS
13 TO WHERE THAT FUNDING GOES. AND THEN UNDER THE
14 DECEMBER SCENARIO THAT WAS AGREED TO WITH THE BOARD
15 AT THAT TIME, THERE WAS MONEY GOING TO
16 TRAINING/CAREER DEVELOPMENT, TO BASIC RESEARCH, AND
17 TO TRANSLATIONAL RESEARCH.

18 SO THIS SUMMARIZES WHAT I WANTED TO SAY TO
19 YOU IN JUST THAT WE'RE IMPLEMENTING THE RESEARCH
20 FUNDING PLAN TO REALIZE THE STRATEGY TO ACHIEVE OUR
21 MISSION. SO I'M HAPPY TO TAKE ANY QUESTIONS YOU MAY
22 HAVE. EXCELLENT.

23 CHAIRMAN THOMAS: MR. SHEEHY.

24 MR. SHEEHY: I WAS A LITTLE CONFUSED ABOUT
25 THERE'S MONEY IN THE AWARDED CATEGORY THAT'S

BARRISTERS' REPORTING SERVICE

1 AVAILABLE. DID I GET A LITTLE --

2 DR. OLSON: THE AWARDED CATEGORY HAS
3 ALWAYS INCLUDED WHAT THE BOARD HAS APPROVED PLUS
4 WHAT IS UP FOR TODAY THAT IS AT LEAST RECOMMENDED.
5 OBVIOUSLY IT'S PENDING YOUR APPROVAL, BUT IT IS
6 INCLUDED THERE. SO THE RECOMMENDED APPLICATIONS IN
7 RESEARCH LEADERSHIP AND IN STRATEGIC PARTNERSHIP
8 ARE, FOR THE SAKE OF THESE PRESENTATIONS, INCLUDED
9 IN THE AWARDED CATEGORY. THE MONEY THAT IS LEFT
10 THAT WAS IN THE CONCEPT WAS MOVED TO STRATEGIC
11 RESERVE.

12 MR. SHEEHY: I THOUGHT I HEARD YOU SAY
13 THERE WAS 500 MILLION.

14 DR. OLSON: OH, SORRY. JUST NOT PAID OUT
15 YET. WE DON'T PAY OUT ALL THE MONEY UP FRONT.
16 THAT'S ALL THAT MEANS.

17 MR. SHEEHY: IT'S NOT FAIR TO ASK YOU
18 THIS, BUT JUST OFF THE TOP OF YOUR HEAD. IT'S
19 REALLY NOT A FAIR QUESTION.

20 DR. OLSON: WELL, LET'S HEAR THE QUESTION
21 BEFORE WE DECIDE.

22 MR. SHEEHY: BUT IT MIGHT BE INTERESTING
23 TO KNOW WHAT PERCENTAGE OF THAT IS TIED UP IN
24 MILESTONE-DRIVEN GRANTS THAT MIGHT BE AVAILABLE TO
25 THE BOARD TO RECOVER -- I MEAN TO THE AGENCY TO

BARRISTERS' REPORTING SERVICE

1 RECOVER AT SOME POINT IF MILESTONES AREN'T MET.

2 DR. OLSON: I'M SURE WE COULD COME UP WITH
3 THAT. IT'S NOT JUST MILESTONES WHERE SOMETIMES
4 THINGS DON'T HAPPEN, PEOPLE MOVE, AND MAYBE THERE'S
5 NOT A GOOD PI TO REPLACE IT, SO AWARDS GET
6 TERMINATED THEN. BUT, YES, I THINK IT MIGHT BE
7 POSSIBLE TO COME UP WITH THAT.

8 MR. SHEEHY: I WAS JUST CURIOUS. THANK
9 YOU.

10 DR. OLSON: OKAY.

11 MR. SHEEHY: THANK, DR. OLSON.

12 DR. OLSON: ANY FURTHER QUESTIONS?

13 CHAIRMAN THOMAS: MR. JUELSGAARD.

14 DR. JUELSGAARD: SO, PAT, JUST TO FOLLOW
15 UP ON JEFF'S QUESTION. BASED ON YOUR EXPERIENCE
16 HISTORICALLY, OUT OF THE AWARDS THAT HAVE BEEN MADE,
17 WHAT'S, GENERALLY SPEAKING, THE PERCENTAGE ON AN
18 ALL-IN BASIS THAT HAVE BEEN SPENT? YOU HAVE A
19 SENSE? I'M SURE IT'S NOT A HUNDRED PERCENT.

20 DR. OLSON: NO.

21 DR. JUELSGAARD: SO IT'S SOMETHING LESS
22 THAN THAT. SO IS IT 90, 80, OR A RANGE?

23 DR. OLSON: LET ME MAKE SURE I UNDERSTAND
24 YOUR QUESTION. YOU'RE SAYING OUT OF THE FUNDS THAT
25 ARE AWARDED, WHAT PERCENTAGE IS ACTUALLY OR WHAT

BARRISTERS' REPORTING SERVICE

1 PERCENTAGE OF THE FUNDS IS ACTUALLY PAID OUT?

2 DR. JUELSGAARD: YES. ON A HISTORICAL
3 BASIS JUST OFF THE TOP OF YOUR HEAD SOME SORT OF
4 RANGE.

5 DR. OLSON: A VERY -- I ACTUALLY FEEL I
6 WOULD BE GUESSING. YOU KNOW, PROBABLY FROM WHAT THE
7 BOARD APPROVES TO WHAT IS PAID OUT BECAUSE STAFF
8 GOES OVER IT, THERE ARE CERTAIN THINGS THAT COME IN,
9 UNALLOWABLE COSTS, I'M JUST GOING TO ESTIMATE 90
10 PERCENT; BUT IN ALL FAIRNESS, I WILL SAY THAT IS
11 MORE OF A GUESS. GUESSTIMATE WOULD BE THE
12 APPROPRIATE ANSWER.

13 DR. JUELSGAARD: ALL RIGHT. THANK YOU.

14 DR. OLSON: I MEAN WE MIGHT BE --

15 DR. JUELSGAARD: THANKS.

16 CHAIRMAN THOMAS: OTHER QUESTIONS?

17 UNIDENTIFIED SPEAKER: CAN WE JUST MAKE A
18 NOTE TO CAPTURE THAT SO WE ACTUALLY GET AN ANSWER
19 BACK?

20 CHAIRMAN THOMAS: OTHER QUESTIONS FROM
21 MEMBERS OF THE BOARD? THANK YOU. I'D LIKE TO
22 NOTICE THAT SENATOR TORRES IS NOW IN THE ROOM.

23 OKAY. NOW WE WILL PROCEED TO ITEM 9,
24 WHICH IS CONSIDERATION OF THE APPLICATIONS FOR RFA
25 09-04, CIRM RESEARCH LEADERSHIP AWARDS. DR. YAFFE.

BARRISTERS' REPORTING SERVICE

1 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE
2 BOARD, MEMBERS OF THE PUBLIC, AND COLLEAGUES, I
3 BRING FOR YOUR CONSIDERATION THIS MORNING --

4 MR. SHEEHY: WHY AREN'T WE DOING THE
5 STRATEGIC PARTNERSHIP?

6 CHAIRMAN THOMAS: WE'RE TAKING THIS ONE
7 FIRST. THE PRINCIPAL REASON IS SHERRY IS GOING TO
8 BE INVOLVED IN THAT AND SHE'S CONFLICTED ON THIS, SO
9 WE'RE DOING THIS FIRST, AND SHE'S EN ROUTE.

10 DR. YAFFE: I BRING FOR YOUR CONSIDERATION
11 THIS MORNING THE RECOMMENDATIONS OF THE GRANTS
12 WORKING GROUP ON THE RESEARCH LEADERSHIP AWARDS MOST
13 RECENT ROUND. THIS IS AGENDA ITEM NO. 9.

14 JUST TO REMIND YOU AND INFORM NEW MEMBERS,
15 THE GOALS OF THIS PROGRAM ARE TO FACILITATE THE
16 RECRUITMENT TO CALIFORNIA OF THE MOST PRODUCTIVE AND
17 PROMISING EARLY TO MIDCAREER SCIENTISTS IN STEM CELL
18 BIOLOGY AND REGENERATIVE MEDICINE AND, FOLLOWING THE
19 RECRUITMENT, TO SUPPORT THEIR ROBUST AND INNOVATIVE
20 RESEARCH PROGRAMS FOCUSED ON FUNDAMENTAL STUDIES OF
21 PLURIPOTENT AND PROGENITOR STEM CELL BIOLOGY AND/OR
22 ON TRANSLATIONAL STUDIES LEADING TO INNOVATIVE STEM
23 CELL THERAPIES FOR DISEASE AND INJURY.

24 THIS PROGRAM IS OPEN TO NONPROFIT
25 CALIFORNIA INSTITUTIONS. THE CANDIDATE OR APPLYING

BARRISTERS' REPORTING SERVICE

1 PRINCIPAL INVESTIGATOR MUST HOLD A POSITION OUTSIDE
2 CALIFORNIA AT THE TIME OF APPLICATION AND HAVE BEEN
3 INDEPENDENT AS AN INDEPENDENT INVESTIGATOR FOR AT
4 LEAST THREE YEARS. AND INDIVIDUAL INSTITUTIONS MAY
5 RECEIVE ONLY ONE OF THESE AWARDS.

6 THE AWARD FEATURES RESEARCH SUPPORT FOR UP
7 TO FIVE YEARS. AWARDEES MUST COMMIT AT LEAST 75
8 PERCENT OF THEIR TIME TO STEM CELL AND REGENERATIVE
9 MEDICINE RESEARCH. AND ELIGIBLE COSTS PROVIDED BY
10 THIS AWARD INCLUDE THE PI'S SALARY, LAB OPERATIONS,
11 LAB RELOCATION, A ONE-TIME PAYMENT, EQUIPMENT COSTS
12 WHICH MUST BE MATCHED ONE TO ONE BY THE INSTITUTION,
13 AND APPROPRIATE FACILITIES AND INDIRECT COSTS.

14 THE CRITERIA WHICH THE GRANTS WORKING
15 GROUP USED TO REVIEW THESE APPLICATIONS IS SHOWN
16 HERE. THERE ARE THREE KEY AREAS THAT THE PROPOSALS
17 WERE EVALUATED ON. THE FIRST IS RESEARCH VISION AND
18 PLANS. IN PARTICULAR, WHAT'S THE SIGNIFICANCE OF
19 THE PROPOSED RESEARCH, ITS IMPORTANCE TO THE FIELD
20 AND TO ADVANCING REGENERATIVE MEDICINE, AND WHAT IS
21 INNOVATIVE ABOUT IT, WHAT IS NOVEL, HOW IS THIS
22 INNOVATION GOING TO DRIVE THE FIELD FORWARD.

23 THE SECOND KEY AREA IS THE PI
24 ACCOMPLISHMENTS AND POTENTIAL. HERE THERE'S
25 CONSIDERATION OF THE CANDIDATE'S RESEARCH

BARRISTERS' REPORTING SERVICE

1 ACHIEVEMENTS AND PARTICULARLY THEIR IMPACT AS WELL
2 AS THE FUTURE POTENTIAL IMPACT OF THE PROPOSED
3 RESEARCH. ALSO A STRONG CONSIDERATION OF THE
4 LEADERSHIP ACTIVITIES, ROLES DEMONSTRATING
5 LEADERSHIP PREVIOUSLY AND ALSO THE POTENTIAL FOR
6 FUTURE LEADERSHIP OF THE FIELD AND AN ASSESSMENT OF
7 ACCOMPLISHMENTS AND POTENTIAL BY LEADERS IN THE
8 FIELD. AND THIS IS PROVIDED IN THE FORM OF LETTERS
9 OF SUPPORT.

10 THE THIRD KEY AREA IS INSTITUTIONAL
11 COMMITMENT AND ENVIRONMENT. HERE REVIEWERS ARE
12 CONCERNED BOTH WITH WHAT WILL THE INSTITUTION AND
13 THE ENVIRONMENT PROVIDE THE CANDIDATE AND ALSO HOW
14 WILL THE CANDIDATE FIT IN AND ADVANCE THE RESEARCH
15 MISSION AT THE INSTITUTION.

16 THIS IS THE 14TH AND, PRESUMABLY, LAST
17 CYCLE OF APPLICATION AND REVIEW FOR THIS AWARD
18 PROGRAM. YOU, THE ICOC, AUTHORIZED THIS ROUND AS AN
19 EXTENSION OF THE ORIGINAL PROGRAM. THAT
20 AUTHORIZATION AND APPROVAL OF A CONCEPT WAS LAST
21 JULY IN WHICH YOU APPROVED FUNDING FOR UP TO FOUR
22 ADDITIONAL AWARDS WITH A BUDGET OF UP TO \$23
23 MILLION.

24 THE APPLICATIONS WERE RECEIVED IN JANUARY.
25 FIVE APPLICATIONS WERE RECEIVED. THESE WERE

BARRISTERS' REPORTING SERVICE

1 REVIEWED BY THE GRANTS WORKING GROUP IN MARCH.

2 SHOWN ON THIS SLIDE ARE THE RESULTS OF
3 THAT REVIEW. THREE OF THE APPLICATIONS RECEIVED
4 SCORES BY THE GRANTS WORKING GROUP WHICH PLACED THEM
5 IN TIER I AND ARE RECOMMENDED FOR FUNDING. THOSE
6 ARE THE TOP THREE. TWO OF THE APPLICATIONS RECEIVED
7 SCORES WHICH PLACED THEM IN TIER II.

8 PRESIDENT MILLS AND THE STAFF HAVE LOOKED
9 AT THESE SCORES AND PROVIDE THE FOLLOWING STAFF
10 RECOMMENDATION. WE RECOMMEND FUNDING OF THE TIER I
11 APPLICATIONS, THREE OF THESE. WE RECOMMEND NOT
12 FUNDING OF TIER II APPLICATIONS UNLESS YOU, THE
13 ICOC, IDENTIFIES A COMPELLING PROGRAMMATIC REASON
14 FOR THAT FUNDING.

15 IN SUMMARY, YOUR APPROVAL IS REQUESTED FOR
16 THREE RESEARCH LEADERSHIP AWARDS, THOSE IN TIER I,
17 FOR A TOTAL COST OF \$16.2 MILLION. AND I'LL BE
18 HAPPY TO TAKE ANY OF YOUR QUESTIONS. THANK YOU.

19 CHAIRMAN THOMAS: MR. HARRISON, YOU LOOK
20 LIKE YOU'RE ITCHING TO SAY SOMETHING.

21 MR. HARRISON: JUST A REMINDER THAT THE
22 APPLICATION REVIEW SUBCOMMITTEE WILL BE CONSIDERING
23 THESE APPLICATIONS. FOR THOSE OF YOU APPOINTED FROM
24 ACADEMIC OR NONPROFIT RESEARCH INSTITUTIONS, YOU ARE
25 PERMITTED TO PARTICIPATE IN THE DISCUSSION OF THESE

BARRISTERS' REPORTING SERVICE

1 APPLICATIONS PROVIDED THAT YOU DON'T HAVE A
2 CONFLICT. YOU SHOULD HAVE YOUR CONFLICT SHEET IN
3 FRONT OF YOU, BUT YOU WILL NOT BE CALLED DURING ANY
4 ROLL CALL VOTE FOR THESE APPLICATIONS.

5 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
6 MUCH, DR. YAFFE.

7 SO JUST A POINT OF ORDER, MR. HARRISON,
8 HERE, DO WE -- BEFORE WE PROCEED TO THE PROGRAMMATIC
9 DISCUSSION HERE, DO WE NEED THE MOTION ON THE TABLE?

10 MR. HARRISON: NO.

11 CHAIRMAN THOMAS: NO. SO WE SHOULD GO
12 FORTHWITH TO PROGRAMMATIC.

13 MR. HARRISON: CORRECT.

14 CHAIRMAN THOMAS: SO, MR. SHEEHY, WE ARE
15 GOING TO PROCEED HERE TO PROGRAMMATIC REVIEW, AND I
16 TURN THE MICROPHONE OVER TO YOU.

17 MR. SHEEHY: THANK YOU, CHAIRMAN THOMAS.
18 I DID HAVE A QUESTION, A COUPLE QUESTIONS FOR DR.
19 YAFFE.

20 DR. YAFFE: YES.

21 MR. SHEEHY: ABOUT HOW MUCH HAVE WE SPENT
22 ON THIS PARTICULAR --

23 DR. YAFFE: PROGRAM?

24 MR. SHEEHY: YEAH.

25 DR. YAFFE: OVERALL THE AWARDS HAVE

BARRISTERS' REPORTING SERVICE

1 TOTALLED \$32.7 MILLION. THOSE ARE SIX AWARDS THAT
2 HAVE BEEN MADE TO DATE.

3 MR. SHEEHY: HOW MANY OF THESE AFTER WE
4 HAVE APPROVED THEM HAVE BEEN TURNED DOWN? WHAT'S
5 OUR BATTING AVERAGE?

6 DR. YAFFE: ABOUT 60 PERCENT.

7 MR. SHEEHY: ABOUT 60 PERCENT. HAVE WE
8 AWARDED OR DO WE ANTICIPATE AWARDING A SINGLE ONE OF
9 THESE TO A WOMAN?

10 DR. YAFFE: NO WOMEN CANDIDATES ARE AMONG
11 THOSE UNDER CONSIDERATION TODAY.

12 MR. SHEEHY: SO WE HAVEN'T BEEN ABLE TO
13 RECRUIT A WOMAN, A SUPERB WOMAN SCIENTIST, TO
14 CALIFORNIA USING THIS MODALITY?

15 DR. YAFFE: ALL OF THE CANDIDATES HAVE
16 BEEN NOMINATED BY THE INSTITUTIONS. THE
17 INSTITUTIONS HAVE NOT PUT UP A CANDIDATE WHO IS A
18 FEMALE TO DATE.

19 MR. SHEEHY: OKAY. THANK YOU, DR. YAFFE.

20 DR. BRYANT: I WAS JUST, ALONG THOSE
21 LINES, I WAS ALSO THINKING ALONG THOSE LINES BECAUSE
22 WE HAVE NO INFORMATION ABOUT WHO THESE APPLICANTS
23 ARE IN THAT RESPECT. AND I WAS WONDERING HAVE WE
24 EVER APPOINTED -- DO WE HAVE ONE ALREADY THAT'S A
25 WOMAN IN THAT CATEGORY? I DON'T THINK SO.

BARRISTERS' REPORTING SERVICE

1 DR. YAFFE: NO, WE DO NOT.

2 DR. BRYANT: OKAY. THANK YOU.

3 MR. SHEEHY: SO DOES ANYONE ELSE -- DR.
4 SAMBRANO, WERE YOU GOING TO -- UNLESS SOMEBODY
5 ELSE -- OH, MR. JUELSGAARD.

6 DR. JUELSGAARD: JUST A QUESTION ON THE
7 BUDGET NUMBERS. SO THERE'S SOME VARIATION IN THE
8 AMOUNTS THAT ARE BEING REQUESTED AMONGST THREE
9 INSTITUTIONS FROM A HIGH OF 6.368 MILLION TO A LOW
10 OF 4.631 MILLION. AND SO THERE'S A 37.5-PERCENT
11 DIFFERENCE. SO HOW DO WE JUDGE WHAT'S A FAIR AMOUNT
12 OF MONEY FOR AN INSTITUTION TO REQUEST GIVEN THAT?
13 WHY IS THAT ONE INSTITUTION REQUESTS CONSIDERABLY
14 LESS THAN ANOTHER? AND HOW DO WE THINK ABOUT THAT
15 DURING THIS WHOLE PROCESS?

16 DR. YAFFE: THOSE DIFFERENCES REFLECT
17 DIFFERENCES IN THE FACILITY'S INDIRECT RATE. WE
18 HAVE FOLLOWED THE NATIONALLY -- NIH NEGOTIATED RATE
19 FOR VARIOUS INSTITUTIONS. THAT RATE VARIES. THERE
20 ARE CERTAINLY MEMBERS OF THE STAFF WHO COULD PROVIDE
21 A MORE INSIGHTFUL EXPLANATION OF THAT RATE AND WHY
22 IT VARIES; BUT IN ALMOST ALL CASES, THE
23 APPLICATIONS, IN FACT, REQUEST THE SAME AMOUNT OF
24 MONEY IN DIRECT FUNDS. SO THIS IS ALL IN INDIRECT
25 FUNDS, AND IT'S SPECIFIC TO THE INDIVIDUAL

BARRISTERS' REPORTING SERVICE

1 INSTITUTIONS.

2 DR. JUELSGAARD: SO WE'VE NEVER REALLY
3 POSITIONED THIS AS A NOT TO EXCEED AMOUNT THAT WE
4 WOULD BE WILLING TO AWARD AND THAT THE INSTITUTION
5 NEEDS TO JUST MAKE UP THE DIFFERENCE THEN BETWEEN
6 WHATEVER THE NOT TO EXCEED AMOUNT IS AND WHAT THEY
7 THINK THEY NEED?

8 DR. YAFFE: WE HAVE DONE AWARDS IN OTHER
9 PROGRAMS THAT ARE OF THAT NATURE, BUT THESE AWARDS
10 ARE NOT.

11 DR. JUELSGAARD: AND WHY THE DIFFERENCE
12 BETWEEN THESE AWARDS AND OTHERS WHERE WE HAVE DONE
13 THAT?

14 DR. OLSON: TYPICALLY WHEN WE HAVE DONE
15 THAT, THEY'RE THE SMALLER RESEARCH-BASED BIOLOGY
16 AWARDS. BUT IF YOU THINK ABOUT IT, FOR AN
17 INSTITUTION -- SO THE FACILITIES DIRECT RATES VARY
18 QUITE SUBSTANTIALLY AMONGST DIFFERENT INSTITUTIONS
19 BECAUSE THEY REFLECT THINGS LIKE, I THINK, INTEREST
20 ON LOANS, DEBT, AND THINGS LIKE THAT. SO THEY VARY
21 SIGNIFICANTLY BETWEEN INSTITUTIONS.

22 IN SOME SENSES FOR THIS TYPE OF AWARD, WE
23 FELT WE SHOULD NOT DISADVANTAGE AN APPLICANT. SO
24 THE COSTS THAT ACTUALLY GOES TO DO THE RESEARCH, THE
25 DIRECT COSTS, ARE FIXED. IT IS THE FACILITIES

BARRISTERS' REPORTING SERVICE

1 DIRECT WHICH IS AN INSTITUTIONALLY NEGOTIATED RATE
2 WITH THE NIH THAT WE USE. AND THEN THE INDIRECT
3 RATE IS ALSO FIXED. SO I DON'T KNOW IF THAT ANSWERS
4 YOUR QUESTION, BUT --

5 DR. JUELSGAARD: IT ACTUALLY PROMPTS
6 ANOTHER QUESTION, WHICH IS WHAT'S THE POSSIBILITY OF
7 SAYING SO WE'RE WILLING TO PROVIDE TWO DIFFERENT
8 LEVELS OF SUPPORT. SO HERE'S THE AMOUNT THAT WE'RE
9 WILLING TO PROVIDE FOR THE DIRECT COSTS OF THE
10 RESEARCH TO BE DONE. AND THEN AS FAR AS THE
11 INDIRECT COSTS, WE'RE WILLING TO PROVIDE THAT UP TO,
12 LET'S SAY, \$5 MILLION. IF THAT'S SHORT OF WHAT YOUR
13 INDIRECT COSTS ARE, SO BE IT. YOU'LL NEED TO FIND
14 SOME OTHER WAY OF SUPPORTING THAT.

15 I GUESS IT BOTHERS ME A LITTLE BIT THAT WE
16 HAVE SUCH VARIATION IN INDIRECT COSTS AND WE SUPPORT
17 THEM NO MATTER WHAT THOSE INDIRECT COSTS ARE. SO
18 ESSENTIALLY I UNDERSTAND THE DEBT ISSUE, BUT A LOT
19 OF IT HAS TO DO WITH A LOT OF OTHER THINGS. SO
20 WE'RE REALLY SUPPORTING VERY WELL DEVELOPED
21 INSTITUTIONS EQUALLY WITH LESS WELL DEVELOPED
22 INSTITUTIONS, IT SEEMS TO ME.

23 DR. OLSON: I BELIEVE THAT THE FACILITIES
24 DIRECT RATE IS ACTUALLY -- IS THAT FIXED BY THE
25 PROPOSITION, JAMES? CAN YOU VERIFY THAT FOR ME?

BARRISTERS' REPORTING SERVICE

1 MR. HARRISON: STEVE, THE FACILITIES RATE
2 IS PART OF THE DIRECT RESEARCH FUNDING UNDER PROP
3 71, AND IT SPECIFIES THAT RESEARCH AWARDS WILL BE
4 ACCOMPANIED BY A MARKET LEASE RATE FOR THE
5 FACILITIES TO REIMBURSE THE GRANTEE FOR THE USE OF
6 THOSE FACILITIES. THE BOARD, IN RESPONSE TO THAT
7 REQUIREMENT IN THE LAW, DECIDED TO RELY UPON THE OMB
8 NEGOTIATED RATE THAT IS PROVIDED TO NIH GRANT
9 RECIPIENTS. AND SO THAT FEDERALLY NEGOTIATED RATE
10 THAT PAT HAS REFERRED TO DOES VARY INSTITUTION BY
11 INSTITUTION SOMEWHAT SIGNIFICANTLY BASED ON THE
12 AGENCY AND NATURE OF THE FACILITIES AT EACH
13 INSTITUTION.

14 DR. JUELSGAARD: SO I'M SORRY. THAT'S
15 BUILT INTO THE PROPOSITION OR THE REGULATIONS?

16 MR. HARRISON: THE REQUIREMENT THAT
17 RESEARCH GRANTS INCLUDE FACILITIES COSTS IS BUILT
18 INTO THE PROPOSITION. THE BOARD MADE A POLICY
19 DECISION, RATHER THAN TRYING TO DETERMINE WHAT THE
20 MARKET LEASE RATE WAS FOR EACH FACILITY, TO USE THE
21 FEDERALLY NEGOTIATED RATE AS A PROXY.

22 DR. JUELSGAARD: ALL RIGHT.

23 MR. SHEEHY: I HAD DR. PRIETO AND THEN DR.
24 LUBIN.

25 DR. PRIETO: I THINK THE ESSENTIAL

BARRISTERS' REPORTING SERVICE

1 PROGRAMMATIC QUESTION HERE IS WILL FUNDING THESE
2 AWARDS FURTHER OUR GOAL AT THIS POINT IN OUR
3 EXISTENCE OF GETTING US MORE RAPIDLY INTO THE CLINIC
4 IN SOME FORM, OF GETTING STEM CELL THERAPY TO
5 PATIENTS? AND ALSO WILL BRINGING THESE PARTICULAR
6 RESEARCHERS TO CALIFORNIA ALLOW THEM TO DO WORK THAT
7 THEY WOULD NOT OTHERWISE DO? AND I'M VERY SKEPTICAL
8 THAT THE ANSWER TO EITHER OF THOSE QUESTIONS IS YES.
9 SO I WOULD HAVE A HARD TIME SUPPORTING THESE AWARDS.

10 CHAIRMAN THOMAS: DR. LUBIN, YOU HAD A
11 COMMENT?

12 DR. LUBIN: I'M REALLY HAPPY TO HAVE DR.
13 MILLS HERE. DR. MILLS' COMMENTS IN ACCEPTING THIS
14 POSITION -- WE'RE VERY HAPPY TO HAVE YOU HERE. YOUR
15 COMMENTS WERE WE SHOULD SUPPORT RESEARCH THAT HAS A
16 BENEFIT IN PATIENTS. AND I JUST WAS CURIOUS, WHEN
17 YOU REVIEWED THESE APPLICATIONS, WAS THE
18 TRANSLATIONAL COMPONENT OF THE ONES THAT WE'RE
19 RECOMMENDING STRONG ENOUGH THAT YOU FELT THAT
20 BRINGING THESE PEOPLE ON BOARD WAS GOING TO ENHANCE
21 THAT MISSION?

22 DR. MILLS: IT'S A FAIR QUESTION, BUT I
23 WASN'T A PART OF THE GRANTS WORKING GROUP THAT
24 REVIEWED THE APPLICATIONS. MY ONLY ROLE IN IT WAS
25 NOTING THAT THE BOARD HAD APPROVED OF THE CONCEPT OF

BARRISTERS' REPORTING SERVICE

1 THE RFA, INSTRUCTED THE GRANTS WORKING GROUP DO
2 THEIR JOB AND EVALUATE THE GRANTS, RECEIVE THE
3 SCORES OF THE GRANTS, AND THEN LISTEN TO THE TEAM'S
4 COMPILATION OF THE GRANTS AND SAY AS A PROCESS THAT
5 PROCESS WAS CARRIED OUT AS THE BOARD REQUESTED.

6 BUT WITH REGARDS TO WHETHER OR NOT IT
7 MEETS THE CRITERIA OF FASTER STEM CELLS OR BRINGING
8 STEM CELL THERAPIES TO PATIENTS FASTER, INCREASING
9 THE LIKELIHOOD OF STEM CELLS REACHING -- IMPROVING
10 THEIR LIKELIHOOD OF SUCCESS, MEETING AN UNMET
11 MEDICAL NEED, THAT WAS NOT A FILTER THAT I USED WITH
12 REGARDS TO THIS. IT WAS PURELY AN ADMINISTRATIVE
13 REVIEW THAT I DID, LIKE, WITHIN THE FIRST SIX HOURS
14 OF MY JOB OR SOMETHING LIKE THAT.

15 MR. SHEEHY: I HAD ONE MORE QUESTION FOR
16 DR. YAFFE. SO IF WE WERE TO APPROVE THESE TODAY, AT
17 WHAT -- APPROXIMATELY HOW LONG DOES IT TAKE THESE
18 INDIVIDUALS TO GET TO CALIFORNIA AND ACTUALLY
19 PRODUCTIVELY START WORKING?

20 DR. YAFFE: SIX MONTHS TO A YEAR PROBABLY
21 TO RELOCATE A LAB. THESE ARE ACTIVE RESEARCHERS WHO
22 HAVE LAB PROGRAMS. SOME OF THEM WILL MOVE FASTER.
23 ALL OF THE RESEARCHERS FROM PREVIOUS ROUNDS ARE NOW
24 HERE. SOME OF THEM TOOK FIVE TO SIX MONTHS, SOME OF
25 THEM TOOK A YEAR.

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: THANK YOU. SO ARE WE READY
2 FOR THE REVIEW? DR. SAMBRANO, WERE YOU JUST GOING
3 TO THROW THIS UP?

4 DR. SAMBRANO: I JUST PUT THIS UP SO THAT
5 YOU CAN KEEP TRACK OF THE TIERED BUDGETS. SO IF
6 THERE ARE APPROVALS OR CHANGES, WE CAN SEE THAT.

7 MR. SHEEHY: THANK YOU, DR. SAMBRANO. PER
8 OUR USUAL PRACTICE, THE FIRST MOTIONS WE GENERALLY
9 ENTERTAIN ARE MOTIONS TO MOVE ANY GRANT OUT OF TIER
10 I INTO THE DO NOT FUND TIER II CATEGORY. AND IF
11 THERE ARE MOTIONS, THEY SHOULD BE MADE FOR
12 INDIVIDUAL GRANTS BECAUSE THERE ARE CONFLICTS.

13 YES, DR. BRYANT.

14 DR. BRYANT: A PIECE OF INFORMATION THAT
15 WOULD HELP ME IS ARE THERE AREAS IN THE FUNDABLE --
16 IN THE ONES THAT ARE RECOMMENDED FOR FUNDING THAT
17 ARE UNIQUE, THAT ARE NEW TO THE PORTFOLIO OR NOT?

18 DR. YAFFE: I WOULD SUGGEST THAT ALL OF
19 THEM HAVE UNIQUE ASPECTS TO THE PORTFOLIO. THEY
20 WERE ALL DESCRIBED BY REVIEWERS AS HIGHLY
21 INNOVATIVE, AS IMPORTANT, AS DOING SIGNIFICANT
22 RESEARCH, AND THEY RECOGNIZED THE -- THE GRANTS
23 WORKING GROUP REVIEWERS RECOGNIZED THE VALUE OF
24 BRINGING THESE PEOPLE TO CALIFORNIA.

25 MR. SHEEHY: DR. FRIEDMAN.

BARRISTERS' REPORTING SERVICE

1 DR. FRIEDMAN: MAY I ASK THE COMPLEMENTARY
2 QUESTION THEN, WHICH IS IN YOUR REVIEW OF THESE, ARE
3 THERE ANY OF THESE THREE THAT ARE RECOMMENDED THAT
4 WOULD SUBSTANTIALLY SUPPORT ONGOING ACTIVITIES
5 EITHER AT THAT INSTITUTION OR AT A SISTER
6 INSTITUTION, LOOKING AT IT FROM A PORTFOLIO POINT OF
7 VIEW?

8 DR. YAFFE: AGAIN, ALL OF THESE WOULD.
9 THEY'RE ALL VERY -- THE CANDIDATES --

10 DR. FRIEDMAN: NO. NO. NO. THIS IS NOT
11 LAKE WOBEGON. I UNDERSTAND THEY'RE ALL --
12 SERIOUSLY, LEGITIMATELY.

13 DR. YAFFE: I MISUNDERSTOOD THE QUESTION.

14 DR. FRIEDMAN: THESE ARE TERRIFIC PEOPLE
15 AND I'M SURE THESE ARE HIGHLY MERITORIOUS. I REALLY
16 MEAN THAT. I'M NOT BEING FACETIOUS.

17 DR. YAFFE: YES.

18 DR. FRIEDMAN: BUT I MEAN IS THERE A
19 SPECIFIC PROGRAMMATIC ACTIVITY, A KEY ACTIVITY, A
20 PATHWAY ACTIVITY THAT THE STAFF HAS LOOKED AT AND
21 SAYS, OH, IF THIS INDIVIDUAL WERE HERE, IT MIGHT
22 COMPLEMENT ONGOING ACTIVITIES?

23 DR. YAFFE: I'M SORRY TO GIVE YOU THE SAME
24 ANSWER, THAT, YES, WE COULD GO THROUGH EACH ONE
25 INDIVIDUALLY IF YOU WOULD PREFER, BUT, IN FACT, THE

BARRISTERS' REPORTING SERVICE

1 FIRST -- THE TOP CANDIDATE, FOR EXAMPLE, IS A
2 BIOENGINEER WORKING ON EXTRACELLULAR MATRICES THAT
3 WILL FORM MATERIALS TO BE USED FOR REPAIR OF NEURAL
4 TISSUE AND CARDIAC. AND THE APPLICANT INSTITUTION
5 IS ONE THAT HAS A VERY ADVANCED CARDIAC PROGRAM
6 DEVELOPING CARDIOMYOCYTES FROM STEM CELLS. THIS IS
7 FITTING TOGETHER LIKE A PUZZLE, AND I THINK WE COULD
8 GO THROUGH THE TOP THREE.

9 GRANTS WORKING GROUP IN THEIR REVIEWS
10 RECOGNIZED AND APPRECIATED THE SYNERGY THAT'S GOING
11 TO BE CREATED BY BRINGING THESE INDIVIDUALS TO THESE
12 INSTITUTIONS.

13 MR. SHEEHY: DO WE HAVE A MOTION TO MOVE
14 ANYTHING OUT OF TIER I INTO --

15 DR. PRIETO: OKAY. AS I UNDERSTAND, WE
16 HAVE TO DO THESE ONE AT A TIME. I'M GOING TO MOVE
17 THAT WE TAKE THE THIRD APPLICATION, 08013, AND MOVE
18 THAT OUT OF THE FUNDABLE CATEGORY.

19 MR. SHEEHY: SO DO WE HAVE A SECOND?

20 DR. JUELGAARD: I'LL SECOND THE MOTION.

21 MR. SHEEHY: DISCUSSION? MS. WINOKUR.

22 MS. WINOKUR: DO WE KNOW OR HAVE ANY IDEA
23 ABOUT WHETHER THE INSTITUTION THEMSELVES WILL
24 RECRUIT THIS PERSON ON ITS OWN WITH ITS OWN FUNDS IF
25 WE DON'T FUND IT?

BARRISTERS' REPORTING SERVICE

1 DR. YAFFE: I DON'T THINK WE KNOW THAT IN
2 ANY CASE. WE KNOW THAT THE INSTITUTIONS IN ALL
3 CASES ARE MAKING SIGNIFICANT CONTRIBUTIONS AND
4 ACTIVITY IN TERMS OF THE RECRUITMENT OF THESE
5 INDIVIDUALS, BUT WE DON'T KNOW WHETHER THE FAILURE
6 OF CIRM TO AWARD ONE OF THESE AWARDS WILL RESULT IN
7 THE INDIVIDUAL NOT COMING OR THE INSTITUTION NOT
8 MAKING THE OFFER.

9 MR. SHEEHY: I HAVE DR. PRIETO. BUT JUST
10 AS A POINT OF INFORMATION, BUT WE DID REJECT THESE
11 ONCE BEFORE AND THE INSTITUTION DID END UP
12 COMPLETING THE RECRUITMENT WITHOUT CIRM FUNDS.

13 DR. PRIETO.

14 DR. PRIETO: TO DIANE'S POINT, I THINK
15 THAT IF THESE CANDIDATES ARE VALUABLE TO THE
16 INSTITUTION -- I THINK WHAT I'M SAYING IS THAT I
17 DON'T THINK THIS IS THE BEST PLACE FOR CIRM TO PUT
18 ITS MONEY RIGHT NOW. IF THE INSTITUTION FEELS THAT
19 IT'S A VERY VALUABLE PLACE TO PUT THEIR MONEY OR TO
20 RAISE OTHER FUNDS, THAT'S WONDERFUL, BUT I DON'T
21 THINK IT'S THE BEST USE OF OUR FUNDS.

22 MR. SHEEHY: DR. DULIEGE AND THEN DR.
23 BOXER.

24 DR. DULIEGE: I'M A LITTLE UNCLEAR HERE.
25 I'D LIKE TO UNDERSTAND IF WE'RE CHALLENGING THE MERE

BARRISTERS' REPORTING SERVICE

1 PRINCIPLE OF THESE AWARDS IN GENERAL OR THAT WE'RE
2 CHALLENGING SPECIFICALLY THIS ONE AND WHY.

3 DR. PRIETO: WE HAVE TO DO THESE ONE BY
4 ONE. BUT, YES, I'M ALSO QUESTIONING THE PRINCIPLE
5 OF DOING THIS WITH OUR MONEY AT THIS TIME.

6 DR. DULIEGE: SO THIS AWARD, ALL THESE
7 AWARDS AND THE WORK THAT WE'RE DOING RIGHT NOW, IS
8 THIS THE TOPIC OF OUR DISCUSSION OR THE TOPIC OF OUR
9 DISCUSSION SPECIFICALLY 13? AND IF THAT'S THE CASE,
10 WHY SPECIFICALLY THIS ONE ARE WE POTENTIALLY
11 RECOMMENDING IT TO NOT BE FUNDED?

12 DR. PRIETO: RIGHT NOW SPECIFICALLY 13
13 BECAUSE WE HAVE TO DO THEM ONE BY ONE AND BECAUSE
14 IT'S THE THIRD. AFTER WE ACT ON THIS ONE, I'LL MAKE
15 A SIMILAR MOTION ON 14 AND THEN ON 15.

16 DR. DULIEGE: IN THAT CASE I WILL THEN
17 OPEN A DISCUSSION TO THE MERE PRINCIPLE BECAUSE
18 THAT'S WHERE YOU WANT TO GO. THERE'S NO POINT IN
19 DISCUSSING THE SCIENTIFIC VALUE OF 13 BECAUSE THAT'S
20 NOT THE CHALLENGE THAT YOU HAVE.

21 MR. SHEEHY: DR. DULIEGE, WE HAVE TO TAKE
22 THEM INDIVIDUALLY BECAUSE PEOPLE HAVE CONFLICTS.

23 DR. DULIEGE: I UNDERSTAND.

24 MR. SHEEHY: SO IN ORDER TO ACCOMPLISH THE
25 PRINCIPLE, YOU MUST DEAL WITH THE INDIVIDUAL.

BARRISTERS' REPORTING SERVICE

1 DR. DULIEGE: OKAY.

2 MR. SHEEHY: SO I HAVE DR. BOXER AND THEN
3 MR. JUELSGAARD AND THEN DR. STEWARD.

4 DR. BOXER: THANK YOU. I GUESS I HAVE A
5 SIMILAR QUESTION HERE. I'M NOT SURE WHY WE WENT
6 AHEAD WITH THIS IF WE'RE NOW QUESTIONING THE
7 PRINCIPLE. AND I KNOW WE CAN'T VOTE, BUT I GUESS
8 I'D LIKE TO SAY THAT IT SEEMS TO ME THAT BRINGING IN
9 HIGH QUALITY SCIENTISTS TO THE STATE OF CALIFORNIA
10 WHO WILL HAVE A MAJOR FOCUS ON STEM CELL RESEARCH IS
11 ABSOLUTELY SOMETHING THAT WE WANT TO DO. AND I
12 GATHER WE'RE NOT QUESTIONING THE SCIENTIFIC REVIEW
13 OR THE QUALITY OF THESE APPLICANTS. SO IT SEEMS A
14 LITTLE AFTER THE FACT TO ME TO NOW QUESTION THE
15 PRINCIPLE OF DO WE WANT TO BRING IN OUTSTANDING
16 SCIENTISTS TO FOCUS ON STEM CELL RESEARCH. AND I
17 GUESS I'M A LITTLE CONFUSED ABOUT THAT AT THIS
18 POINT.

19 MR. SHEEHY: I'LL HAVE MR. JUELSGAARD THEN
20 DR. STEWARD. BUT JUST AS A CLARIFICATION, THIS WAS
21 NOT UNANIMOUSLY APPROVED AS A CONCEPT PLAN BY THE
22 BOARD. SO SEVERAL FOLKS AT THE TIME OF CONCEPT WERE
23 NOT SUPPORTIVE.

24 MR. JUELSGAARD.

25 DR. JUELSGAARD: SO TWO THINGS. FIRST IN

BARRISTERS' REPORTING SERVICE

1 RESPONSE TO DR. BOXER. SO I THINK IT'S ALWAYS
2 INCUMBENT -- SO WE'RE SPENDING SOMEBODY ELSE'S
3 MONEY. WE'RE SPENDING TAXPAYERS' MONEY, RIGHT? AND
4 SO WE HAVE A CERTAIN RESPONSIBILITY TO SPEND IT
5 WISELY. AND AS TIME GOES ON, THE NOTION OF SPENDING
6 WISELY MAY CHANGE IN PARTICULAR INDIVIDUAL'S POINT
7 OF VIEW. AND PARTICULARLY AS WE BEGIN TO LOOK AT
8 WHERE WE'RE HEADED, WHAT WE'VE GOT LEFT TO SPEND,
9 WHAT WE'VE GOT LEFT TO DO, ETC., DIFFERENT
10 PERSPECTIVES MAY EMERGE. SO I THINK IT'S FAIR THAT
11 WE HAVE A CONVERSATION LIKE THIS EVEN THOUGH SOME
12 TIME AGO WE APPROVED IN CONCEPT THE NOTION OF DOING
13 THIS.

14 WHERE THIS VOTE COMES OUT IS NOT YET
15 DETERMINED, BUT CERTAINLY SOME PEOPLE HAVE
16 QUESTIONS. AND I THINK THAT'S FAIR AND LEGITIMATE.

17 THE SECOND POINT ON THIS ONE SPECIFICALLY,
18 I WOULD POINT THIS GROUP TO THE DESCRIPTION THAT WAS
19 PROVIDED WITH THIS APPLICATION. ON THE SECOND PAGE
20 UNDER RESEARCH VISION AND PLANS AND THE THIRD
21 PARAGRAPH, AND I COULD READ IT IF YOU'D LIKE, BUT I
22 PREFER NOT TO, BUT THE POINT OF IT IS IS THAT THERE
23 WERE SOME DIFFERENCES OF OPINION AMONGST THE
24 REVIEWERS ABOUT THE POTENTIAL IMPACT OF THIS WORK ON
25 THE STEM CELL FIELD. AND SO UNLIKE, AT LEAST FROM A

BARRISTERS' REPORTING SERVICE

1 PURE MERITS OF THIS ONE POINT OF VIEW, THERE WERE
2 MORE QUESTIONS THAN CERTAINLY I NOTED IN THE OTHER
3 TWO THAT ARE STILL -- WE HAVEN'T ADDRESSED YET.

4 SO, AGAIN, I KNOW WE HAVE A GWG REVIEW AND
5 THERE WAS A SCORE ETC., ETC.; BUT IN MY MIND,
6 PARTICULARLY GIVEN WHERE WE MAY BE HEADED WITH
7 RESPECT TO THE USE OF OUR MONEY AND USING IT WISELY
8 FOR REALLY ADVANCING THE FIELD OF THERAPY, IT'S NOT
9 CLEAR TO ME THAT THIS IS REALLY THE BEST USE OF OUR
10 MONEY GIVEN SOME OF THE RESERVATIONS THAT WERE
11 EXPRESSED IN THE REVIEW.

12 MR. SHEEHY: SO I HAVE DR. STEWARD AND
13 THEN DR. DULIEGE.

14 DR. STEWARD: SO JUST TO REMIND EVERYBODY,
15 THIS IS THE PROGRAMMATIC PART OF THE REVIEW WHICH
16 WAS REFERRED FROM THE GRANTS WORKING GROUP TO THE
17 BOARD SEVERAL REVIEW CYCLES AGO. IN FACT, THIS IS
18 THE POINT AT WHICH WE CONSIDER THE DEGREE TO WHICH
19 THESE PROPOSALS FIT THE BROADER SCOPE OF THE RFA IN
20 THE BEGINNING AND THE DEGREE TO WHICH THESE
21 PROPOSALS ARE REALLY IMPORTANT FOR STEM CELL
22 PROGRESS IN BRINGING CURES TO PEOPLE SUFFERING FROM
23 DISEASES AND DISORDERS.

24 SO THAT'S THE CONTEXT IN WHICH WE'RE
25 TALKING HERE. SO EVEN THOUGH WE APPROVED THE

BARRISTERS' REPORTING SERVICE

1 CONCEPT TO ISSUE THESE, IT'S STILL FAIR TO TALK
2 ABOUT EACH ONE OF THESE INDIVIDUALLY AS TO WHETHER
3 THEY MEET OUR VISION OF THAT INITIAL CONCEPT. AND
4 SO I JUST WANTED TO SAY THAT.

5 AND NOW A QUESTION. SO ACTUALLY GOING
6 BACK TO MICHAEL FRIEDMAN'S QUESTION TO YOU, COULD
7 YOU UNPACK A LITTLE BIT THE DEGREE TO WHICH THIS
8 PROPOSAL HAS IMPACT BEYOND ITSELF, IF IT DOES?

9 DR. YAFFE: DR. GRISHAMMER WILL FIELD
10 THIS.

11 DR. GRIESHAMMER: GOOD MORNING. SO JUST
12 TO GET YOU ALL ONTO THE SAME PAGE, THIS IS A
13 PROPOSAL FOR AN EARLY CAREER PRINCIPAL INVESTIGATOR
14 WHO HAS EXPERTISE WITH VERY CUTTING-EDGE IMAGING
15 TECHNOLOGY. AND I WILL SAY THAT'S WHAT MOSTLY
16 EXCITED THE REVIEWERS ABOUT THIS INDIVIDUAL. THEY
17 ALSO DID FIND THAT THIS PERSON WAS TRAINED IN
18 BIOLOGY, WHICH FOR TECHNOLOGY-FOCUSED RESEARCHERS
19 WAS CONSIDERED AS AN IMPORTANT PLUS IN THIS
20 CANDIDATE'S EXPERTISE.

21 SO THE GOAL OF THIS RESEARCH IS TWOFOLD.
22 THIS PERSON WANTS TO FURTHER THIS IMAGING TECHNOLOGY
23 THEY HAVE DEVELOPED AS WELL AS APPLY THIS IMAGING
24 TECHNOLOGY TOWARD BETTER UNDERSTANDING HOW GENE
25 EXPRESSION IS REGULATED IN CELLS.

BARRISTERS' REPORTING SERVICE

1 AND IT IS THIS PIECE OF THE RESEARCH GOALS
2 THAT HAS IMPORTANT IMPLICATIONS FOR UNDERSTANDING
3 AND MANIPULATING CELL FATE, WHICH IS A SUBJECT
4 RELEVANT TOWARD ADVANCING REGENERATIVE MEDICINE.

5 SO LIKE I ALREADY SAID, THE REVIEWERS WERE
6 EXTREMELY EXCITED ABOUT THE TECHNOLOGY THIS PERSON
7 WOULD BRING TO CALIFORNIA AS WELL AS THIS PERSON'S
8 ROLE IN HAVING DEVELOPED IT. SO THERE WAS GREAT
9 BUZZ ABOUT THAT. THEY FELT THAT THIS PERSON HAS A
10 GREAT POTENTIAL AS A SCIENTIFIC LEADER.

11 AS WAS ALREADY MENTIONED, THE REVIEWERS
12 DIFFERED IN THEIR OPINIONS ABOUT THE SPECIFIC
13 RELEVANCE TO STEM CELL RESEARCH. SOME WERE VERY
14 EXCITED ABOUT APPLYING THIS NEW TECHNOLOGY TOWARD
15 THESE QUESTIONS IN STEM CELL BIOLOGY; WHEREAS,
16 OTHERS FELT THAT THIS RESEARCH WAS PERHAPS FOCUSED
17 TOO MUCH ON A SPECIFIC CELLULAR MECHANISM WHEN A
18 BROADER APPROACH TO LOOKING AT GENE EXPRESSION WOULD
19 BE MORE APPROPRIATE.

20 THE LETTERS FROM THE COLLEAGUES THAT WERE
21 WRITTEN FOR THIS INDIVIDUAL WERE EXTREMELY GLOWING:
22 VERY CREATIVE SCIENTIST, A PRIZE RECRUIT FOR
23 CALIFORNIA. AND WITH REGARD TO BRINGING SOMETHING
24 TO THE UNIVERSITY TO WHICH THIS INDIVIDUAL WOULD GO,
25 IT WAS ACTUALLY CONSIDERED AN IDEAL FIT FOR AN

BARRISTERS' REPORTING SERVICE

1 ALREADY VERY INNOVATIVE IMAGING PROGRAM THAT EXISTS
2 AT THIS UNIVERSITY, AND THIS PERSON WOULD BRING A
3 NEW ASPECT TO THIS BURGEONING FACILITY THERE.

4 CHAIRMAN THOMAS: CAN I JUST ASK DR.
5 GRISHAMMER A QUESTION? SO WHAT IS YOUR VIEW OF THAT
6 CRITIQUE ABOUT WHETHER THE FOCUS ON THE SINGLE CELL
7 IS NOT ADVISABLE OR WOULD BE USEFUL?

8 DR. GRIESHAMMER: SO FOCUSING ON SINGLE
9 CELLS IS ACTUALLY EXTREMELY IMPORTANT IN STEM
10 CELL -- CONSIDERED EXTREMELY IMPORTANT AND EXTREMELY
11 INNOVATIVE CURRENTLY IN STEM CELL RESEARCH. AS PART
12 OF OUR GENOMICS INITIATIVE, FOR INSTANCE, THAT WAS
13 ONE OF THE MAIN REASONS FOR FUNDING THE GENOMICS
14 CENTER THAT WE HAVE, THAT THERE WAS A VERY CRITICAL
15 SINGLE CELL GENOMICS EXPERTISE IN THAT APPLICATION.
16 NOW, HERE, THE SINGLE CELL APPROACH IS AN ENTIRELY
17 DIFFERENT ONE. IT'S THROUGH IMAGING RATHER THAN
18 THROUGH GENOMICS RESEARCH. AND SO IN THAT SENSE I
19 WOULD SAY, CONSIDERING HOW IMPORTANT IT IS TO LOOK
20 AT SINGLE CELLS AS OPPOSED TO A HETEROGENEOUS
21 POPULATION, THAT'S CONSIDERED AN IMPORTANT
22 ADVANCEMENT RIGHT NOW IN THE STEM CELL FIELD AND
23 BETTER UNDERSTANDING STEM CELL POPULATIONS.

24 CHAIRMAN THOMAS: AND IS THAT SOMETHING
25 THAT, IF DEVELOPED TO ITS ULTIMATE CAPACITY, WOULD

BARRISTERS' REPORTING SERVICE

1 BE USEFUL ACROSS THE BOARD FOR A VARIETY OF
2 INDICATIONS?

3 DR. GRIESHAMMER: WELL, I WILL SAY THAT
4 THIS WORK DOES CONSTITUTE BASIC RESEARCH. MY -- I
5 THINK YOU ASKED ME FOR MY PERSONAL OPINION ON HOW
6 THIS KIND OF RESEARCH WOULD FORWARD THIS. AND I
7 WOULD SAY THERE'S GREAT POTENTIAL FOR GETTING NEW
8 INSIGHTS INTO THE BASIC BIOLOGY OF STEM CELL
9 POPULATIONS. AND THEN THE GENERAL COMMENT THAT I
10 CAN MAKE IS THAT, OF COURSE, OFTEN THOSE GENERAL
11 INSIGHTS LEAD TO FURTHER ADVANCEMENT EVEN IN
12 TRANSLATIONAL RESEARCH. BUT THE FOCUS HERE IS
13 RATHER BASIC.

14 CHAIRMAN THOMAS: AND IS THERE ANYBODY
15 WITH THIS PARTICULAR TALENT CURRENTLY DOING SIMILAR
16 THINGS ELSEWHERE IN THE STATE?

17 DR. GRIESHAMMER: ELSEWHERE IN THIS STATE?
18 FROM WHAT I HEARD FROM THE REVIEWERS, I REALLY DON'T
19 THINK SO. THERE IS A GROUP IN NEW YORK FROM WHOM
20 THIS PERSON ORIGINALLY CAME AND THAT'S DRIVING THIS
21 INNOVATION. AND THERE WAS DEFINITELY GREAT
22 EXCITEMENT OVER BRINGING THIS PARTICULAR TECHNOLOGY
23 INTO THE STATE BECAUSE IT DOESN'T -- IT HARDLY
24 EXISTS ANYWHERE, AND I DON'T THINK IT EXISTS IN
25 CALIFORNIA.

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: SO I HAVE DR. PRIETO AND THEN
2 MR. PANETTA UNLESS I MISSED SOMEONE.

3 DR. PRIETO: I JUST WANT TO MAKE IT CLEAR
4 THAT I'M NOT ARGUING AT ALL AGAINST THIS ON THE
5 MERITS OR THE SCIENCE, BUT PURELY ON PROGRAMMATIC
6 GROUNDS THAT I DON'T THINK THIS IS WHERE TO SPEND
7 OUR MONEY.

8 MR. SHEEHY: MR. PANETTA AND THEN DR.
9 DULIEGE.

10 MR. PANETTA: THANK YOU, MR. SHEEHY. I
11 WASN'T HERE LAST JULY WHEN THIS WAS APPROVED IN
12 CONCEPT, SO I GUESS I'M A LITTLE BIT CONFUSED AS TO
13 WHY IT WAS APPROVED AND NOW WE'RE TALKING ABOUT
14 BACKTRACKING AND DISAPPROVING IT IN SOME WAY. AND
15 I'M NO SCIENTIST, SO I'M NOT GOING TO CRITIQUE THE
16 REVIEW OF THE ACTUAL APPLICATION THAT WE'RE
17 DISCUSSING. BUT WHAT CONCERNS ME MORE IS THAT WHEN
18 I SEE THAT WE HAVE A PARTICULARLY CREATIVE SCIENTIST
19 WHO IS DESCRIBED AS A PRIZE RECRUIT AT A TIME WHEN
20 WE HAVE SUCH GREAT COMPETITIVENESS NATIONALLY AND
21 INTERNATIONALLY IN RECRUITING SCIENTIFIC TALENT AND
22 AT A TIME WHEN YOUNG TALENT IS FINDING IT MORE AND
23 MORE DIFFICULT TO OBTAIN NIH GRANT FUNDING, I DON'T
24 SEE WHY WE WOULD NOT TAKE ADVANTAGE OF AN
25 OPPORTUNITY TO RECRUIT SOMEONE WHO SEEMS TO BE OF A

BARRISTERS' REPORTING SERVICE

1 VERY HIGH CALIBER. AND I THINK WE JUST HEARD THAT
2 THIS IS A VERY RELEVANT FIELD OF RESEARCH AS WELL.
3 SO I'M NOT SURE WHERE WE'RE GOING WITH THIS, BUT TO
4 ME THIS SEEMS LIKE A GREAT OPPORTUNITY. THANK YOU.

5 MR. SHEEHY: DR. DULIEGE.

6 DR. DULIEGE: AND I UNDERSTAND THAT SOME
7 OF US ARE FOCUSING THE DISCUSSION ON THE OVERALL WHY
8 ARE WE NOW FUNDING IN GENERAL THIS TYPE OF AWARD.
9 SO I'LL JUST ANSWER TO THIS ONE, AND THEN I'LL COME
10 BACK TO THE SPECIFIC ONE.

11 I JUST WOULD LIKE TO SAY IN PRINCIPLE FOR
12 ME AS A TEAM WE SHOULD NOT REVISIT DECISIONS
13 RECENTLY MADE, AND I WOULD CONSIDER LAST JULY RECENT
14 BECAUSE WE KNEW EXACTLY HOW MUCH MONEY WE STILL HAD,
15 UNLESS THERE ARE A MATERIAL EVENT THAT JUSTIFY
16 RECHALLENGING WHY WE MADE A DECISION.

17 THE SECOND IS, IN GENERAL, WHEN A TEAM HAS
18 REACHED A DECISION MADE BY CONSENSUS, EVEN IF THERE
19 WERE PEOPLE THAT DISAGREED WITH THAT DECISION, WE
20 SHOULD CONTINUE TO SUPPORT THAT DECISION ALL ALONG
21 AND RALLY AROUND THAT DECISION. SO THAT'S FOR THE
22 PRINCIPLE. AND HENCE, I HAVE A LITTLE BIT OF AN
23 ISSUE CHALLENGING AGAIN AND GOING BACK TO SQUARE ONE
24 AS TO WHY WE'RE DOING THESE AWARDS.

25 IN REGARD TO THIS SPECIFIC ONE, I WOULD

BARRISTERS' REPORTING SERVICE

1 SECOND WHAT JOE JUST SAID.

2 MR. SHEEHY: THANK YOU. DO WE HAVE
3 FURTHER DISCUSSION? I THINK FOLKS -- DR. BOXER.

4 DR. BOXER: WELL, I'LL KEEP IT BRIEF, BUT
5 I WOULD JUST SAY I THINK THIS IS VERY SHORTSIGHTED
6 TO GO BACK ON THIS. I THINK THAT THIS IS THE FUTURE
7 OF STEM CELL RESEARCH IN CALIFORNIA, AND WE SHOULD
8 BE RECRUITING STARS LIKE THIS TO THIS STATE.

9 MR. SHEEHY: DR. VUORI.

10 DR. VUORI: I'LL SIMPLY ECHO WHAT LINDA
11 JUST SAID. I THINK WE ARE IN A VERY UNIQUE
12 OPPORTUNITY, THAT IS CALIFORNIA, TO ATTRACT THE BEST
13 AND THE BRIGHTEST. AND WHEN WE LOOK AT THESE
14 APPLICATIONS, I THINK THEY ARE HIGHLY MERITORIOUS
15 SCIENTIFICALLY AS INDIVIDUAL PROJECTS, BUT WE ARE
16 NOT ONLY GETTING THE PROJECTS, WE ARE ACTUALLY
17 GETTING THESE PEOPLE WHO CAN BE LEADERS IN THE STEM
18 CELL FIELD FOR YEARS TO COME IN OUR STATE.

19 MR. SHEEHY: DR. STEWARD.

20 DR. STEWARD: I'M SORRY. I JUST AGAIN
21 WANT TO EMPHASIZE THAT THIS IS A PROGRAMMATIC
22 REVIEW. AND I, FOR ONE, WOULD NOT WANT TO GO BACK
23 AND REVISIT THE CONCEPT EITHER, BUT IT'S IMPORTANT
24 TO THINK ABOUT WHETHER EACH OF THESE FIT THAT
25 CONCEPT TO THE EXTENT THAT WE CONCEIVED IT. THAT'S

BARRISTERS' REPORTING SERVICE

1 WHAT WE'RE DOING HERE. WE'RE NOT TALKING ABOUT THE
2 CONCEPT. WE'RE NOT TALKING ABOUT REVISITING. WE'RE
3 TALKING ABOUT ONE APPLICATION. IS IT REALLY GOING
4 TO BE TRANSFORMATIVE IN TERMS OF BRINGING STEM CELL
5 TECHNOLOGIES TO THE POINT THAT THEY'RE GOING TO
6 IMPACT ON PEOPLE? THAT'S THE QUESTION. THAT'S
7 PROGRAMMATIC. WE'RE NOT REVIEWING THE SCIENCE.

8 MR. SHEEHY: DR. PRIETO.

9 DR. PRIETO: I WOULD REPEAT THAT AGAIN.
10 AND JUST TO ANSWER ANNE-MARIE'S POINT, I THINK THE
11 MATERIAL EVENT THAT'S TAKING PLACE IS THAT SINCE THE
12 ORIGINAL DECISION IS THAT WE HAVE A NEW PRESIDENT,
13 AND I WANT TO GIVE HIM MAXIMUM FLEXIBILITY IN
14 SHAPING THE DIRECTION OF OUR PROGRAM.

15 DR. DULIEGE: VERY FAIR.

16 MR. SHEEHY: OKAY. UNLESS THERE'S FURTHER
17 DISCUSSION, PUBLIC COMMENT ON THIS ITEM? DR. LUBIN.

18 DR. LUBIN: SO I JUST -- I GUESS AS A
19 SCIENTIST WHO COLLABORATES WITH PEOPLE ALL OVER THE
20 WORLD AND, IN FACT, OUR FIRST GENE THERAPY
21 THALASSEMIA PROGRAM THAT ALAN BROUGHT TO OUR
22 ATTENTION IS DONE FROM A COMPANY OUT OF BOSTON, BUT
23 THE STUDY WILL BE DONE IN OAKLAND. THE FACT THAT
24 YOU'RE IN CALIFORNIA OR OUT OF CALIFORNIA DOESN'T
25 MEAN YOU CAN'T WORK TOGETHER. IS OUR GOAL HERE JUST

BARRISTERS' REPORTING SERVICE

1 TO MAKE CALIFORNIA DIFFERENT THAN EVERYONE ELSE, OR
2 IS IT TO ADVANCE STEM CELLS SO THEY TREAT PATIENTS?
3 AND I THINK THAT'S AN IMPORTANT THING TO KEEP IN
4 MIND AS WE GO FORWARD.

5 MR. SHEEHY: THANK YOU, DR. LUBIN. ARE WE
6 READY FOR -- NO PUBLIC COMMENT. ARE PEOPLE READY TO
7 CALL THE ROLL?

8 MR. HARRISON: IF I COULD, JUST SO I
9 UNDERSTAND, THE MOTION, THEN, IS NOT TO FUND
10 APPLICATION -- RESEARCH LEADERSHIP APPLICATION
11 08013.

12 DR. PRIETO: TO MOVE IT OUT OF THE
13 FUNDABLE CATEGORY. SO AN AYE VOTE WOULD BE A VOTE
14 NOT TO FUND.

15 MR. HARRISON: THANK YOU.

16 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

17 DR. DULIEGE: NO.

18 MS. BONNEVILLE: STEVE JUELSGAARD.

19 DR. JUELSGAARD: AYE.

20 MS. BONNEVILLE: JOE PANETTA.

21 MR. PANETTA: NO.

22 MS. BONNEVILLE: FRANCIS PRIETO.

23 DR. PRIETO: AYE.

24 MS. BONNEVILLE: JEFF SHEEHY.

25 MR. SHEEHY: YES.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: OS STEWARD.

2 DR. STEWARD: YES.

3 MS. BONNEVILLE: JONATHAN THOMAS.

4 CHAIRMAN THOMAS: NO.

5 MS. BONNEVILLE: ART TORRES.

6 MR. TORRES: NO.

7 MS. BONNEVILLE: DIANE WINOKUR.

8 MS. WINOKUR: NO.

9 MR. HARRISON: THE MOTION FAILS WITH FOUR
10 YES VOTES AND FIVE NO VOTES.

11 MR. SHEEHY: OKAY. IS IT WORTH TRYING TO
12 DO ANYTHING -- I JUST WANT TO SAY I JUST -- I GO
13 BACK. I HATE TO EDITORIALIZE ON THIS, BUT WE ONLY
14 PLANNED ONE ROUND OF THIS, AND NOW WE'RE ON OUR
15 FOURTH. HALF THE PEOPLE DON'T COME. WE'RE NOT
16 CREATING ANY NEW SCIENTIFIC CAPACITY. WE'RE TAKING
17 PEOPLE WHO ARE PRODUCTIVELY WORKING AND MOVING THEM
18 TO CALIFORNIA FOR THE BENEFIT OF INSTITUTIONS WHOSE
19 MEMBERS SERVE ON THIS BOARD. AND I JUST THINK THAT
20 THIS WHOLE ROUND HAS BEEN A LITTLE PREPOSTEROUS IN
21 TERMS OF DELIVERING THERAPIES TO PATIENTS. SO
22 THAT'S MY EDITORIAL COMMENT ON THAT, AND WE ALL KNOW
23 THAT.

24 SO ARE THERE ANY OTHER MOTIONS TO MOVE
25 ANYTHING OUT OF TIER I?

BARRISTERS' REPORTING SERVICE

1 DR. BOXER: CAN I JUST RESPOND TO THAT
2 WITH ANOTHER EDITORIAL COMMENT? SO I THINK THAT'S
3 AN INTERESTING WAY TO LOOK AT IT, BUT I WOULD JUST
4 SAY THAT I VIEW IT AS BRINGING TALENTED RESEARCHERS
5 WHO MAYBE DON'T HAVE A MAJOR FOCUS ON STEM CELL
6 RESEARCH AND ARE COMING HERE TO APPLY THEIR TALENTS
7 AND NEW TECHNIQUES OR INNOVATIVE WAYS OF THINKING TO
8 STEM CELL RESEARCH. AND I GUESS I DON'T SEE HOW YOU
9 CAN GO WRONG WITH THAT.

10 MR. SHEEHY: I THINK WE SPENT \$2 BILLION
11 AND WE HAVE A BILLION LEFT, AND I THINK WE NEED TO
12 GET SOMETHING TO PATIENTS. NOW, YOU MAY HAVE A
13 DIFFERENT SENSE OF WHAT WE PROMISED IN 2004, BUT I
14 THOUGHT WE PROMISED TO CURE PEOPLE. AND TO TAKE
15 SOMEBODY AND HAVE THEM NOT GET HERE FOR SIX MONTHS
16 TO A YEAR TEN YEARS INTO THIS PROGRAM, TEN YEARS
17 AFTER WE'VE DONE STUFF WE PROMISED THE VOTERS AT THE
18 EXPENSE OF THINGS THAT MAY ACTUALLY GET TO PATIENTS
19 JUST IT SEEMS TO ME BIZARRE. SO DR. BRENNER.

20 DR. BRENNER: SO I WANT TO MAKE LIKE A
21 UNIFORM -- UNIFYING HYPOTHESIS HERE. SO I THINK
22 WHAT HAPPENED INITIALLY WHEN WE FIRST DID THIS IS
23 THAT WE THOUGHT THERE WERE CRITICAL EXPERTISE
24 MISSING IN CALIFORNIA THAT WE NEEDED TO GET, THIS IS
25 SEVEN YEARS AGO, TO DO THE THINGS WE WANTED TO DO,

BARRISTERS' REPORTING SERVICE

1 TO ACTUALLY DEVELOP NEW THERAPIES. SO WE HAVE THIS
2 PROGRAM AND IT BROUGHT SOME AMAZING PEOPLE. I
3 THINK, THOUGH, MAYBE WE KEPT IT GOING TOO LONG AND
4 THAT AT SOME POINT WE SHOULD HAVE SWITCHED TO A MORE
5 TRANSLATIONAL MODE AND NOT BRINGING IN BASIC PEOPLE
6 TO ADD, WHICH I THINK IS A VERY IMPORTANT THING, BUT
7 IT'S PROBABLY NOT OUR MISSION TODAY LIKE IT WAS FIVE
8 YEARS AGO.

9 SO WHEN RANDY AND I HAD DISCUSSION
10 YESTERDAY, WE SAID THAT WE HAVE TO CHANGE THE WAY
11 WE'RE DOING BUSINESS GOING FORWARD DIFFERENT FROM
12 WHAT WE DID IN THE PAST. SO I THINK I WOULD LIKE TO
13 SAY THAT THIS DID WORK FIVE YEARS AGO AND I THINK IT
14 WAS IMPORTANT, BUT AT THE VERY LEAST WE SHOULDN'T DO
15 ANOTHER ROUND. AT LEAST WE SHOULD LEARN AND NOT
16 KEEP GOING. SO I THINK THAT'S FAIR.

17 MR. SHEEHY: AND AT SOME POINT WE WON'T
18 HAVE ANY MONEY. WE'LL HAVE TO FACE THE VOTERS AND
19 THE PEOPLE OF CALIFORNIA. YOU KNOW, I'M JUST AN
20 ORDINARY JOE HERE. SO I JUST HAVE A DIFFERENT
21 PERSPECTIVE ON THIS. STANFORD HAS ALMOST GOTTEN
22 \$300 MILLION.

23 DR. BOXER: THANK YOU.

24 MR. SHEEHY: YOU'RE WELCOME. YOU'RE
25 WELCOME. AND I JUST THINK THAT THE PUBLIC

BARRISTERS' REPORTING SERVICE

1 DESERVES -- THEY DESERVE SOMETHING TO GO INTO A
2 PATIENT THAT MAKES A DIFFERENCE IN A PATIENT'S LIFE.

3 DR. BOXER: I THINK YOU KNOW STANFORD IS
4 ABOUT TO PUT SOME THINGS INTO PATIENTS.

5 MR. SHEEHY: DR. PRIETO.

6 DR. PRIETO: AND I DON'T WANT TO BEAT THIS
7 DEAD HORSE, BUT I THINK THAT IT IS A QUESTION OF
8 JUST CONTINUING TO DO SOMETHING THAT WE'VE DONE
9 UNDER OUR PREVIOUS PRESIDENT AND HAD JUST CONTINUED
10 DOING ROUTINELY THAT MAY NOT BE APPROPRIATE AT THIS
11 POINT IN OUR EXISTENCE. AND I THINK WHATEVER THE
12 SCIENTIFIC MERITS, AND I THINK THE SCIENTIFIC MERITS
13 ARE CERTAINLY OUTSTANDING, IT JUST MAY NOT BE OUR
14 ROLE TO DO THIS AT THIS POINT.

15 MR. SHEEHY: AND ABOUT TO ISN'T DOING. SO
16 I'LL JUST ADD THAT.

17 SO DO WE HAVE ANY OTHER MOTIONS ON -- \$300
18 MILLION IN ABOUT TEN YEARS AND ABOUT TO PUT
19 SOMETHING INTO A PATIENT IS NOT A RECORD OF
20 ACHIEVEMENT. AT LEAST FOR ME AS A PERSON IN
21 CALIFORNIA, IT DOESN'T IMPRESS ME.

22 SO ARE THERE ANY OTHER MOTIONS TO REMOVE
23 SOMETHING FROM TIER I --

24 DR. DULIEGE: JEFF, IF I CAN HAVE AN
25 EDITORIAL COMMENT HERE. I THINK WE SHOULD STOP, AS

BARRISTERS' REPORTING SERVICE

1 A BOARD, POINTING OUT A PARTICULAR UNIVERSITY
2 BECAUSE I DON'T WANT TO EVEN GET CLOSE TO DEBATE AS
3 TO WHAT WE DID WITH STANFORD. THERE ARE MANY, MANY
4 THINGS THAT ARE GETTING THINGS CLOSER TO PATIENTS BY
5 ALLOCATING MONEY IN THE UNIVERSITIES WE HAVE. SO
6 LET'S NOT GET INTO THAT TANGENT.

7 JUST TO PUT A CLOSURE ON THIS, ALL OF US
8 FEEL A LITTLE UNCOMFORTABLE WITH HOW THIS DISCUSSION
9 IS GOING. I ASSUME, JAMES, THERE'S NO WAY THAT WE
10 COULD REVISIT AT THIS POINT THIS CONCEPT. IF
11 APPARENTLY SOME BOARD MEMBERS HAVE SUCH A STRONG
12 DESIRE, AND MAYBE UNDERSTANDABLY SO, TO REVISIT A
13 CONCEPT, THE OVERALL CONCEPT, NOT INDIVIDUALLY.

14 MR. HARRISON: THAT UNFORTUNATELY RAISES
15 SOME CONFLICT CHALLENGES FOR US BECAUSE WE ALREADY
16 HAVE APPLICATIONS THAT HAVE BEEN SUBMITTED. SO
17 THOSE INDIVIDUALS FROM INSTITUTIONS THAT HAVE
18 SUBMITTED THE APPLICATIONS WOULDN'T BE PERMITTED TO
19 PARTICIPATE IN THAT DISCUSSION.

20 DR. DULIEGE: I UNDERSTAND. IT'S TOO BAD.

21 DR. STEWARD: IF I COULD, I JUST WANT TO
22 GO BACK TO THE PRINCIPLE HERE, PROGRAMMATIC REVIEW.
23 WE HAD A ROUND WHERE WE DIDN'T FUND ANYTHING. WE
24 COULD DO THAT THIS ROUND IF WE FELT THAT NONE OF
25 THESE APPLICATIONS ACTUALLY FIT OUR BILL. AND

BARRISTERS' REPORTING SERVICE

1 THAT'S, I THINK, THE ONLY THING THAT WE SHOULD BE
2 TALKING ABOUT HERE, NOT THE PAST.

3 DR. PRIETO: EXACTLY. THIS IS A
4 PROGRAMMATIC DISCUSSION. IS THIS THE RIGHT THING
5 FOR US TO BE DOING AT THIS TIME?

6 MR. SHEEHY: SENATOR TORRES.

7 MR. TORRES: I'D LIKE TO ASK A QUESTION
8 THROUGH THE CHAIR. THERE'S BEEN A COMMENT MADE THAT
9 WE'RE NOT DOING ENOUGH TO BRING TREATMENTS TO
10 PATIENT OR CURES TO PATIENTS. AND THAT'S NOT JUST
11 TODAY. I MEAN PEOPLE HAVE TALKED ABOUT THAT AS WELL
12 AS WE REVIEW OUR RECORD AND WHERE WE'RE HEADED. DO
13 WE HAVE AN INVENTORY OF WHICH GRANTS WE HAVE
14 REJECTED THAT WOULD HAVE GONE TO PATIENTS?

15 DR. YAFFE: IN THIS PROGRAM OR FOR THE
16 ENTIRE AGENCY?

17 MR. TORRES: OVERALL. OVERALL BECAUSE I
18 DON'T THINK YOU CAN TAKE A PARTICULAR PROGRAM AND
19 USE THAT AS A PANOPLY FOR THE ENTIRE INSTITUTE
20 BECAUSE THAT DOESN'T GIVE A TRUE REFLECTION OF THE
21 RECORD. SO I WANT TO MAKE SURE THAT -- AND JEFF AND
22 I HAVE HAD THIS CONVERSATION BEFORE WHERE SOMETIMES
23 WE THINK PROJECTS MAY HAVE BEEN REJECTED THAT COULD
24 HAVE GONE DIRECTLY TO TREATMENT. AND I WANT TO KNOW
25 ARE THERE SUCH PROJECTS THAT WE HAVE REJECTED WHERE

BARRISTERS' REPORTING SERVICE

1 WE COULD HAVE GONE MUCH FASTER TO TREATMENT?

2 DR. YAFFE: I'M NOT AWARE OF THEM. WE
3 HAVEN'T TRACKED ACTIVITIES THAT WE DIDN'T FUND. ONE
4 MIGHT FIND ANECDOTES BY GOING BACK AND LOOKING AT
5 OUR HISTORY.

6 MR. TORRES: IS IT CORRECT ALSO, AND I
7 KNOW THIS TO BE THE CASE, BUT IS IT CORRECT ALSO, TO
8 GET IT ON THE RECORD, THAT IN SOME INSTANCES WE HAVE
9 STOPPED CERTAIN PROJECTS BECAUSE THEY WEREN'T
10 REACHING THEIR GOALS, THEREFORE, SAVING THE
11 TAXPAYERS MONEY AS WELL?

12 DR. YAFFE: ABSOLUTELY.

13 MR. TORRES: SO I THINK THAT'S IMPORTANT
14 TO NOTE AS WE LOOK AT THE WHOLE PICTURE. I'M NOT
15 INSENSITIVE. IN FACT, I'M VERY SUPPORTIVE OF WHAT
16 JEFF HAS SAID. WE ARE GOING TO BE HELD ACCOUNTABLE
17 TO THE TAXPAYERS OF THIS STATE. AND AS WE PROCEED
18 FORWARD, WE HAVE TO HAVE OUR MESSAGE INTACT. WE
19 HAVE TO HAVE OUR MESSAGE COMPLETE. WE HAVE TO HAVE
20 OUR MESSAGE, WHICH I THOUGHT WERE SOME GOOD COMMENTS
21 BY MS. BOXER AND DR. DULIEGE, AS WE MOVE FORWARD AS
22 WELL. AND THERE WILL BE DISCUSSIONS, AND I THINK
23 THOSE ARE HEALTHY TO HAVE THOSE KINDS OF DISPUTES
24 AND DISAGREEMENTS AND DIFFERENT OPINIONS. BUT AT
25 THE END OF THE DAY, WE REALLY HAVE TO MAKE SURE THAT

BARRISTERS' REPORTING SERVICE

1 THE MESSAGE THAT WE'RE PROVIDING TO THE PEOPLE OF
2 CALIFORNIA IS A MESSAGE CONSISTENT WITH WHAT WE'VE
3 DONE OVERALL, NOT NECESSARILY ON ONE PARTICULAR
4 PROJECT OR ANOTHER INDEPENDENT OF AN OVERALL REVIEW.

5 MR. SHEEHY: YES. DR. THOMAS.

6 CHAIRMAN THOMAS: I'D JUST LIKE TO FOLLOW
7 UP DR. DULIEGE'S COMMENT WHICH IS TO NOTE THAT AS WE
8 WELL KNOW, WE'VE GOT PROJECTS FUNDED STATEWIDE IN 39
9 CURRENTLY INCURABLE DISEASES AND CONDITIONS, 65 PLUS
10 OR MINUS INSTITUTIONS WHO ARE RECIPIENTS OF THOSE
11 FUNDS, AND AT EACH OF THEM THERE IS A CONTINUUM OF
12 PROGRESS BEING MADE WHICH IS MARCHING INEXORABLY
13 TOWARDS GETTING INTO CLINICAL TRIALS, OBVIOUSLY ONLY
14 FOR THE BEST OF THOSE, BUT WE ARE MAKING GREAT
15 STRIDES. AND I DON'T WANT TO GIVE ANYBODY THE
16 IMPRESSION THAT, REGARDLESS OF INSTITUTION, THIS
17 ISN'T A PORTFOLIO THAT'S HIGHLY VALUABLE AND IS
18 GOING EXACTLY ALONG TRYING TO COME UP WITH WHAT
19 WE HOPE WILL BE THERAPIES AND CURES, AND WE THINK
20 THAT THIS IS A PORTFOLIO OF PARTICULARLY
21 TRANSLATIONAL PROJECTS THAT'S SECOND TO NONE IN THE
22 WORLD AND WILL ONLY CONTINUE TO REINFORCE THAT AS
23 TIME MARCHES ON.

24 SO AS A GENERAL FRAMEWORK COMMENT
25 NONSPECIFIC TO ANY PARTICULAR INSTITUTION, I THINK

BARRISTERS' REPORTING SERVICE

1 THAT THAT'S OBVIOUSLY SOMETHING WE ALL FERVENTLY
2 BELIEVE AND WANT TO MAKE SURE THAT THAT MESSAGE IS
3 PROPERLY CONVEYED.

4 MR. SHEEHY: THAT KIND OF BRINGS UP
5 ANOTHER POINT. THANK YOU, DR. THOMAS. WHAT KIND OF
6 PRODUCTIVITY HAVE WE GOTTEN OUT OF THE RESEARCH
7 LEADERSHIP AWARDS TO DATE? IS ANYBODY ACTIVELY
8 ENGAGED IN A CLINICAL TRIAL?

9 DR. YAFFE: NO. THE GOAL OF THE
10 LEADERSHIP AWARDS WAS NOT NECESSARILY TO BRING
11 TRANSLATIONAL SCIENTISTS HERE. THAT'S AMONG THE
12 GOALS. OUR GOALS ARE TO BRING LEADERS IN STEM CELL
13 OR LEADERS AND POTENTIAL LEADERS IN STEM CELL
14 RESEARCH. THERE'S BEEN -- WE HAVE SOME DATA. MANY
15 OF THESE AWARDS HAVE ONLY BEGUN OVER THE LAST YEAR,
16 SO WE DON'T REALLY HAVE OUTPUT DATA ON THOSE. WE
17 KNOW ALREADY THAT MORE THAN 35 NEW SCIENTISTS HAVE
18 COME TO CALIFORNIA WITH THE -- AND POSITIONS HAVE
19 BEEN ESTABLISHED. THERE'S BEEN NEW HIRING. THERE'S
20 BEEN ADDITIONAL GRANTS THAT HAVE BEEN
21 SYNERGISTICALLY OBTAINED BY EARLIEST LEADERSHIP
22 AWARDEES. THERE ARE A NUMBER OF PROMINENT RESEARCH
23 PAPERS THAT HAVE BEEN PUBLISHED BY THOSE AWARDEES
24 UNDER THESE AWARDS, AWARDEES SUCH AS ANDREW MCMAHON
25 WHO NOW HEADS THE STEM CELL PROGRAM AT USC. HIS

BARRISTERS' REPORTING SERVICE

1 RECRUITMENT TO CALIFORNIA, HE TOLD ME, WAS DEPENDENT
2 ON THIS AWARD. HE WOULD NOT HAVE COME FROM HARVARD
3 FROM THE STEM CELL CENTER THERE UNLESS THIS AWARD
4 HAD BEEN PROVIDED.

5 PETER COFFEY AT UC SANTA BARBARA, WHO WAS
6 ONE OF OUR AWARDEES, IS AT THE FOREFRONT OF THE
7 DEVELOPMENT OF TREATMENTS FOR MACULAR DEGENERATION.
8 HE'S INVOLVED WITH OUR TEAM. HE'S ALSO INVOLVED AS
9 A COLLABORATOR WITH THE LONDON TEAM. WE ARE VERY
10 OPTIMISTIC AND HOPEFUL THAT THAT THERAPY AND THAT
11 TRANSLATIONAL PROGRAM WILL MOVE FORWARD RAPIDLY.
12 HE'S DOING REALLY NOVEL AND INNOVATIVE STUDIES ALSO
13 ON OTHER EYE DISEASES.

14 BARRY STRIPP, WHO WAS RECENTLY RECRUITED
15 TO CEDARS-SINAI, IS AMONG THE LEADERS IN LUNG STEM
16 CELL DEVELOPMENT WITH SOME TREMENDOUS EXCITING
17 POTENTIAL COLLABORATIVE PROGRAMS THERE AT CEDARS ON
18 LUNG DISEASE.

19 WE DON'T HAVE COMPREHENSIVE DATA YET
20 BECAUSE MANY OF THESE, PARTICULARLY THE ONES THAT
21 WERE CHOSEN LAST YEAR, ARE JUST SHOWING UP NOW AND
22 GETTING THEIR RESEARCH PROGRAMS ESTABLISHED. THE
23 EARLY INDICATION IS THAT THIS PROGRAM IS
24 PHENOMENALLY SUCCESSFUL IN BRINGING EXCITING
25 RESEARCHERS HERE WHO ARE DRIVING STEM CELL RESEARCH

BARRISTERS' REPORTING SERVICE

1 IN CALIFORNIA.

2 I WANT TO ALSO JUST ADD MY OWN PERSONAL
3 COMMENT, THAT THESE ARE GOING TO BE THE LEADERS TEN
4 YEARS FROM NOW. I REALIZE WE DON'T KNOW WHAT THE
5 STATUS OF OUR AGENCY WILL BE, AND WE'RE ALL
6 CERTAINLY PULLING TOWARDS THOSE TREATMENTS AND CURES
7 FOR DISEASE AND INJURY, BUT WE'RE ALSO LAYING THE
8 FOUNDATION FOR STEM CELL RESEARCH IN CALIFORNIA
9 THAT'S GOING TO GO ON AND ON FOR DECADES. THESE
10 PEOPLE WHO ARE MOSTLY EARLY IN THEIR CAREER ARE
11 GOING TO BE THE ONES WHO ARE AT THE FOREFRONT OF
12 THAT 10, 15, 20 YEARS FROM NOW.

13 MR. SHEEHY: MS. WINOKUR.

14 MS. WINOKUR: THE GRANTS WORKING GROUP
15 REVIEWS THE PROPOSALS IN TERMS OF THE PERSON BEING
16 RECRUITED. AND I HAVE NO ARGUMENT WITH THE QUALITY,
17 ATTRIBUTES, AND POTENTIAL OF THE PEOPLE WHO HAVE
18 BEEN SELECTED. THERE'S ANOTHER SIDE OF THESE
19 GRANTS, HOWEVER, AND THAT IS THE INSTITUTIONAL SIDE.
20 THAT'S NOT APPROPRIATE FOR THE GRANTS WORKING GROUP
21 TO DISCUSS; HOWEVER, WE HAVE DISCUSSED IT HERE. AND
22 SEVERAL POINTS HAVE BEEN BROUGHT UP THAT RAISE
23 SERIOUS QUESTIONS.

24 FOR EXAMPLE, JEFF'S POINT ABOUT IN OUR
25 WHOLE PROGRAM WE'VE NEVER RECRUITED A WOMAN. GIVEN

BARRISTERS' REPORTING SERVICE

1 THE COMPOSITION OF OUR BOARD AND WHAT WE KNOW, THEY
2 HAVE TO EXIST AND BE POTENTIAL. ALSO WE HAVE NO
3 IDEA WHETHER THE PERSON WOULD BE RECRUITED BY THE
4 INSTITUTION IF WE DIDN'T FUND THE RECRUITMENT. AND
5 THESE ARE ALL TROUBLESOME ISSUES. SEVERAL OF THE
6 OTHERS I DIDN'T INCLUDE IN MY DESCRIPTION, BUT THERE
7 ARE SEVERAL, AND THAT'S THE OTHER SIDE OF THIS RFP.

8 MR. SHEEHY: DR. MILLS.

9 DR. MILLS: SO I KIND OF HEAR EVERYTHING
10 THAT'S GOING ON, AND I HEAR THIS SHOULD OR SHOULDN'T
11 WE DO THIS CONCEPT. AND I THINK IT'S THE WRONG
12 QUESTION. SO I AM A REAL SERIOUS BELIEVER AND LOVER
13 IN CLARITY. I LOVE CLARITY OF DIRECTION BECAUSE IT
14 ENDS UP BEING A VERY POWERFUL DRIVER TO GET THINGS
15 DONE. AND PROBABLY THE GREATEST EXAMPLE OR ONE OF
16 THE GREATEST EXAMPLES OF THAT IN HISTORY IS WHEN
17 KENNEDY SAYS EARLY ON IN THE '60S WE'RE GOING TO PUT
18 A MAN ON THE MOON BY THE END OF THE DECADE. IT'S
19 VERY CLEAR. WE KNEW WE WERE GOING TO KNOW IF WE DID
20 OR DIDN'T DO IT. WE KNEW WHERE WE WERE GOING. WE
21 KNEW WHEN WE WERE GOING.

22 AND SO I DON'T THINK -- AND SO IN ORDER TO
23 DO THAT, THE NECESSARY COUNTERPART TO CLEAR
24 DIRECTION IN ORDER TO ACHIEVE YOUR GOAL IS TO BUILD
25 THE RIGHT TEAM IN ORDER TO GET THERE. AND YOU NEED

BARRISTERS' REPORTING SERVICE

1 TO HAVE A GREAT TEAM AND YOU NEED TO HAVE CLEAR
2 DIRECTION. YOU PUT THOSE TWO THINGS TOGETHER AND
3 YOU'RE GOING TO GET WHERE YOU WANT TO GO.

4 THE PROBLEM THAT I SEE WITH THIS IN ITS
5 CURRENT FORM ISN'T ARE WE ATTRACTING PEOPLE INTO THE
6 STATE OF CALIFORNIA. IT'S THAT WE'RE GOING BACK TO
7 THE ROCKET SHIP ANALOGY. WE'RE NOT SAYING, HEY, WE
8 NEED AN ASTRONAUT AND A GUY THAT WORKS ON JET
9 PROPULSION. WE'RE JUST SAYING WE WANT PEOPLE THAT
10 ARE INTERESTED IN SPACE EXPLORATION, AND WE MIGHT
11 HAVE 12 JET PROPULSION GUYS AND NO ASTRONAUT. AND
12 THAT'S THE THING THAT CONCERNS ME HERE IS WE'RE
13 HIRING WITHOUT POSITIONS, WITHOUT SPECIFIC NEEDS
14 THAT ARE COMPLETELY ALIGNED WITH OUR MISSION.

15 SO IF THAT'S FORESHADOWING ON WHAT YOU CAN
16 EXPECT GOING FORWARD, I THINK IT'S NOT THAT I DON'T
17 LIKE THE CONCEPT OF RECRUITING GREAT PEOPLE TO HELP
18 US ADVANCE OUR MISSION. IT'S JUST WE HAVE TO MAKE
19 SURE WE RECRUIT THE PEOPLE WE NEED.

20 MR. SHEEHY: SO HERE WE ARE. WE HAVE
21 DECIDED TO LET THE LOWEST SCORE APPLICATION IN THE
22 FUNDABLE CATEGORY TO REMAIN IN THE FUNDABLE
23 CATEGORY, ASTONISHINGLY WITH A 50 FROM ONE OF THE
24 REVIEWERS WHO OBVIOUSLY WAS NOT AS ENTHUSIASTIC AS
25 STAFF HAS REPORTED, BUT I DON'T -- ASSUMING THAT

BARRISTERS' REPORTING SERVICE

1 PEOPLE WILL CONTINUE TO VOTE THE WAY THAT THEY
2 VOTED, I DON'T KNOW, UNLESS SOMEONE -- DO WE WANT TO
3 HAVE A MOTION ON THE NEXT -- DO YOU INTEND TO
4 CONTINUE TO MAKE YOUR MOTIONS, DR. PRIETO? IT'S
5 FINE IF YOU'D LIKE TO.

6 DR. PRIETO: I THINK I'LL LEAVE THIS TO
7 SOMEONE ELSE TO MAKE A MOTION ON THE FIRST TWO.

8 DR. JUELSGAARD: I'LL MAKE A DIFFERENT
9 MOTION. I MOVE THAT WE APPROVE FOR FUNDING ALL OF
10 THE PROJECTS THAT ARE TIER I AND WE'LL MOVE ON.

11 MR. SHEEHY: SO...

12 DR. STEWARD: JUST POINT OF ORDER. I
13 THINK WE DO NEED TO AT LEAST ENTERTAIN WHETHER OR
14 NOT THERE'S A MOTION TO MOVE PROJECTS UP INTO TIER I
15 FROM BELOW.

16 MR. SHEEHY: EXACTLY. I WAS LOOKING TO
17 COUNSEL TO FIGURE OUT HOW WE MOVE OUR WAY THROUGH
18 THIS SPACE. BEFORE WE TAKE MR. JUELSGAARD'S, WE
19 SHOULD TAKE THE ORDER -- MOVE UP.

20 MR. HARRISON: GENERALLY, AS YOU
21 INDICATED, JEFF, WE TRY TO START WITH ASKING FOR
22 MOTIONS TO REMOVE ITEMS FROM TIER I, AND THEN WE ASK
23 FOR MOTIONS TO MOVE THINGS INTO TIER I SO THAT WE
24 CAN THEN TAKE A FINAL VOTE ON WHAT'S IN TIER I.

25 DR. JUELSGAARD: I WITHDRAW MY MOTION.

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: SO DO WE HAVE ANY MOTIONS TO
2 MOVE ANY OF THE APPLICATIONS IN TIER II INTO TIER I?

3 DR. BRYANT: COULD I ASK A QUESTION ABOUT
4 ONE OF THE ONES IN TIER II?

5 MR. SHEEHY: SURE.

6 DR. BRYANT: DO WE HAVE -- WELL, JUST THE
7 GENERAL AREA. ARE WE ALREADY FUNDING MUSCLE CELL
8 REGENERATION IN HUMANS OR NOT IN A DIFFERENT WAY?

9 DR. YAFFE: YES, WE ARE. WE'RE FUNDING
10 DR. HELEN BLAU AT STANFORD UNIVERSITY AND TOM RANDO.
11 WE HAVE ALSO FUNDED SEVERAL OTHERS.

12 MR. PANETTA: SO IN LIGHT OF THE
13 DISCUSSION WE HAD ABOUT WHETHER IT'S APPROPRIATE TO
14 MOVE FORWARD WITH THIS CONCEPT IN THE FUTURE, THIS
15 WAS APPROVED FOR FUNDING OF UP TO FOUR ADDITIONAL
16 AWARDS. AND SO I'M ASSUMING THAT IF WE APPROVE
17 THREE, WE'RE DONE WITH THIS CYCLE; IS THAT CORRECT?

18 MR. SHEEHY: WELL, WE WOULD HAVE TO
19 APPROVE A NEW CONCEPT PLAN TO BE ABLE TO FUND ANY
20 MORE.

21 MR. PANETTA: THANK YOU.

22 MR. SHEEHY: SO WOULD YOU LIKE TO MAKE
23 YOUR MOTION NOW, MR. JUELGAARD? I THINK THE
24 APPROPRIATE FORM WOULD BE TO FUND EVERYTHING IN TIER
25 I AND NOT TO FUND ANY OF THE APPLICATIONS IN TIER

BARRISTERS' REPORTING SERVICE

1 II.

2 DR. JUELSGAARD: I MOVE THAT WE FUND ALL
3 APPLICATIONS THAT ARE TIER I AND NOT FUND ANY
4 APPLICATIONS THAT ARE IN TIER II.

5 MR. SHEEHY: AND THEN FOR A SECOND, I
6 THINK WE NEED A SECOND WHO DOES NOT HAVE A CONFLICT.

7 MR. PANETTA: I'LL SECOND IT.

8 MR. SHEEHY: MR. PANETTA. HAVE I DONE
9 THAT RIGHT? THANK YOU. SO DO WE HAVE ANY PUBLIC
10 COMMENT?

11 DR. NOLTA: THIS IS ABOUT NO. 8012. THANK
12 YOU VERY MUCH FOR CONSIDERING THE LARGER PICTURE
13 THAT THIS CANDIDATE COULD BRING TO CALIFORNIA.
14 AFTER THE DISCUSSION THIS MORNING, I FEEL THAT THIS
15 IS VERY RELEVANT. WE'RE PASSIONATE ABOUT OUR CHOSEN
16 CANDIDATE.

17 WE HAVE A COUPLE OF IMPORTANT PERSPECTIVES
18 FOR THE BOARD TO PLEASE CONSIDER IN THREE MINUTES.
19 MOST IMPORTANTLY, OUR CANDIDATE WOULD BRING TO
20 CALIFORNIA A SIGNIFICANT LEVEL OF EXPERTISE IN
21 BRIDGING THE GAP BETWEEN ACADEMIA AND INDUSTRY. HIS
22 RESEARCH HAS ALREADY ENABLED SEVERAL OF HIS INDUSTRY
23 PARTNERS TO SUCCESSFULLY OBTAIN FDA APPROVAL FOR
24 THEIR FIRST-IN-HUMAN CLINICAL TRIALS OF STEM CELL
25 THERAPY.

BARRISTERS' REPORTING SERVICE

1 AS THE BOARD MAY KNOW, UC DAVIS HAS A
2 LARGE STEM CELL PROGRAM. OUR FOCUS IS ON
3 TRANSLATIONAL MEDICINE AND NOVEL CLINICAL TRIALS.
4 WE'VE HAD TEN STEM CELL AND REGENERATIVE MEDICINE
5 CLINICAL TRIALS CURRENTLY ONGOING OR RECENTLY
6 COMPLETED, AND WE HAVE ANOTHER 18 IN THE PIPELINE,
7 AND FIVE OF THOSE ARE CIRM-FUNDED. THANK YOU SO
8 MUCH FOR THOSE.

9 OUR FOCUS IS ON TEAMWORK AND PROVIDING A
10 SERVICE ROLE FOR OTHER INVESTIGATORS THROUGHOUT THE
11 STATE. AN IMPORTANT PART OF THIS MISSION IS TO WORK
12 CLOSELY WITH OUR NUMEROUS INDUSTRY PARTNERS TO
13 PROVIDE IND-ENABLING STUDIES AND GMP MANUFACTURING
14 ON BOTH COLLABORATIVE AND A FEE FOR SERVICE BASIS AT
15 VERY REASONABLE RATES.

16 AND AFTER SEVERAL YEARS OF SEARCHING
17 INTERNATIONALLY, OUR CANDIDATE WAS CHOSEN AS THE
18 BEST PERSON TO HELP US PROVIDE THESE SERVICES TO THE
19 STATE OF CALIFORNIA AND TO ACCELERATE THE
20 DEVELOPMENT OF NOVEL THERAPIES. HE'S ALREADY SHOWN
21 EXTENSIVE LEADERSHIP ABILITIES. WE'VE ATTACHED A
22 LIST TO OUR COMMUNICATION TO THE BOARD THAT DIDN'T
23 FIT WITHIN THE SHORT BIOSKETCH FORM ALLOWED BY THE
24 RFA. AND IMPORTANTLY, HE WAS THE RECIPIENT OF THE
25 MCDONALD SCHOLARSHIP LEADERSHIP AWARD ISSUED BY THE

BARRISTERS' REPORTING SERVICE

1 HEART AND STROKE FOUNDATION OF CANADA. AND THIS IS
2 AWARDED TO THE TOP NEW INVESTIGATOR IN CANADA.

3 SO IN SUMMARY, THROUGH OUR EXTENSIVE
4 ANALYSIS OF POTENTIAL CANDIDATES OVER THE PAST FEW
5 YEARS, THIS INVESTIGATOR STOOD OUT AS TRULY
6 EXCEEDING THE CRITERIA FOR THE AWARD AS AN
7 OUTSTANDING LEADER, TRANSLATIONAL SCIENTIST,
8 COLLABORATOR, MENTOR, AND COMMUNITY PARTICIPANT.
9 THIS IS A VERY UNIQUE SKILL SET AND I BELIEVE WHAT
10 WE NEED. WE'RE EAGER TO BRING HIS VAST KNOWLEDGE,
11 EXPERTISE, AND ENTHUSIASM TO THE STATE OF CALIFORNIA
12 TO ENHANCE THE PACE OF CLINICAL TRIAL DEVELOPMENT.

13 AND, AGAIN, THANK YOU FOR CONSIDERING THIS
14 CANDIDATE.

15 MS. PARSONS: HI. I'M XUEJUN PARSONS.
16 I'M THE FOUNDER OF THE SAN DIEGO REGENERATIVE
17 MEDICINE INSTITUTE AND A COMPANY CALLED XCEL THERA,
18 INC. WE'RE ONE OF THE FIRST COMPANIES FORMED IN
19 CALIFORNIA TO TRANSLATE HUMAN EMBRYONIC STEM CELL
20 RESEARCH. WE ACTUALLY HAVE CIRM GRANT REVIEW
21 PROCESS, WE HAVE EXTREMELY DIFFICULT TO GET FUNDING
22 FROM CIRM. WE ACTUALLY GOT A GRANT REVIEW COMMENTS
23 SAY HUMAN ES CELL IS NOT TRANSLATABLE CELLS. AND I
24 HAVE NO COMMERCIAL (UNINTELLIGIBLE). WE COULD NOT
25 EVEN PASS THROUGH THE PREAPPLICATION.

BARRISTERS' REPORTING SERVICE

1 I MEAN WE UNDERSTAND CIRM IS FUNDED BY
2 PROPOSITION 71 WHICH IS SUPPOSED TO HUMAN EMBRYONIC
3 STEM CELL RESEARCH. WE ACTUALLY IS THE FIRST
4 COMPANY TO COMMERCIALIZE A HUMAN ES CELL FOR HEART
5 DISEASE AND NEUROLOGIC DISEASE.

6 I'M HERE TO ASK THE QUESTION. I ACTUALLY
7 ASK THE SAME QUESTION A FEW YEARS AGO. I HOPE BOARD
8 MEMBERS REMEMBER. I WONDER THE LEADERSHIP AWARD,
9 WHY THE LEADERSHIP AWARD RECRUIT ANY SCIENTIST IN
10 CALIFORNIA BECAUSE PROPOSITION 71 SUPPOSED TO
11 BE -- IS PASSED IN CALIFORNIA. WHY NOT SUPPORT ANY
12 LEADER IN CALIFORNIA AND ONLY LIKE DISCRIMINATED US.
13 YOU ACTUALLY HAD TO BE OUT-OF-STATE TO GET THOSE
14 KIND OF SUPPORT.

15 A QUESTION ALSO. I LOOK AT YOUR TIER I.
16 I THINK TWO OF THE CANDIDATE ACTUALLY HAVE NOT DONE
17 ANY STEM CELL RESEARCH. I'M SURE THE PERSON WAS SAY
18 HE WAS ACCOMPLISHING THE PLURIPOTENT STEM CELL
19 PROGENITOR SYSTEM. MAYBE IT'S BETTER TO AT LEAST
20 ACCOMPLISH WE CAN SAY BECAUSE WE DON'T EVEN SAY
21 ANYTHING.

22 MR. SHEEHY: THANK YOU.

23 DR. VAIL: THANK YOU, LADIES AND
24 GENTLEMEN, MEMBERS OF CIRM AND THE ICOC. MY NAME IS
25 THOMAS VAIL. I'M CHAIRMAN OF THE DEPARTMENT OF

BARRISTERS' REPORTING SERVICE

1 ORTHOPEDIC SURGERY AT UCSF. I THANK YOU FOR THE
2 OPPORTUNITY TO MAKE A FEW SIMPLE POINTS ADDRESSING
3 THE COMPELLING PROGRAMMATIC REASONS FOR THE
4 LEADERSHIP AWARD ENTITLED "REJUVENATION OF HUMAN
5 SKELETAL MUSCLE STEM CELL FUNCTION DURING AGING,
6 INJURY, AND DISEASE."

7 THIS PROPOSAL TARGETS REPAIR AND
8 REGENERATION OF MUSCLE THAT COULD IMPACT A MYRIAD OF
9 MUSCULOSKELETAL DISORDERS, INCLUDING TRAUMATIC
10 INJURY, CHILDHOOD MUSCLE DYSTROPHY, AND MUSCLE
11 WASTING. MUSCULOSKELETAL DISORDERS AND DISEASES ARE
12 THE MOST COMMON HEALTH CONDITIONS IN CALIFORNIA AND
13 THE UNITED STATES. THEY ARE A LEADING CAUSE OF
14 DISABILITY AND AFFECT ALL AGE GROUPS, CHILDREN AND
15 ADULTS, ACCOUNT FOR MORE THAN HALF OF ALL CHRONIC
16 CONDITIONS IN PEOPLE OVER THE AGE OF 50. THE TOTAL
17 DIRECT EXPENDITURES FOR MUSCULOSKELETAL CONDITIONS
18 HAVE BEEN ESTIMATED TO BE CLOSE TO A TRILLION
19 DOLLARS OR ABOUT 7 PERCENT OF THE GDP. YET, IN
20 SPITE OF THE EVER GROWING POPULATION OF PATIENTS
21 SUFFERING WITH MUSCULOSKELETAL CONDITIONS,
22 COMPARATIVELY FEW RESEARCH DOLLARS HAVE BEEN
23 ALLOCATED FOR MUSCULOSKELETAL DISORDERS IN
24 CALIFORNIA.

25 CIRM HAS FUNDED 29 OUT OF 621

BARRISTERS' REPORTING SERVICE

1 MUSCULOSKELETAL APPLICATIONS. THIS REPRESENTS ABOUT
2 4 PERCENT OF THE TOTAL DOLLARS AWARDED BY CIRM.
3 APPLICANTS WORKING SPECIFICALLY IN THE AREA OF
4 MUSCULAR DYSTROPHY, AROUND 1 PERCENT, AND SKELETAL
5 MUSCLE, WHICH OUR CANDIDATE'S SPECIFIC AREA OF
6 EXPERTISE LIES, IS LESS THAN ONE-HALF OF 1 PERCENT
7 OF THE TOTAL. NONE OF THE LEADERSHIP AWARDS HAVE
8 GONE IN THIS DIRECTION SPECIFICALLY.

9 REGARDING THE CANDIDATE, UCSF PLACES THE
10 HIGHEST PRIORITY ON IDENTIFYING AND HIRING
11 EXCEPTIONALLY PROMISING SCIENTISTS. OUR CANDIDATE'S
12 TRAINING AND CAREER TRAJECTORY SEEMED TO FIT
13 PERFECTLY WITH THE GOALS OF THE CIRM LEADERSHIP
14 AWARD. THIS IS A PROMINENT, MIDCAREER, TENURED
15 FACULTY MEMBER IN ONE OF THE NATION'S LEADING STEM
16 CELL INSTITUTES WHO LOOKS AT CELL FATE DECISIONS OF
17 ADULT MUSCLE STEM CELLS OF ACUTE INTEREST TO
18 CLINICIANS IN A DEPARTMENT OF ORTHOPEDIC SURGERY AND
19 THEIR PATIENTS.

20 THERE SHOULD NOT BE ANY CONCERN ABOUT THE
21 COMMITMENT OF UCSF TO THE CANDIDATE. COMBINING
22 COMMITMENTS FROM THE SCHOOL OF MEDICINE AND THE
23 DEPARTMENT OF ORTHOPEDIC SURGERY, OUR CANDIDATE WILL
24 HAVE SUBSTANTIAL ONGOING RESOURCES BEYOND THE
25 LEADERSHIP AWARD, TOTALING APPROXIMATELY \$6 MILLION,

BARRISTERS' REPORTING SERVICE

1 INCLUDING A MILLION DOLLARS FOR DISCRETIONARY
2 FUNDING FOR PROGRAM DEVELOPMENT, A PERMANENT
3 SPONSORED FTE FOR SALARY SUPPORT, SPACE IN THE
4 STATE-OF-THE-ART REGENERATION MEDICAL BUILDING, AND
5 A CAMPUSWIDE LEADERSHIP POSITION AS DIRECTOR OF
6 TRANSLATIONAL MUSCULOSKELETAL BIOLOGY.

7 SO IN THIS WAY THIS CANDIDATE WILL BE A
8 NUCLEATING PRESENCE FOR DISCOVERY AND TRANSLATION OF
9 MUSCLE AND MUSCULOSKELETAL BIOLOGY, INTERFACE WITH
10 CLINICIANS AND SCIENTISTS AND TRAINEES IN VARIOUS
11 PROGRAMS ON OUR CAMPUS AND OTHER INSTITUTIONS.
12 OVERALL WE ARE CERTAIN THAT THIS CANDIDATE IS AN
13 EXCEPTIONAL AND HIGHLY VISIBLE APPLICANT. HIS
14 RESEARCH IS CLOSELY ALIGNED WITH THE MISSION OF
15 CIRM, ADDRESSES AN UNMET NEED, AND THIS CANDIDATE
16 HAS THE HORSEPOWER TO USE STEM CELLS AND
17 REGENERATIVE MEDICINE TO RELIEVE HUMAN SUFFERING AND
18 DEBILITATING INJURY TO MUSCLE. THANK YOU.

19 DR. KRIEGSTEIN: MY NAME IS DR. ARNOLD
20 KRIEGSTEIN. I'M THE DIRECTOR OF THE STEM CELL
21 PROGRAM AT UCSF, AND I'D ALSO LIKE TO COMMENT ON THE
22 SAME PROPOSAL. AS MANY OF YOU KNOW, THE PROGRAM AT
23 UCSF IN STEM CELLS HAS OVER 70 PARTICIPATING
24 LABORATORIES. IT MAKES IT ONE OF THE LARGEST IN THE
25 STATE, INDEED IN THE COUNTRY. AND YET WE DON'T HAVE

BARRISTERS' REPORTING SERVICE

1 ANYONE WITH THE EXPERTISE OF THIS PARTICULAR
2 CANDIDATE ON OUR FACULTY.

3 WE INTEND TO EMBED THIS INVESTIGATOR INTO
4 A CLUSTER OF OTHER SCIENTISTS WITH COMPLEMENTARY
5 AREAS OF EXPERTISE WORKING IN STEM CELL TISSUE
6 ENGINEERING, BONE AND CARTILAGE DIFFERENTIATION,
7 MESENCHYMAL TISSUE REGENERATION. THE CAMPUS WE HAVE
8 IN MIND IS ON THE PARNASSUS SITE. AS MANY OF YOU
9 KNOW, THAT'S WHERE OUR CLINIC IS. THAT'S WHERE THE
10 HOSPITALS ARE. THAT'S ALSO WHERE THE CLINICAL
11 TRANSLATIONAL SCIENCE IS INSTITUTED, THE NIH-FUNDED
12 STSI IS LOCATED. AND WE FULLY INTEND THAT THIS
13 CANDIDATE WOULD HELP INTEGRATE CLINICAL AND
14 TRANSLATIONAL ACTIVITIES AS YOU JUST HEARD FROM OUR
15 CHAIR OF ORTHOPEDIC SURGERY.

16 AND WITH THE OPENING OF THE NEW BENIOFF
17 CHILDREN'S HOSPITAL AT UCSF, THERE WILL BE AN
18 INCREASING PROMINENCE OF MUSCULAR DYSTROPHIES. AND
19 THIS IS ANOTHER AREA WHERE WE HAVE ENORMOUS CLINICAL
20 EXPERTISE AND ARE LOOKING TO SEED, BLEND THAT WITH A
21 SYNERGIZED RESEARCH PROGRAM.

22 PERHAPS I COULD MENTION THAT WHEN I FIRST
23 MOVED TO CALIFORNIA FROM NEW YORK, OUR NEXT DOOR
24 NEIGHBOR HAD A LOVELY CHILD, A BOY, WHO WASN'T ABLE
25 TO SIT UP AND WASN'T ABLE TO WALK, AND IT TURNED OUT

BARRISTERS' REPORTING SERVICE

1 THAT HE WAS DIAGNOSED WITH MUSCULAR DYSTROPHY. THEY
2 EVENTUALLY MOVED AWAY, AND NOW THEY'RE BUILDING A
3 HOUSE WITH RAMPS TO MANAGE TO ACCOMMODATE HIS
4 WHEELCHAIR. BUT WHEN HE LEARNED THAT I WAS A STEM
5 CELL DIRECTOR, HE, OF COURSE, ASKED ME IF THERE WAS
6 HOPE FOR STEM CELL THERAPY TO HELP A PATIENT LIKE
7 HIS SON. AND I GAVE HIM MY USUAL ANSWER, WHICH IS
8 NOT YET, BUT WE AND OTHERS ARE WORKING HARD FOR THE
9 DAY WHEN WE WILL HAVE SOMETHING TO OFFER.

10 AND I HAVE TO SAY, AT LEAST WITH THIS
11 CANDIDATE RIGHT NOW, THAT RECRUITING THIS PERSON
12 WOULD REALLY PUT MUSCULOSKELETAL DISEASE SQUARELY ON
13 THE STEM CELL AGENDA FOR CALIFORNIA, FOR CIRM, AND
14 CERTAINLY FOR CHILDREN LIKE HIM. SO THANK YOU FOR
15 THE OPPORTUNITY TO MAKE THIS STATEMENT.

16 MR. SHEEHY: THANK YOU. SO ANY FURTHER
17 BOARD DISCUSSION OR ANYTHING, OR SHOULD WE JUST GO
18 STRAIGHT TO THE VOTE? AND THEN COULD COUNSEL
19 PERHAPS INFORM US AS TO HOW WE SHOULD VOTE. NOT HOW
20 WE SHOULD VOTE.

21 DR. PRIETO: IN WHAT MANNER?

22 MR. SHEEHY: THE FORMULA.

23 MR. HARRISON: JUST AS A REMINDER, THE
24 MOTION IS TO FUND THE RESEARCH LEADERSHIP
25 APPLICATIONS IN TIER I AND NOT TO FUND THE REMAINING

BARRISTERS' REPORTING SERVICE

1 APPLICATIONS. FOR THOSE ON THE APPLICATION REVIEW
2 SUBCOMMITTEE, TO THE EXTENT THAT YOU HAVE A CONFLICT
3 WITH RESPECT TO ONE OF THE APPLICATIONS, YOU SHOULD
4 VOTE YES OR NO EXCEPT WITH RESPECT TO THOSE
5 APPLICATIONS OR APPLICATION IN WHICH YOU HAVE A
6 CONFLICT.

7 DR. PRIETO: JUST TO BE CLEAR, A YES VOTE
8 HERE IS A VOTE TO FUND.

9 MR. SHEEHY: TO FUND THE ONES IN TIER I
10 AND NOT TO FUND THE ONES IN TIER II.

11 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

12 DR. DULIEGE: AYE.

13 MS. BONNEVILLE: STEVE JUELSGAARD.

14 DR. JUELSGAARD: YES.

15 MS. BONNEVILLE: JOE PANETTA.

16 MR. PANETTA: YES.

17 MS. BONNEVILLE: FRANCIS PRIETO.

18 DR. PRIETO: NO.

19 MR. HARRISON: DR. PRIETO, EXCEPT FOR
20 THOSE --

21 DR. PRIETO: I'M SORRY. NO, EXCEPT FOR
22 THOSE FOR WHICH I HAVE A CONFLICT.

23 MS. BONNEVILLE: JEFF SHEEHY.

24 MR. SHEEHY: NO EXCEPT FOR THOSE WITH
25 WHICH I HAVE A CONFLICT.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: OS STEWARD.

2 DR. STEWARD: YES.

3 MS. BONNEVILLE: JONATHAN THOMAS.

4 CHAIRMAN THOMAS: YES.

5 MS. BONNEVILLE: ART TORRES.

6 MR. TORRES: AYE.

7 MS. BONNEVILLE: DIANE WINOKUR.

8 MS. WINOKUR: ABSTAIN.

9 MR. HARRISON: MOTION CARRIES WITH SIX YES
10 VOTES, TWO NO VOTES, AND ONE ABSTENTION.

11 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
12 MUCH, MR. SHEEHY, FOR DIRECTING PROGRAMMATIC REVIEW.
13 WE'RE GOING TO TAKE A BREAK NOW TO GIVE OUR --

14 DR. YAFFE: I WANTED TO PUT UP A SLIDE
15 WITH THE NAMES OF THE PEOPLE YOU JUST APPROVED
16 BECAUSE THOSE NAMES HAVEN'T BEEN REVEALED BEFORE TO
17 THE PUBLIC.

18 CHAIRMAN THOMAS: THANK YOU, DR. YAFFE.

19 DR. YAFFE: THEY ARE DR. TODD MCDEVITT
20 GOING TO THE GLADSTONE INSTITUTE. HE'S ALSO BEEN A
21 LONG-STANDING MEMBER OF OUR GRANTS WORKING GROUP.
22 DR. JOHN CHUTT GOING TO UC LOS ANGELES, AND
23 DR. XAVIER DARZACQ TO UC BERKELEY.

24 CHAIRMAN THOMAS: THANK YOU, DR. YAFFE.
25 WE'RE GOING TO TAKE A BREAK NOW TO GIVE OUR

BARRISTERS' REPORTING SERVICE

1 STENOGRAPHER HERE A CHANCE TO REST HER WELL WORN
2 FINGERS. CONVENE BACK IN TEN MINUTES OR SO. THANK
3 YOU.

4 (A RECESS WAS TAKEN.)

5 CHAIRMAN THOMAS: WE ARE -- WE'RE GOING TO
6 DO SOMETHING A BIT OUT OF ORDER. WE HAVE A NUMBER
7 OF FOLKS HERE WHO WANTED TO SPEAK IN PUBLIC COMMENT
8 WHO I THINK IT WOULD BENEFIT THEM IF THEY COULD
9 SPEAK SOONER RATHER THAN LATER AND HAVING TO WAIT
10 AROUND TILL THE END OF THE MEETING. SO WE'RE GOING
11 TO DO THE FINAL PUBLIC COMMENT RIGHT NOW. I KNOW,
12 DR. LORING, YOU HAVE SOME FOLKS HERE WHO WOULD LIKE
13 TO SPEAK TO THE BOARD.

14 DR. LORING: THANK YOU VERY, VERY MUCH,
15 DR. THOMAS. I'M JEANNE LORING. AND WITH MELISSA
16 HOUSER, WHO I'M JUST ABOUT TO INTRODUCE, WE HAVE
17 WITH PHILANTHROPIC FUNDS INITIATED A PRECLINICAL
18 RESEARCH FOR AN AUTOLOGOUS INDUCED PLURIPOTENT STEM
19 CELL-DERIVED THERAPY FOR PARKINSON'S DISEASE. WE'VE
20 IDENTIFIED EIGHT PATIENTS, SOME OF WHOM ARE HERE
21 TODAY. AND WE'VE TAKEN THEIR SKIN CELLS, WE'VE
22 REPROGRAMMED THEM, AND WE'VE TURNED THEM INTO
23 DOPAMINERGIC NEURONS. WE'VE ALSO SHOWN THAT THESE
24 DOPAMINERGIC NEURONS ARE EFFECTIVE IN A RAT MODEL.
25 SO I'D LIKE TO INTRODUCE MELISSA WHO WILL

BARRISTERS' REPORTING SERVICE

1 INTRODUCE HER PATIENTS.

2 DR. HOUSER: THANK YOU SO MUCH FOR
3 ALTERING THE AGENDA FOR MY PATIENTS. THEY HAVE BEEN
4 HERE, MOST OF THEM, SINCE 9 O'CLOCK AND MAYBE NEED
5 TO GO. SO I REALLY APPRECIATE IT.

6 I AM THE DIRECTOR OF THE PARKINSON'S
7 DISEASE AND MOVEMENT DISORDER CENTER AT SCRIPPS
8 CLINIC RIGHT HERE IN LA JOLLA, AND THESE ARE MY
9 PATIENTS. AND THIS HAS BEEN THE MOST PHENOMENAL
10 PROJECT THAT I'VE EVER SEEN. VERY REVERSE, VERY
11 INTERESTING THE WAY THIS PROJECT WAS FUNDED AS HOW
12 IT'S COME TO FRUITION, AND I'D LIKE THEM TO TELL YOU
13 A LITTLE BIT MORE ABOUT IT. THANK YOU.

14 MS. PETERS: HELLO. MY NAME IS CASSANDRA
15 PETERS. I'M ONE OF DR. HOUSER'S PATIENTS. AND I'VE
16 HAD PARKINSON'S DISEASE NOW FOR CLOSE TO 15 YEARS.
17 TIME IS OF THE ESSENCE FOR THIS PARTICULAR DISEASE
18 AND THIS PROJECT. WE HAVE EVERYTHING THAT YOU NEED,
19 THAT YOU STATE IN YOUR MISSION STATEMENT THAT THAT
20 IS YOUR PURPOSE. THIS PROJECT IS NOT PIE IN THE
21 SKY. THE SCIENCE IS VERY WELL PROVEN. THE NOBEL
22 COMMITTEE AWARDED DR. YAMANAKA, THE INVENTOR OF THIS
23 PARTICULAR SCIENCE, THE NOBEL PRIZE FOR MEDICINE IN
24 2012. THAT RIGHT THERE SHOULD SPEAK VOLUMES.

25 BUT I WANT TO THANK YOU ALL FOR STAYING ON

BARRISTERS' REPORTING SERVICE

1 TRACK AND ALLOWING OUR PROJECT TO BE HEARD, TO BE
2 RECOGNIZED, AND HOPEFULLY MAKE IT HAPPEN FOR US.
3 THANK YOU VERY MUCH.

4 MR. WITMER: HI. MY NAME IS CHRIS WITMER.
5 I APOLOGIZE AHEAD OF TIME IF I STAMMER. ONE OF THE
6 LESS TALKED ABOUT SIDE EFFECTS OF PARKINSON'S IS THE
7 INABILITY TO HIDE THE FACT THAT YOU'RE NERVOUS.

8 IN 2007 I WAS DIAGNOSED WITH PARKINSON'S.
9 I'M PROUD FATHER OF TWO. I HAVE A GREAT FAMILY. I
10 WAS DEVASTATED NOT SO MUCH FOR MYSELF BUT WHAT THE
11 FACT MEANT FOR MY FAMILY. THE THOUGHT THAT I
12 WOULDN'T BE ABLE TO DO THE THINGS THAT MOST FATHERS
13 DO WITH THEIR CHILDREN, NOT TO SEE MY DAUGHTER OR
14 WALK MY DAUGHTER DOWN THE AISLE AT HER MARRIAGE, NOT
15 TO EVENTUALLY BE A GRANDFATHER.

16 TO DATE THE TREATMENTS AVAILABLE TO ME
17 TREAT MY SYMPTOMS, BUT DO NOTHING TO REDUCE THE
18 PROGRESS OF THE DISEASE. THEN I MET DR. MELISSA
19 HOUSER AND SHERRIE GOULD. I BECAME FAMILIAR WITH
20 THEIR STEM CELL PROJECT. I WAS AMAZED AT THE
21 SCIENCE AND THE APPLICATION OF THAT SCIENCE TO THIS
22 DISEASE. I SHOULD SAY THE LOGICAL APPLICATION OF
23 THAT SCIENCE TO THIS DISEASE.

24 I'M A CAUTIOUS MAN BY NATURE. I VALUE THE
25 TIME I HAVE LEFT WITH MY FAMILY. I WOULD NOT RISK

BARRISTERS' REPORTING SERVICE

1 THAT TIME ON SOMETHING THAT I THOUGHT HAD A LOW
2 PROBABILITY OF SUCCESS. I BELIEVE THIS IS THE
3 FUTURE FOR THE TREATMENT OF PARKINSON'S AND MANY
4 DISORDERS LIKE IT.

5 WITH THAT IN MIND, I WANT TO ASK YOU, YOU
6 KNOW, THIS MIGHT BE AN OPPORTUNITY FOR YOU. SO MANY
7 HAVE DONE SO MUCH TO BRING THIS PROJECT THIS FAR.
8 THIS IS NOT THEORY OR CONJECTURE, BUT ACTUAL APPLIED
9 SCIENCE TODAY. THERE ARE TENS OF THOUSANDS OF
10 FATHERS, MOTHERS, GRANDFATHERS, AND THEIR CHILDREN
11 THAT YOU ARE IN A POSITION TO HELP BENEFIT. I
12 INVITE EACH OF YOU TO FAMILIARIZE YOURSELF WITH THIS
13 RESEARCH. COME TO THE LAB AND SEE FOR YOURSELF. IF
14 YOU SAW FIRSTHAND THE THINGS THAT WERE HAPPENING
15 THERE, YOU WOULD SUPPORT THIS PROJECT WITHOUT
16 RESERVATION.

17 I WANT THANK YOU FOR THE OPPORTUNITY TO
18 SPEAK. AND FROM ALL OF US SUFFERING FROM
19 PARKINSON'S AND MANY OTHER DISORDERS, I APPRECIATE
20 YOUR TIME AND HOPE TO GET YOUR SUPPORT IN THE
21 FUTURE. THANK YOU.

22 MR. REYES: GOOD AFTERNOON. MY NAME IS
23 PHIL REYES. I'M 52 YEARS OLD AND I WAS BORN IN SAN
24 DIEGO. I HAVE A BEAUTIFUL WIFE AND THREE HANDSOME
25 SONS. THEIR AGES ARE 20, 19, AND 9. I AM AN

BARRISTERS' REPORTING SERVICE

1 ARCHITECT, AND UNTIL NOW I HAVE BEEN RELUCTANT TO
2 SPEAK OUT ABOUT MY PARKINSON'S DISEASE. I DIDN'T
3 WANT TO BE KNOWN AS A SHAKY ARCHITECT.

4 BUT SERIOUSLY, THIS PROJECT IS GETTING SO
5 CLOSE TO FINDING SUCCESS AND A CURE, THAT I CAN'T
6 KEEP IT A SECRET ANYMORE.

7 I WAS DIAGNOSED IN AUGUST OF 2010.
8 ALTHOUGH MY SYMPTOMS MAY NOT BE ALL TOO APPARENT
9 NOW, I'M SHAKING, THE DRUGS ARE GOOD NOW. THEY
10 WON'T MAINTAIN THEIR EFFECTIVENESS FOREVER AND IN
11 THE END THE DISEASE PREVAILS. PARKINSON'S HAS
12 AFFECTED MY ABILITY TO WORK. AT 52 YEARS OLD I
13 SHOULD BE REACHING MY PRIME. ARCHITECTS USUALLY GET
14 THEIR PROJECTS IN THEIR '50S. UNFORTUNATELY I'M NOT
15 ABLE TO KEEP THE AMOUNT OF WORKLOAD THAT I ONCE DID,
16 AND I'M NOT ABLE TO HANDLE THE COMPLEXITIES OF
17 MULTIPLE PROJECTS AT ONE TIME. I OFTEN STRUGGLE
18 WITH THE UNSTEADY HAND AND DOING SIMPLE THINGS LIKE
19 ROLLING UP A SET OF DRAWINGS.

20 I FEEL QUITE FORTUNATE TO HAVE BEEN
21 SELECTED TO BE A PART OF THE SUMMIT4STEMCELL PROJECT
22 TO CURE PARKINSON'S. I KNOW THAT BIOTECHNOLOGY AND
23 CELL THERAPY HAS ADVANCED TO THIS POINT WHERE MY OWN
24 SKIN CELLS CAN BE TRANSFORMED INTO DOPAMINE
25 PRODUCING NEURONS THAT CAN BE PLACED IN THE DOPAMINE

BARRISTERS' REPORTING SERVICE

1 PRODUCING MOTOR CENTER OF MY BRAIN AND SUPPLY MY
2 BODY ONCE AGAIN WITH THE DOPAMINE THAT IS MISSING IS
3 TRULY AMAZING. THIS BRINGS NEW VALUE TO YOUR SKIN.
4 YOU SHOULD THINK TWICE ABOUT ITCHING YOUR SKIN.
5 THAT SKIN CELL COULD BECOME YOUR REPLACEMENT KNEE
6 CARTILAGE, HEART, KIDNEY, NOSE, OR EAR. IT SOUNDS
7 LIKE SCIENCE FICTION, BUT THIS IS OUR NEXT GREAT
8 MEDICAL ADVANCEMENT IN THE HUMAN EXPERIENCE.

9 I AM EXCITED TO THINK THAT MY GROSS FINE
10 AND MOTOR SKILLS BRAIN POWER AND GENERAL ABILITIES
11 TO MOVE AND TALK SMOOTHLY WILL RETURN. IT WILL BE
12 SUCH A GIFT, YOU HAVE NO IDEA. BUT I'M ALSO SCARED,
13 SCARED BECAUSE IT MEANS BRAIN SURGERY. WHO REALLY
14 IS LOOKING FORWARD TO THAT? JUST YESTERDAY MY SON
15 NOAH, 9 YEARS OLD, ASKED, "WHEN'S PAPA GOING TO GET
16 HIS STEM CELL THERAPY?" SURGERY THAT IS. HE'S
17 HOPEFUL FOR MY RETURN TO NORMAL. HE NEEDS ME TO BE
18 ACTIVE AND TO KEEP UP WITH HIM. MY TWO OLDER SONS
19 NEED ME TO BE PRODUCTIVE AS WELL TO KEEP PLUGGING
20 AWAY TO PAY THEIR COLLEGE BILLS AND TO KEEP STRIVING
21 FOR THAT ONE GREAT PROJECT.

22 I THINK THE HARDEST HIT IN MY FAMILY WAS
23 MY WIFE. IT TOOK A LOT OF SOUL SEARCHING TO ACCEPT
24 THE PARKINSON'S -- WHAT PARKINSON'S CAN DO DOWN THE
25 ROAD. THE INCLUSION IN THIS TRIAL HAS GIVEN US A

BARRISTERS' REPORTING SERVICE

1 LOT OF HOPE. IT IS A BRIGHT LIGHT AT THE END OF A
2 LONG, DARK TUNNEL. ONE OUT OF TEN OF YOU, YOUR
3 PARENTS, SIBLINGS OR SPOUSES OR CHILDREN COULD
4 LIKELY EXPERIENCE THIS SAME DISEASE.

5 TO LOSE YOUR FLUID ABILITY TO MOVE FAST IS
6 A HUGE LOSS THAT YOU REALLY MISS ONCE YOU DON'T HAVE
7 IT ANYMORE. TO LOSE THE ABILITY TO CONCENTRATE AND
8 SPEAK LOUD AND CLEAR AND TO KEEP UP WITH EVERYONE
9 ELSE IS REALLY SAD AND A BIT DEPRESSING. THERE ARE
10 RISKS INVOLVED, AND I KNOW THAT EIGHT OF US IN THIS
11 TRIAL ALL FEEL THE RISK OF OUR LIVES IS WORTH THE
12 CHANCE TO GET BACK THE HEALTH THAT WE ONCE HAD AND
13 NOT GET WORSE. NOT JUST FOR OURSELVES, BUT FOR OUR
14 FAMILIES AS WELL.

15 I'LL WRAP IT UP. FOR YOU, THE CIRM BOARD,
16 WE POSE THE SMALLEST RISK TO YOUR REMAINING FUNDS,
17 AND WE'RE PROBABLY THE CLOSEST TO FINDING A SUCCESS
18 IN THE REALM OF REGENERATIVE MEDICINE IN THE VERY
19 NEAR FUTURE. WE COULD BE INTO HUMAN TRIALS AS SOON
20 AS ONE YEAR. AND IF THE SCIENCE GATHERED SO FAR
21 HOLDS TRUE, WE SHOULD SEE OUR TREMORS, STIFFNESS,
22 AND SHUFFLING STEPS FADE AWAY WITHIN A FEW MONTHS
23 AFTER SURGERY. THIS TRIAL WILL HAVE A HUGE
24 SIGNIFICANCE FOR TREATING OTHER NEURODEGENERATIVE
25 DISEASES SUCH AS ALZHEIMER'S. THIS PROJECT

BARRISTERS' REPORTING SERVICE

1 AMAZINGLY HAS COME A LONG WAY WITHOUT FEDERAL FUNDS,
2 AND IT HAS BEEN ALL GRASS ROOTS THUS FAR WITH A
3 COMMITTED COMMUNITY SUPPORTING THIS FANTASTIC
4 ADVANCEMENT IN MEDICINE. IF YOU WANT TO GET THE
5 BIGGEST BANG FOR YOUR BUCK, WE ARE IT. WE ARE THE
6 LOW HANGING FRUIT. WE ARE NOT ASKING FOR A
7 BUILDING, LAB FACILITIES. ALL WE ASK IS YOUR
8 COMPARATIVELY SMALL MONETARY SUPPORT OF \$2.5
9 MILLION, 5 MILLION IN TOTAL, TO GET THE REMAINING
10 WORK DONE JUST TO GET THOSE DOPAMINE CELLS IN OUR
11 BRAINS. SO PLEASE SUPPORT US IN THIS AMAZING
12 GROUNDBREAKING STEM CELL PROJECT. LET'S WORK
13 TOGETHER AND LET'S MAKE HISTORY TOGETHER. THANK
14 YOU.

15 MS. SANTOS: HI. I'M JILL SANTOS. I'M
16 44. I'VE BEEN DIAGNOSED WITH YOUNG ONSET
17 PARKINSON'S FOR THE PAST ALMOST FIVE YEARS. I'M ONE
18 OF THE EIGHT PATIENTS INVOLVED IN THE
19 SUMMIT4STEMCELL PROJECT WITH THE SCRIPPS RESEARCH
20 INSTITUTE AND SCRIPPS CLINIC HERE IN SAN DIEGO. I'M
21 HERE TODAY TO SHOW MY SUPPORT FOR ALL THE PROMISING
22 RESEARCH BEING SUPPORTED BY CIRM AND CALIFORNIA
23 TAXPAYERS AND THEIR EFFORTS TO FIND CURES FOR MANY
24 DEBILITATING DISEASES. MOST OF ALL, I'M HERE TO
25 SHOW MY SUPPORT FOR THE SUMMIT4STEMCELL PROJECT AND

BARRISTERS' REPORTING SERVICE

1 TO LET YOU KNOW OF MY BELIEF THAT AS A RESULT OF THE
2 SCIENTISTS' AND DOCTORS EFFORTS', THAT THEY WILL BE
3 ABLE TO REPLACE MY OWN DYING DOPAMINE NEURONS WITH
4 NEW ONES THAT HAVE BEEN GROWN USING IPS TECHNIQUES
5 USING MY OWN SKIN CELLS.

6 AS A RESULT OF THIS PROJECT, THERE ARE
7 SEVERAL THINGS I WILL BE LOOKING FORWARD TO. I'LL
8 BE LOOKING FORWARD TO GETTING MY OLD VOICE BACK, THE
9 ONE THAT COULD BE HEARD AND COULD SING LOUD AND
10 STRONG. I'M LOOKING FORWARD TO BE ABLE TO WALK AND
11 RUN WITHOUT PAIN AND TO HAVE MY RIGHT HAND AND FOOT
12 KEEP UP WITH MY LEFT. I'M LOOKING FORWARD TO BE
13 ABLE TO SLEEP ALL NIGHT, AND I'M LOOKING FORWARD TO
14 BEING HAPPY AND OPTIMISTIC AND NOT BEING PRONE TO
15 FALLING INTO THE PIT OF DARK DEPRESSION WHERE I'M
16 ANGRY AT EVERYONE, ISOLATE MYSELF, AND SEE NO HOPE
17 AND NO JOY EVERYWHERE.

18 I'M ALSO LOOKING FORWARD TO NOT HAVING TO
19 TAKE MEDS FOUR TIMES A DAY. AND I'M ALSO LOOKING
20 FORWARD TO NOT WORRYING ABOUT WHEN I CAN EXPECT THE
21 PROGRESSION OF MY SYMPTOMS TO INCREASE. WHEN WILL
22 THE DYSKINESIAS START? WHEN WILL THE STIFFNESS AND
23 TREMORS AFFECT MY RIGHT AND LEFT SIDES? WHEN WILL I
24 BE UNABLE TO DRIVE? WHEN WILL I BE UNABLE TO WALK?
25 WHEN WILL I CHOKE ON MY FOOD, BE UNABLE TO SPEAK

BARRISTERS' REPORTING SERVICE

1 CLEARLY, DROOL? WHEN WILL I LOSE MY COGNITION AND
2 MEMORY? WHO ARE YOU? ASIDE FROM THOSE THINGS, MOST
3 OF ALL I'M LOOKING FORWARD TO WHAT THE SUCCESS OF
4 THIS PROJECT WILL DO FOR PD PATIENTS AND THEIR
5 QUALITY OF LIFE AND HOW THE SUCCESS OF THIS PROJECT
6 WILL TRANSLATE TO SIMILAR SUCCESS FOR HUNTINGTON'S
7 DISEASE, ALZHEIMER'S, ALS, MS, OCULAR ALBINISM AND
8 MORE. THANK YOU.

9 MR. MADDOX: HELLO. MY NAME IS BILL
10 MADDOX. I TOO AM ALSO PART OF THE SUMMIT4STEMCELL
11 GROUP. I WANT TO TALK TO YOU ABOUT HOPE. I WANT TO
12 TALK TO YOU ABOUT SOMETHING RELEVANT TO EVERYBODY IN
13 THIS ROOM. THAT'S HOPE.

14 TEN YEARS AGO I VOTED ON A TAX THAT
15 CREATED AN ORGANIZATION TO FUND RESEARCH FOR
16 REGENERATIVE MEDICINE. I VOTED YES BECAUSE I HOPE
17 THAT WE AS A STATE WOULD MAINTAIN OUR LEADERSHIP
18 POSITION IN THE DEVELOPMENT OF NEW TECHNOLOGIES
19 BENEFICIAL TO THE HEALTH. SEVEN YEARS AGO I WAS
20 DIAGNOSED WITH PARKINSON'S. SINCE THEN I'VE TRIED A
21 MULTITUDE OF TREATMENTS, SUPPLEMENTS, VITAMINS,
22 HERBS, YOU NAME IT, AND EVEN EXERCISE. I EVEN
23 CLIMBED MOUNT EVEREST AS PART OF A FUND-RAISING
24 EVENT FOR SUMMIT4STEMCELL.

25 BUT LAST, BUT NOT LEAST, I TRIED MEDICINE,

BARRISTERS' REPORTING SERVICE

1 AND THE MEDICINE WAS GREAT; BUT AFTER A FEW YEARS,
2 IT STARTS TO LOSE ITS EFFECTIVENESS AND BEGINS TO
3 HAVE ITS OWN SIDE EFFECTS. BUT THE BEST MEDICINE IS
4 STILL HOPE. WITH HOPE WE CAN LOOK FORWARD TO THE
5 FUTURE. WITH HOPE WE CAN LOOK FORWARD TO YOUR
6 FUTURE VOTE, A VOTE OF YES TO FUND RESEARCH ON A NEW
7 EFFECTIVE THERAPY BEING DEVELOPED RIGHT HERE IN SAN
8 DIEGO RIGHT NOW. THANK YOU FOR YOUR TIME.

9 MS. GOULD: HELLO. MY NAME IS SHERRIE
10 GOULD. I'M A NURSE PRACTITIONER AT SCRIPPS CLINIC.
11 I WORK WITH DR. MELISSA HOUSER, AND I AM HUGELY
12 INVOLVED IN THE SUMMIT4STEMCELL PROJECT.

13 PARKINSON'S DISEASE HAS BEEN SEVERELY
14 UNREPRESENTED ON THE CIRM BOARD. I DO UNDERSTAND
15 THAT A PERSON HAS OFFERED HER RESIGNMENT, BUT WE
16 DEFINITELY NEED MORE REPRESENTATION FOR PARKINSON'S
17 DISEASE ON YOUR BOARD. SO THAT WOULD BE MY VERY
18 FIRST PLUG. ALSO, IF YOU LOOK AT STATISTICALLY HOW
19 MUCH MONEY CIRM HAS ACTUALLY GIVEN TOWARDS
20 PARKINSON'S DISEASE, IT IS EXTREMELY MINIMAL. IT'S
21 LESS THAN AN EIGHTH OF 1 PERCENT IN TERMS OF
22 PARKINSON'S PROJECTS. WE DO REPRESENT YOUR IDEAL
23 PROJECT. WE HAVE COME THIS FAR COMPLETELY BY
24 PATIENT SUPPORT, BY COMMUNITY SUPPORT, BY DOING
25 INCREDIBLE, INCREDIBLE THINGS. AND THE NUMBER,

BARRISTERS' REPORTING SERVICE

1 HUNDREDS OF PEOPLE, THAT HAVE GOTTEN INVOLVED TO SEE
2 THIS PROJECT TO THIS POINT HAS BEEN PHENOMENAL.
3 NINE HUNDRED PEOPLE HAVE VOLUNTEERED THEIR MONEY,
4 NOT TO SPEAK OF THE HUNDREDS THAT HAVE VOLUNTEERED
5 THEIR TIME AND CLIMBING MOUNTAINS AND EVERYTHING
6 ELSE BECAUSE WE BELIEVE IN THIS PROJECT.

7 AND I'D LIKE FOR EVERYBODY FROM
8 SUMMIT4STEMCELL OR REPRESENTING THIS PROJECT TO
9 PLEASE STAND UP. WE ARE HERE BECAUSE WE BELIEVE IN
10 THIS PROJECT. THIS IS AN AMAZING PROJECT, AND IT
11 HAS SUCH A GREAT CHANCE OF SUCCESS. CIRM, YOU HAVE
12 A CHANCE TO BE INCREDIBLY PROUD THAT YOU
13 PARTICIPATED TO SEE THIS THROUGH TO THE END. WE ARE
14 SO CLOSE. THE RAT TRIALS ARE SO PROMISING, AND
15 WE'RE READY. ANYWAY, WITH THAT I THANK YOU VERY
16 MUCH.

17 MS. ROBERT: GOOD AFTERNOON. THANK YOU
18 FOR THE OPPORTUNITY TO SPEAK TODAY. I'M ELHE
19 ROBERT. I AM THE CHAIRPERSON OF SUMMIT4STEMCELL.
20 AND IF YOU'D SEEN THE EFFORT THAT HAS GONE THROUGH
21 WITH THE COMMUNITY AND ALL OF THE FAMILIES AND OUR
22 PATIENTS TO RAISE EVEN 700,000 OVER THE LAST THREE
23 YEARS TO THE POINT OF CLIMBING MOUNTAINS, AND I'M
24 INVOLVED BECAUSE MY HUSBAND HAS HAD PARKINSON'S FOR
25 26 YEARS. AND I'VE LIVED WITH ALL THE UPS AND DOWNS

BARRISTERS' REPORTING SERVICE

1 THAT YOU KNOW HAPPEN WHEN SOMEONE HAS PARKINSON'S
2 THAT LONG. AND I JUST THINK THAT WE ARE SO CLOSE.
3 WE NEED FDA APPROVAL NOW, AND THAT GETS VERY COSTLY.
4 AND WE NEED YOUR HELP. WE NEED YOUR SUPPORT.

5 I'M NOT GOING TO EMPHASIZE EVERYTHING THAT
6 EVERYBODY ELSE HAS DONE, BUT I JUST WANT YOU TO LOOK
7 VERY SERIOUSLY AT OUR SUMMIT PARKINSON'S DISEASE
8 NONEMBRYONIC CELL THERAPY THAT WE'RE TRYING TO DO.
9 AND THANK YOU FOR YOUR TIME TODAY.

10 MR. HENBERGER: HI. MY NAME IS JERRY
11 HENBERGER. I'M THE EXECUTIVE DIRECTOR WITH THE
12 PARKINSON'S ASSOCIATION. WE HAVE OFFICES IN LOS
13 ANGELES AND HERE IN SAN DIEGO. THERE'S OVER A
14 HUNDRED THOUSAND PEOPLE IN SOUTHERN CALIFORNIA THAT
15 HAS PARKINSON'S. WE PUBLISH A MAGAZINE CALLED THE
16 *PARKINSONIAN*. WE HAVE A PROGRAM CALLED "MINDS IN
17 MOTION" WHICH OFFERS PSYCHOLOGICAL COUNSELING AND
18 THERAPY FOR PEOPLE WITH PARKINSON'S DISEASE.

19 AND YOU'VE HEARD FROM EIGHT PATIENTS THAT
20 REALLY HAVE THEIR WHOLE LIFE AHEAD OF THEM, AND THEY
21 SEE THAT HAPPENING BECAUSE OF WHAT YOU'RE ABLE TO DO
22 FOR THEM. BUT WHAT YOU DON'T SEE ARE THE OTHER
23 100,000 PEOPLE THAT ARE ALSO WATCHING THIS VERY,
24 VERY CAREFULLY. IT'S A DEGENERATIVE DISEASE.
25 THERE'S NO CURE. THEIR LIFE IS LOOKING VERY BLEAK

BARRISTERS' REPORTING SERVICE

1 AS THE DISEASE COMES TOWARDS A CONCLUSION. THIS
2 PROVIDES HOPE, AND THAT HOPE ALSO INCLUDES QUALITY
3 OF LIFE.

4 AND SO WHAT CIRM HAS DONE FOR SO MANY
5 DISEASES AND SO MANY COMMUNITIES HAS BEEN SO
6 WONDERFUL, AND I JUST WANT TO THANK YOU FOR YOUR
7 SUPPORT AND THE PROMISE AND HOPE THAT YOU'RE
8 PROVIDING THIS WONDERFUL COMMUNITY. SO THANK YOU
9 VERY MUCH FOR YOUR CONSIDERATION.

10 MR. BRATT-LEAL: MY NAME IS ANDRES
11 BRATT-LEAL, AND I'M A SENIOR SCIENTIST AT THE
12 PARKINSON'S ASSOCIATION, AND I'LL JUST WRAP THIS UP.
13 WE'D LIKE TO WELCOME THE NEW PRESIDENT, AND WE HOPE
14 IN THE FUTURE, WE HAVE A LOT OF PEOPLE THAT ARE
15 REALLY EXCITED ABOUT STEM CELLS AND PARKINSON'S, AND
16 WE HOPE IN THE FUTURE THAT THE CIRM BOARD WILL PAY
17 MORE ATTENTION TO PARKINSON'S DISEASE AND TO MOVE
18 FORWARD QUICKLY ON CHOOSING A NEW REPRESENTATIVE FOR
19 PARKINSON'S. THANK YOU.

20 CHAIRMAN THOMAS: OKAY. I'D JUST LIKE TO
21 THANK EVERYBODY FOR COMING HERE AND GIVING YOUR MOST
22 IMPORTANT COMMENTS TO THE BOARD. I KNOW IT'S A BIG
23 DEAL TO MAKE A TRIP OVER HERE TO TALK TO US, AND WE
24 VERY MUCH APPRECIATE EVERYTHING YOU'VE SAID.

25 I WOULD LIKE TO GIVE YOU JUST A MINUTE

BARRISTERS' REPORTING SERVICE

1 HERE ON THE PROCESS FOR REPLACING JOAN SAMUELSON ON
2 THE BOARD BECAUSE I KNOW THAT'S VERY IMPORTANT. SO
3 AS YOU MAY BE AWARE, MOST OF THE SEATS ON THIS BOARD
4 COME VIA APPOINTMENT BY ONE PERSON OR ANOTHER. MANY
5 ARE APPOINTED BY CONSTITUTIONAL OFFICERS OF THE
6 STATE OF CALIFORNIA. IN THIS INSTANCE, THIS
7 PARTICULAR SEAT IS A STATE CONTROLLER APPOINTMENT.
8 THE STATE CONTROLLER IS AWARE THAT JOAN IS STEPPING
9 DOWN AND IS MOVING WITH A PROCESS TO EVALUATE AND
10 MAKE A DECISION ON WHO HER SUCCESSOR SHOULD BE IN
11 VERY SHORT ORDER.

12 SO WE FULLY UNDERSTAND AND AGREE WITH YOU
13 THAT WE NEED TO HAVE THAT VOICE ON THE BOARD, AND
14 THAT WILL BE TAKEN CARE OF VERY SHORTLY. SO REST
15 ASSURED OF THAT.

16 OKAY. SO THANK YOU VERY MUCH, EVERYBODY.
17 WE APPRECIATE IT. SENATOR TORRES.

18 MR. TORRES: THANK YOU TO ALL THE FOLKS
19 WHO APPEARED HERE TODAY AND TO LET YOU KNOW THAT, AS
20 CHAIRMAN THOMAS SAID, THAT THE CONTROLLER IS ALREADY
21 ON THE SEARCH FOR A REPLACEMENT FOR OUR DEAR FRIEND
22 JOAN. AND IF YOU HAVE ANY RECOMMENDATIONS, I WOULD
23 URGE YOU TO SEND THEM OFF TO THE STATE CONTROLLER
24 JOHN CHIANG IN SACRAMENTO. AND I'M SURE HE WILL
25 REVIEW THEM WITH VERY, VERY CAREFUL SCRUTINY.

BARRISTERS' REPORTING SERVICE

1 SECONDLY, I JUST WANT YOU TO KNOW THAT MY
2 UNCLE SUFFERED FROM PARKINSON'S. SO IT'S A VERY
3 PERSONAL ISSUE FOR ME AS WELL. AND SO YOUR COMMENTS
4 REALLY TOUCHED MY HEART TODAY. THANK YOU.

5 CHAIRMAN THOMAS: DR. STEWARD.

6 DR. STEWARD: YEAH. AND I JUST WANT TO
7 SAY THANK YOU VERY MUCH FOR COMING. I WANT YOU TO
8 KNOW I'M THE PATIENT ADVOCATE FOR SPINAL CORD
9 INJURY, BUT I THINK, LIKE EVERY OTHER PATIENT
10 ADVOCATE ON THIS BOARD, WE CONSIDER OURSELVES
11 PATIENT ADVOCATES, PERIOD. AND WE ALL ARE ACUTELY
12 AWARE OF THE NEED FOR RESEARCH IN PARKINSON'S
13 DISEASE. IT WAS CLEARLY ONE OF THE ICONS FOR PROP
14 71 IN THE BEGINNING. AND WE'RE ALSO ACUTELY AWARE
15 THAT IT HAS NOT RECEIVED AS MUCH FUNDING AS SOME OF
16 THE OTHER DISEASES OR DISORDERS UP TO NOW. SO JUST
17 TO SAY WE MISS JOAN TERRIBLY, BUT THERE ARE OTHERS
18 OF US ON THE BOARD WHO ARE ALSO THINKING OF YOU.

19 CHAIRMAN THOMAS: DR. DULIEGE.

20 DR. DULIEGE: JUST AGAIN TO ADD AND TO
21 SECOND WHAT WAS SAID. IT'S SO IMPORTANT. I WANT TO
22 THANK YOU NOT ONLY FOR COMING HERE TODAY, THAT'S
23 IMPORTANT, BUT ALSO FOR THE TESTIMONY THAT YOU
24 PROVIDE EVERY DAY, EVERY MINUTE OF YOUR LIFE, AND
25 FOR THE COURAGE THAT YOU HAVE TO STAND FOR THE

BARRISTERS' REPORTING SERVICE

1 FUTURE AND FOR OTHERS. AND IT'S FOR THIS EVERY
2 SINGLE DAY COURAGE THAT WE WANT TO THANK YOU AND
3 CONGRATULATE YOU.

4 I WOULDN'T GO INTO PERSONAL MATTERS, BUT
5 BECAUSE SENATOR TORRES MENTIONED HIS FAMILY
6 SITUATION, MY OWN FATHER DIED OF PARKINSON'S
7 DISEASE. HE DIED OF PARKINSON'S DISEASE AFTER 15,
8 20 YEARS OF DISEASE. MY GRANDMOTHER DIED OF IT AND
9 MY UNCLE DIED OF IT. SO THERE'S MANY, MANY --
10 SEVERAL OF US, I ASSUME, THAT HAVE IN ADDITION TO
11 OUR MAJOR SCIENTIFIC DESIRE TO HELP HERE, ALSO
12 UNDERSTAND THAT FROM A PERSONAL STANDPOINT.

13 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
14 MUCH. WE WILL NOW -- LET'S SEE. WE HAVE MARCY
15 JOINING US IN FIVE MINUTES ON THE PHONE. SO WE'RE
16 GOING TO TAKE A COUPLE OF QUICK ITEMS BEFORE WE GET
17 TO THAT. SO LET'S GO TO THE -- LET'S FIRST DO THE
18 MOST -- LET'S GO TO THE CONSIDERATION OF THE NEW
19 MEMBERS OF THE GRANTS WORKING GROUP. DR. SAMBRANO.

20 DR. SAMBRANO: THANK YOU, MR. CHAIR. WE
21 HAVE SEVEN NOMINEES WHOSE BIOGRAPHIES ARE IN YOUR
22 BOOKS. THEY BRING EXPERTISE IN THE AREAS OF SPINAL
23 CORD INJURY, CARDIOVASCULAR DISEASE, PRODUCT
24 INVESTMENT, AND REGULATORY AFFAIRS. THE INDIVIDUALS
25 ARE DRs. JOHN CROWLY, ADRIAN GEE, JAMES GUEST, ROBIN

BARRISTERS' REPORTING SERVICE

1 JENKINS, KATHLEEN KIRBY, JAY TRAVERSE, AND MICHELLE
2 WILLIAMS. SO WE SEEK YOUR APPROVAL OF THESE
3 NOMINEES FOR THE GRANTS WORKING GROUP MEMBERSHIP.

4 CHAIRMAN THOMAS: HEAR A MOTION TO THAT
5 EFFECT?

6 DR. STEWARD: SO MOVED.

7 MR. SHEEHY: SO MOVED. SECOND.

8 CHAIRMAN THOMAS: MOVED BY DR. STEWARD,
9 SECONDED BY MR. SHEEHY. ANY DISCUSSION BY MEMBERS
10 OF THE BOARD? ANY PUBLIC COMMENT ON THIS TOPIC?
11 HEARING NONE, I THINK VOICE VOTE WILL SUFFICE, MR.
12 HARRISON.

13 MR. HARRISON: EXCEPT FOR DR. HAWGOOD IF
14 HE'S STILL ON THE PHONE.

15 CHAIRMAN THOMAS: OKAY. SO ALL THOSE IN
16 FAVOR OF THE MOTION PLEASE SAY AYE. OPPOSED?
17 ABSTENTIONS? DEAN HAWGOOD, IF YOU'RE STILL ON THE
18 PHONE WITH US.

19 DR. HAWGOOD: I AM.

20 CHAIRMAN THOMAS: THANK YOU. AND YOUR
21 VOTE IS?

22 DR. HAWGOOD: AYE.

23 CHAIRMAN THOMAS: THANKS VERY MUCH. IT'S
24 UNANIMOUSLY APPROVED. THANK YOU. MARIA.

25 MS. BONNEVILLE: I WAS JUST GOING TO SEE

BARRISTERS' REPORTING SERVICE

1 IF MARCY IS ON. MARCY, ARE YOU ON?

2 MS. FEIT: YES, I AM.

3 MS. BONNEVILLE: GREAT.

4 CHAIRMAN THOMAS: HELLO, MARCY. J.T.

5 HERE. HOW ARE YOU?

6 MS. FEIT: I'M FINE. HOW ARE YOU, J.T.?

7 CHAIRMAN THOMAS: WE'RE GREAT. AND WE ARE

8 ALL GATHERED HERE NOW TO GIVE YOU GREAT ACCLAIM.

9 MS. FEIT: THANK YOU VERY MUCH.

10 CHAIRMAN THOMAS: AND I'M GOING TO TURN

11 THIS OVER TO SHERRY TO LEAD THE DISCUSSION.

12 MS. LANSING: WELL, MARCY, I WISH YOU WERE

13 HERE IN PERSON BECAUSE ALL OF US AROUND THE TABLE

14 VALUE YOUR INCREDIBLE PASSION AND YOUR INCREDIBLE

15 DEDICATION TO THE CAUSE. YOU HAVE BEEN HERE, AS FAR

16 AS I CAN REMEMBER, FROM THE BEGINNING. SO I HOPE

17 I'M RIGHT ABOUT THAT, BUT I CAN'T IMAGINE OUR BOARD

18 WITHOUT YOU.

19 YOUR INTELLIGENCE, YOUR CALM, RATIONAL

20 APPROACH, YOU WERE KIND OF LIKE THE CONSCIENCE FOR

21 ALL OF US. AND YOU ALWAYS KEPT US ON TRACK AND

22 FOCUSED. I NEVER EVER SAW YOU LOSE YOUR TEMPER, BUT

23 I ALWAYS SAW YOU BE PASSIONATE AND CARING AND NEVER

24 LOSE SIGHT OF THE MISSION WHICH WAS ABOUT SAVING

25 LIVES THROUGH OUR WORK.

BARRISTERS' REPORTING SERVICE

1 ON A PERSONAL LEVEL, I JUST REALLY FEEL AS
2 IF YOU'RE A GIRLFRIEND OF MINE. DO YOU KNOW? MAYBE
3 THAT'S NOT THE MOST PROFESSIONAL THING TO SAY, BUT
4 IT'S REALLY THE TRUTH. I ALWAYS ENJOY YOUR COMPANY.
5 I ALWAYS LIKE TO SIT NEXT TO YOU AT LUNCH. I ALWAYS
6 LIKE TO TALK TO YOU. AND THE ONLY THING I CAN SAY
7 IS I WILL MISS YOUR SERVICE ON THE BOARD, BUT I HOPE
8 THAT OUR FRIENDSHIP CONTINUES FOREVER. SO THANK YOU
9 FOR EVERYTHING.

10 MS. FEIT: I DO TOO. THANK YOU, SHERRY.
11 AND I FEEL THE SAME WAY. IT'S BEEN AN HONOR AND A
12 DELIGHT TO KNOW YOU.

13 CHAIRMAN THOMAS: SENATOR TORRES.

14 MR. TORRES: I LOVE YOU, MARCY.

15 MS. FEIT: I LOVE YOU TOO.

16 MR. TORRES: AND MAYBE A GIRLFRIEND IN A
17 DIFFERENT WAY, BUT CERTAINLY A DIFFERENT WAY. YOU
18 KNOW, MARCY FEIT, PEOPLE DON'T REALIZE THAT SHE
19 COMBATED A TREMENDOUS AMOUNT OF OPPOSITION. SHE WAS
20 A NURSE FROM STANFORD AND RUNNING A MAJOR MEDICAL
21 FACILITY. AND SOMETIMES DOCTORS CAN BE A LITTLE
22 INSENSITIVE, ESPECIALLY MALE DOCTORS, TO A WOMAN CEO
23 WHO'S JUST A NURSE. BUT YET SHE HAD AN INCREDIBLE
24 40-YEAR RECORD IN RUNNING VALLEY VIEW CENTER. AND
25 HER SIGNATURE WAY OF CREATING PREVENTIVE CARE

BARRISTERS' REPORTING SERVICE

1 MAY NOT ALWAYS HAVE HELD GOOD SWAY WITH THE
2 ACCOUNTANTS AND THEIR PENCILS, BUT CERTAINLY HAD
3 GOOD SWAY WITH THE HEALTHCARE OF PEOPLE THAT WERE
4 INVOLVED IN THOSE PROCEDURES.

5 SHE HELPED CREATE A CENTER FOR VETERANS
6 COMING BACK FROM IRAQ AND AFGHANISTAN. NOBODY ELSE
7 WAS DOING THAT, CERTAINLY NOT THE VA AS WE'VE BEEN
8 HEARING, BUT ALSO PROVIDED AN OPPORTUNITY FOR THE
9 POOR IN THOSE COMMUNITIES TO HAVE ACCESS TO
10 HEALTHCARE, TO PREVENTIVE CARE, PROVIDING FOOD
11 DRIVES FOR PEOPLE. SHE WAS MORE THAN JUST AN
12 EXECUTIVE AND A CEO. SHE WAS REALLY A HUMANITARIAN
13 WORKING VERY, VERY HARD WITH HER PASSION. AND MOST
14 PEOPLE DON'T KNOW THAT SHE GREW UP POOR IN
15 CALIFORNIA FARMING COMMUNITIES. AND THE LESSONS SHE
16 LEARNED FROM HER PARENTS WAS TERRIFIC.

17 I'M VERY PROUD OF HER AS A LATINA AND A
18 REPUBLICAN LATINA THAT I RESPECT, BUT NONETHELESS
19 SHE PROVIDED LEADERSHIP FOR OUR COMMUNITY AND
20 CLEARLY FOR THE GENERAL COMMUNITY, AND HER SERVICE
21 HERE ON THIS BOARD IS GOING TO BE SORELY MISSED. I
22 MISS YOU ALREADY, AND I HOPE TO SEE YOU SOON.

23 MS. FEIT: THANK YOU, ART. I DO TOO. AND
24 I THINK ART AND I CAN DEMONSTRATE THAT BOTH SIDES
25 CAN COME TOGETHER AND LOVE EACH OTHER AND WORK

BARRISTERS' REPORTING SERVICE

1 TOGETHER FOR THE BETTER OF EVERYBODY.

2 CHAIRMAN THOMAS: OTHER COMMENTS BY
3 MEMBERS OF THE BOARD? MR. SHEEHY.

4 MR. SHEEHY: YES. SO, MARCY, YOUR GOING
5 OFF THE BOARD IS REALLY FOR ME SUCH -- I HATE TO SAY
6 IT MAKES ME SAD BECAUSE IT'S BEEN SUCH A JOY TO
7 SERVE WITH YOU, BUT IT REALLY DOES ALMOST BREAK MY
8 HEART. I THINK YOU MAY BE THE WISEST PERSON I'VE
9 KNOWN. THERE ARE A LOT OF SMART PEOPLE AROUND THE
10 TABLE. THERE HAVE ALWAYS BEEN A LOT OF SMART PEOPLE
11 AROUND THE TABLE, BUT YOUR WISDOM HAS BEEN
12 ABSOLUTELY ESSENTIAL TO THE SUCCESS OF THIS
13 ENTERPRISE. AND THE AMOUNT OF WORK YOU PUT IN, I
14 DON'T KNOW HOW YOU COULD DO IT. I MEAN YOU WERE AT
15 THE WORKING GROUPS, THE COMMITTEE MEETINGS, THE
16 BOARD MEETINGS, AND I'M JUST SO GRATEFUL TO KNOW
17 YOU. AND THANK YOU. AND I'LL MISS YOU. I LOVE
18 YOU.

19 MS. FEIT: I'LL MISS YOU TOO, JEFF. IT
20 WAS WONDERFUL GETTING TO BE YOUR FRIEND AND WORKING
21 WITH YOU AS A COLLEAGUE ON THIS BOARD. IT WAS MY
22 HONOR AND MY PLEASURE.

23 CHAIRMAN THOMAS: DR. PRIETO.

24 DR. PRIETO: MARCY, THIS IS FRANCISCO. I
25 JUST WANTED TO SAY THAT I MISS YOU TERRIBLY TOO, AND

BARRISTERS' REPORTING SERVICE

1 I WISH YOU WERE HERE. AND I HOPE I'LL SEE YOU AGAIN
2 SOON.

3 MS. FEIT: YES, YOU WILL. AND, FRANCISCO,
4 THANK YOU SO MUCH FOR YOUR SUPPORT IN THE PAST FEW
5 MONTHS. IT'S BEEN TREMENDOUS. THANK YOU SO MUCH.

6 CHAIRMAN THOMAS: DR. STEWARD.

7 DR. STEWARD: MARCY, THIS IS OS STEWARD.
8 I JUST WANT TO ECHO THE THINGS THAT EVERYONE ELSE
9 HAS SAID. WHENEVER WE HAD INTERESTING, SOMETIMES
10 DIVISIVE DISCUSSIONS, YOU WERE THE PERSON I OFTEN
11 LOOKED TO AND KIND OF WATCHED WHICH WAY YOU WERE
12 LEANING. WHAT JEFF SAID ABOUT YOUR WISDOM IS JUST
13 ABSOLUTELY TRUE. YOU WERE THE ROCK ON WHICH SO MANY
14 THINGS WERE BUILT. SO THANK YOU AND WE WILL ALL
15 MISS YOU. I WILL MISS YOU ESPECIALLY.

16 MS. FEIT: THANK YOU, OS.

17 CHAIRMAN THOMAS: OTHER COMMENTS BY
18 MEMBERS OF THE BOARD?

19 SO, MARCY, GREAT PRIVILEGE FOR ME. I'M
20 SORT OF THE NEWER GUY IN TOWN COMPARED TO EVERYBODY
21 WHO'S SPOKEN WHO HAD THE PRIVILEGE OF WORKING WITH
22 YOU FOR MANY YEARS HERE AND WERE PARTY TO YOUR
23 CENTRAL ROLE IN SO MANY THINGS THAT HELPED DEVELOP
24 CIRM TO WHERE IT IS TODAY. I JUST WANT TO SAY THAT
25 IN MY TIME I SO ENJOYED WORKING WITH YOU. YOUR SAGE

BARRISTERS' REPORTING SERVICE

1 GUIDANCE AS CO-CHAIR OF OUR FINANCE SUBCOMMITTEE IN
2 TERMS OF ALL BUDGETARY MATTERS AND ALL FISCAL
3 MATTERS WAS SOMETHING THAT WAS SO HELPFUL TO ME AND
4 TO THE AGENCY.

5 AND AS A PATIENT ADVOCATE WHO WAS
6 ADVOCATING IN THE HIGHEST RESPECT FOR PATIENTS
7 EVERYWHERE OF ALL CONDITIONS, I JUST WANT TO SAY
8 THANK YOU SO MUCH ON BEHALF OF EVERYBODY HERE AT
9 CIRM. WE HAVE, OF COURSE, HAVE A VERY NICE
10 RESOLUTION FOR YOU, WHICH WE WON'T READ BECAUSE IT
11 WOULD TAKE TOO LONG AND YOU WOULD BE BLUSHING FROM
12 AFAR, BUT WE WILL FRAME IT AND SEND IT TO YOU AND
13 HOPE THAT IT TAKES A PROMINENT SPOT ON YOUR WALL IN
14 NORTH CAROLINA. AND THANK YOU SO MUCH FOR
15 EVERYTHING YOU'VE DONE FOR CIRM AND FOR THE PATIENTS
16 OF THE WORLD EVERYWHERE.

17 MS. FEIT: THANK YOU SO MUCH. IT'S BEEN
18 MY HONOR AND MY PLEASURE TO BE A PART OF THIS.
19 TODAY I WAS THINKING BACK ABOUT THE EARLY DAYS IN
20 THE INSTITUTE AND THE STRUGGLES. AND THERE ARE SO
21 MANY PEOPLE WHO HAD THE VISION TO STAY THERE, STAY
22 THE COURSE, AND I THINK THE AMERICAN PEOPLE AND THE
23 PEOPLE ALL OVER THE WORLD WHO EVENTUALLY WILL
24 BENEFIT BY THE THERAPIES THAT COME FORWARD FROM ALL
25 OF YOUR WORK HAVE NO IDEA OF THE CONTRIBUTION THAT

BARRISTERS' REPORTING SERVICE

1 YOU HAVE ALL MADE. AND IT'S BEEN MY HONOR TO KNOW
2 ALL OF YOU AND WORK BESIDE YOU AND BE PART OF THIS.

3 I THINK ONE OF THE HARDEST THINGS THAT
4 HAVE HAPPENED TO ME IN THE LAST THREE MONTHS HAVE
5 BEEN LEAVING CALIFORNIA AND HAVING TO LEAVE CIRM
6 BECAUSE I SO, SO ENJOYED AND WANTED TO BE A PART OF
7 WHAT WAS HAPPENINGS. AND I WILL ALWAYS KEEP YOU IN
8 MY THOUGHTS AND HOPE THAT WE CAN CONTINUE THE WORK
9 OF STEM CELL RESEARCH AND THERAPIES IN THE FUTURE AS
10 WE ALL AGE IN PLACE. LOOKING FORWARD TO BETTER
11 THINGS, TO HAVE BETTER QUALITY OF LIFE IS WHAT WE
12 ALL ASPIRE TO, AND I THINK THAT THE INSTITUTE WILL
13 PRODUCE THAT HOPE FOR EVERYONE. SO THANK YOU ALL
14 VERY MUCH. THIS IS VERY KIND, AND I WILL ALWAYS BE
15 THINKING OF ALL OF YOU. THANK YOU.

16 CHAIRMAN THOMAS: THANK YOU, MARCY.

17 (APPLAUSE.)

18 CHAIRMAN THOMAS: OKAY. MARCY, YOU'RE
19 WELCOME IF YOU WANT TO LISTEN TO THE REST OF THE
20 MEETING.

21 MS. FEIT: WELL, ONLY IF YOU PROMISE TO GO
22 TILL 5 O'CLOCK. I APPRECIATE IT ALL. THANK YOU
23 VERY MUCH.

24 MS. LANSING: THAT'S THE ONE THING YOU
25 WON'T MISS.

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: OKAY. MARIA, WHAT
2 TIME -- THE SPOTLIGHT IS STARTING.

3 MS. BONNEVILLE: LUNCH AND SPOTLIGHT ARE
4 AT NOON.

5 CHAIRMAN THOMAS: OKAY. SO LET'S DO A
6 SECOND RESOLUTION. WE HAVE A NUMBER OF COMMENTS FOR
7 ALAN WHO WE HAD HOPED COULD JOIN US HERE TODAY, BUT
8 WAS NOT ABLE TO. BUT NONETHELESS, THIS BEING THE
9 FIRST MEETING AT WHICH HE HAS NOT PRESIDED IN SIX
10 AND A HALF YEARS, WE WANTED TO GIVE FULL
11 APPRECIATION FOR WHAT HE HAS DONE. I'LL START WITH
12 SHERRY.

13 MS. LANSING: I HOPE YOU'RE LISTENING,
14 ALAN. I HAD AN OPPORTUNITY TO TALK TO YOU ON THE
15 PHONE LAST WEEK, SO I WAS ABLE TO SAY A LOT OF THIS
16 TO YOU, NOT IN PERSON AS I WOULD HAVE LIKED, BUT AT
17 LEAST OVER THE PHONE. AND I DO HOPE YOU'RE
18 LISTENING BECAUSE ALL OF US HERE ARE EXTRAORDINARILY
19 GRATEFUL TO YOU.

20 I STILL REMEMBER BEING ON THE SEARCH
21 COMMITTEE WHEN WE FIRST APPOINTED YOU AND HOW
22 EXCITED ALL OF US WERE BECAUSE OF YOUR ENORMOUS
23 SCIENTIFIC BACKGROUND AND HOW GRATEFUL WE WERE FOR
24 ALL THAT YOU HAVE DONE -- ALL THAT YOU HAD DONE
25 BEFORE YOU CAME TO CIRM. AND ACTUALLY I WAS

BARRISTERS' REPORTING SERVICE

1 STUNNED, NOT ONLY BY YOUR SCIENTIFIC KNOWLEDGE AND
2 YOUR BACKGROUND AND THE WORK THAT YOU HAD DONE, BUT
3 ALSO BY YOUR DEDICATION AND PASSION TO THIS CAUSE.
4 AND NONE OF IT IS MORE EVIDENT THAN THE FACT THAT
5 YOU WERE WILLING TO LEAVE YOUR HOME IN AUSTRALIA, TO
6 LEAVE YOUR FAMILY, AND TO MAKE A COMMITMENT AS YOU
7 HAVE HONORED FOR THE LAST SIX AND A HALF YEARS.
8 THAT IS TRUE DEDICATION. AND I KNOW HOW HARD THIS
9 HAS BEEN ON YOU ON A PERSONAL LEVEL, BUT YOU NEVER
10 LOST YOUR FOCUS AND YOU NEVER LOST YOUR DEDICATION,
11 AND YOU NEVER LOST YOUR ABILITY TO WORK HARD.

12 WHEN PEOPLE TALK ABOUT CIRM, NO MATTER
13 WHAT ANYBODY SAYS, NO MATTER WHAT KIND OF CRITICISMS
14 THAT MAY COME FROM THE OUTSIDE, NO ONE EVER
15 QUESTIONS THE SCIENCE. EVERYONE ALWAYS SAYS THAT
16 THE SCIENCE IS IMPECCABLE. AND WE ARE WHERE WE ARE
17 TODAY WITH THE SCIENCE BECAUSE OF YOUR HARD WORK AND
18 YOUR LEADERSHIP, ALAN. THERE ARE NO WORDS TO
19 DESCRIBE AS A PATIENT ADVOCATE ON BEHALF OF ALL OF
20 US HOW GRATEFUL WE ARE THAT WE ARE WHERE WE ARE
21 TODAY AND HOW WE KNOW THAT THIS HAPPENED BECAUSE OF
22 YOUR LEADERSHIP.

23 I KNOW THAT YOU'RE GOING TO CONTINUE YOUR
24 WORK, AND SO I HAVE NO DOUBT THAT OUR PATHS WILL
25 CROSS AGAIN. I HAVE NO DOUBT THAT OUR FRIENDSHIP

BARRISTERS' REPORTING SERVICE

1 WILL ENDURE, AND I HAVE NO DOUBT THAT IN ANOTHER WAY
2 YOU WILL CONTINUE TO BE PART OF CIRM. SO THANK YOU
3 WITH DEEP GRATITUDE, AND THERE ARE NO WORDS, AGAIN,
4 TO EXPRESS HOW GRATEFUL ALL OF US ARE AND HOW MUCH
5 WE WILL MISS YOU. SO THANK YOU, ALAN.

6 CHAIRMAN THOMAS: ALAN, LET ME ADD TO
7 THAT. THERE ARE TIMES IN ALL ORGANIZATION'S LIVES
8 WHERE A PARTICULAR PERSON IS NEEDED TO LEAD THAT
9 ORGANIZATION TO MOVE IT AHEAD TO THE NEXT STAGE. IN
10 THE PAST SIX AND A HALF YEARS, THE ROLE OF
11 DEVELOPING THE SCIENTIFIC PROGRAMS, THE PIPELINE,
12 THE RESEARCH MOVING FORWARD TOWARDS THE CLINIC
13 DEMANDED SOMEBODY WITH GREAT BACKGROUND IN THE
14 SCIENCE WITH A KEEN INTELLECT, WITH A NETWORK OF
15 CONTACTS THROUGHOUT CALIFORNIA, NATIONALLY, AND
16 INTERNATIONALLY, AND THAT PERSON, ALAN, WAS YOU.

17 YOU WERE THE ONE WHO DROVE THE SCIENTIFIC
18 AGENDA. YOU WERE THE ONE WHO BROUGHT US CLOSER
19 TOGETHER WITH THOSE AROUND THE WORLD AND THE COUNTRY
20 AND THE STATE. YOU WERE THE ONE WHOSE CREATIVITY
21 WAS THE DRIVING FORCE BEHIND A NUMBER OF THE MAJOR
22 PROGRAMS THAT WE HAVE HERE AT CIRM, SUCH AS THE IPS
23 CELL BANK, THE GENOMICS INITIATIVE, ETC. AND YOU
24 HAVE BROUGHT US TO A STAGE NOW WHERE WE'RE HANDING
25 THINGS OVER TO RANDY TO TAKE THINGS ON FROM WHERE WE

BARRISTERS' REPORTING SERVICE

1 ARE TODAY INTO TRANSLATION AND DEVELOPMENT AND HAVE
2 POSITIONED US TO BE ABLE TO CONTINUE TO BE THE
3 LEADING DRIVING FORCE IN STEM CELL RESEARCH IN THE
4 WORLD.

5 SO AS SOMEBODY WHO WORKED WITH YOU FOR THE
6 PAST NOW ALMOST THREE YEARS, I WANT TO ECHO SHERRY'S
7 COMMENTS AND THANK YOU FOR YOUR SIGNIFICANT
8 CONTRIBUTION TO CIRM AND SIGNIFICANT CONTRIBUTION TO
9 THE WORLD OF STEM CELL RESEARCH. CIRM TODAY IS A
10 BETTER PLACE FOR HAVING HAD YOU HERE, AND WE WANT TO
11 THANK YOU ON BEHALF OF THE BOARD FOR ALL THAT YOU
12 HAVE DONE.

13 AND I GUESS I WILL SEE YOU AT ISSCR. ARE
14 THERE ANY OTHER COMMENTS FROM MEMBERS OF THE BOARD?
15 ALAN, WE HAVE A RESOLUTION FOR YOU AS WELL WHICH
16 WE'LL MAKE SURE WE GET TO YOU AND TO TAKE BACK WITH
17 YOU TO AUSTRALIA AND HAVE IT PROMINENTLY DISPLAYED
18 AND HOPE THAT IT CONTINUES TO GIVE YOU GREAT
19 THOUGHTS ABOUT YOUR TIME AND CONSIDERABLE EXPERIENCE
20 HERE.

21 IS THAT ALAN? A LIGHTNING BOLT.

22 OKAY. SO THANK YOU. I GUESS NOW WE HAVE
23 ANOTHER FEW MINUTES.

24 MS. BONNEVILLE: LUNCH IS READY.

25 CHAIRMAN THOMAS: OKAY. LET'S DISPENSE

BARRISTERS' REPORTING SERVICE

1 WITH THE MOST CONTROVERSIAL ITEM ON THE AGENDA WHICH
2 IS THE APPROVAL OF THE LAST MEETING'S MINUTES.

3 MS. LANSING: I MOVE THEM.

4 MR. TORRES: SECOND.

5 CHAIRMAN THOMAS: SO MOVED. SENATOR
6 TORRES SECONDS. I WILL NOT ENTERTAIN DISCUSSION.
7 ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED? MOTION
8 CARRIES UNANIMOUSLY.

9 MARIA, SHOULD WE TRY TO GET ANYTHING ELSE
10 OR SHOULD WE ADJOURN TO LUNCH NOW?

11 MS. BONNEVILLE: I THINK WE COULD GET NO.
12 16 DONE.

13 CHAIRMAN THOMAS: NO. 16, YES. THIS IS AN
14 ANNUAL AGENDA TOPIC WHICH WE ALL LOOK FORWARD TO,
15 WHICH IS THE APPROVAL OF THE CONTRACT FOR MR.
16 HARRISON.

17 MR. TORRES: WHO?

18 MS. BONNEVILLE: HE WON'T LOOK AT YOU.

19 CHAIRMAN THOMAS: MR. HARRISON IS
20 SHIELDING HIS EYES.

21 MR. TORRES: WE HAVE A RESOLUTION FOR HIM?

22 CHAIRMAN THOMAS: IS HE RETIRING?

23 DR. PRIETO: IS THIS APPROPRIATE AT THIS
24 POINT IN THE LIFE OF THE AGENCY?

25 CHAIRMAN THOMAS: SO THIS TOPIC DOES NOT

BARRISTERS' REPORTING SERVICE

1 NEED MUCH DISCUSSION. EVERYBODY UNDERSTANDS THE
2 EXTREMELY CRUCIAL ROLE MR. HARRISON PLAYS IN HIS
3 CAPACITY AS COUNSEL TO THE BOARD AND HAS PLAYED
4 SINCE INCEPTION OF THE AGENCY. HE IS A PIVOTAL
5 PERSON IN ALL DISCUSSIONS AFFECTING ALL OF THE MAJOR
6 ISSUES AND MANY OF THE MINOR ISSUES THAT THE AGENCY
7 DEALS WITH ON A DAY-TO-DAY BASIS AND DOES JUST
8 OUTSTANDING WORK. I'M SURE SENATOR TORRES WILL ECHO
9 THIS HAVING BEEN A GOVERNMENT OFFICIAL IN ANOTHER
10 CAPACITY PRIOR TO CIRM. WE DEAL WITH OUTSIDE
11 COUNSEL FROM MANY DIFFERENT PLACES. AND AS I'VE
12 COMMENTED REPEATEDLY, AND, JAMES, YOU DON'T HAVE TO
13 HEAR THIS, THAT I HAVE NOT HAD THE PRIVILEGE OF
14 WORKING WITH ANY BETTER THAN MR. HARRISON. HE DOES
15 YEOMAN'S WORK FOR US AT A SIGNIFICANT DISCOUNT TO
16 HIS NORMAL RATE, IF I UNDERSTAND THAT CORRECTLY, MR.
17 HARRISON.

18 MR. HARRISON: THAT IS CORRECT.

19 CHAIRMAN THOMAS: THAT IS CORRECT. SO --

20 MR. TORRES: SO MOVED.

21 CHAIRMAN THOMAS: MOTION APPROVED BY
22 SENATOR TORRES.

23 MS. LANSING: SECOND.

24 CHAIRMAN THOMAS: SECONDED BY SHERRY. DO
25 WE HAVE OTHER COMMENTS ON THIS AGENDA TOPIC?

BARRISTERS' REPORTING SERVICE

1 HEARING NONE, LET'S PROCEED -- DO WE HAVE ANY PUBLIC
2 COMMENT ON THIS? HEARING NONE, LET'S PROCEED TO A
3 VOICE VOTE EXCEPT FOR DEAN HAWGOOD WHO WE WILL POLL
4 INDIVIDUALLY. ALL THOSE IN FAVOR OF APPROVING THE
5 REMCHO CONTRACT PLEASE SAY AYE. OPPOSED? DEAN
6 HAWGOOD.

7 DR. HAWGOOD: AYE.

8 CHAIRMAN THOMAS: IT IS UNANIMOUS. MR.
9 HARRISON, YOU'VE LIVED TO FIGHT ANOTHER DAY. THANK
10 YOU VERY MUCH.

11 OKAY. NOW MARIA.

12 MS. BONNEVILLE: LUNCH.

13 CHAIRMAN THOMAS: NOW LUNCH IS IN THE
14 ROOM --

15 MS. BONNEVILLE: IF EVERYONE COULD GRAB
16 THEIR LUNCH, IT'S WHERE BREAKFAST WAS THIS MORNING,
17 AND COME BACK IN, WE HAVE A SPOTLIGHT DURING
18 LUNCHTIME.

19 CHAIRMAN THOMAS: OKAY. AND FOR THOSE WHO
20 DIDN'T GO TO BREAKFAST IN THE MORNING, IT'S OUT THIS
21 DOOR AND BACK TO THE RIGHT. THANK YOU. WE WILL
22 RECONVENE IN A FEW MINUTES ONCE EVERYBODY HAS GOTTEN
23 THEIR LUNCH. SAM, I HOPE YOU HAVE SOMETHING TASTY
24 LINED UP ON YOUR END.

25 (A RECESS WAS TAKEN.)

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: OKAY. RESUMING WITH THE
2 AGENDA, WE ARE NOW GOING TO ITEM NO. 8,
3 CONSIDERATION OF THE APPLICATION FOR RFA DEALING
4 WITH THE STRATEGIC PARTNERSHIP III AWARDS. ONE
5 MOMENT WHILE WE READJUST THE VISUAL HERE. OKAY.
6 ARE WE ALL SET TO GO HERE?

7 MS. BONNEVILLE: YES, WE ARE.

8 CHAIRMAN THOMAS: WE'LL GIVE A MINUTE
9 HERE. IF EVERYBODY COULD PLEASE TAKE THEIR SEATS.
10 OKAY. WE'RE GOING TO GO NEXT TO ITEM NO. 8,
11 CONSIDERATION OF THE STRATEGIC PARTNERSHIP III
12 AWARDS. DR. CARAS.

13 DR. CARAS: THANK YOU. MR. CHAIRMAN,
14 MEMBERS OF THE BOARD, AND PUBLIC, I'M GOING TO
15 PRESENT THE RECOMMENDATIONS FROM THE GRANTS WORKING
16 GROUP ON THE STRATEGIC PARTNERSHIP III AWARDS.

17 SO JUST TO REMIND YOU, THE PURPOSE OF THE
18 STRATEGIC PARTNERSHIP INITIATIVE IS TO ATTRACT
19 INDUSTRY ENGAGEMENT AND INVESTMENT IN CIRM-FUNDED
20 STEM CELL RESEARCH. AND THE INTENT BEHIND THIS IS,
21 FIRST, TO PROVIDE A SOURCE OF CO-FUNDING IN THE
22 EARLY STAGES OF THE DEVELOPMENT. SECOND, AND VERY
23 IMPORTANT, TO ENHANCE THE LIKELIHOOD THAT
24 CIRM-FUNDED PROJECTS ARE GOING TO OBTAIN FOLLOW-ON
25 FINANCING TO FUND THE LATEST STAGES OF DEVELOPMENT

BARRISTERS' REPORTING SERVICE

1 THAT CIRM WILL BE UNABLE TO FUND. AND THIRDLY, TO
2 ENABLE CIRM-FUNDED PROJECTS TO ACCESS THE EXTENSIVE
3 DEVELOPMENT EXPERTISE THAT EXISTS WITHIN LARGE
4 PHARMA AND BIOTECH COMPANIES.

5 AGAIN, TO REMIND YOU, THIS INITIATIVE HAS
6 TWO UNIQUE FEATURES. FIRST, IT REQUIRES APPLICANTS
7 TO DEMONSTRATE COMMERCIAL VALIDATION; IN OTHER
8 WORDS, TO SHOW THAT THEY HAVE FINANCIAL CAPACITY TO
9 MOVE THE PROJECT THROUGH DEVELOPMENT. AND THIS CAN
10 BE EVIDENCED EITHER BY DEMONSTRATING FINANCIAL
11 STRENGTH, WHICH WOULD BE BASED ON INVESTMENTS PLUS
12 LIQUID ASSETS, OR BY HAVING A RESEARCH OR
13 DEVELOPMENT AGREEMENT WITH A LARGE PHARMA OR BIOTECH
14 COMPANY THAT'S COMMITTED TO PROVIDING SUPPORT FOR
15 THE PROPOSED PROJECT.

16 AND SECOND, APPLICANTS ARE REQUIRED TO
17 PROVIDE CO-FUNDING FOR THE PROPOSED PROJECT.

18 JUST A BIT OF BACKGROUND. THE STRATEGIC
19 PARTNERSHIP INITIATIVE WAS APPROVED BY THE ICOC IN
20 2011 AND AMENDED IN 2012. THE CURRENT CONCEPT
21 DIRECTS CIRM TO IMPLEMENT AN RFA PROCESS WITH
22 SOLICITATIONS EVERY APPROXIMATELY SIX TO NINE
23 MONTHS. AS THE NAME IMPLIES, STRATEGIC PARTNERSHIP
24 III IS THE THIRD SOLICITATION UNDER THIS INITIATIVE.
25 THE AWARD AMOUNT IS UP TO 10 MILLION OVER FOUR YEARS

BARRISTERS' REPORTING SERVICE

1 PER AWARD WITH A POSSIBILITY TO INCREASE THAT TO 15
2 MILLION IN EXTRAORDINARY CIRCUMSTANCES, AND UP TO \$8
3 MILLION HAVE BEEN ALLOCATED FOR THIS PROGRAM.

4 THE OBJECTIVE OF A STRATEGIC PARTNERSHIP
5 III AWARD IS COMPLETION WITHIN FOUR YEARS OF AN
6 EARLY STAGE CLINICAL TRIAL. THAT MEANS PHASE I OR
7 PHASE II. THE FOUR-YEAR PROJECT CAN INCLUDE
8 PRECLINICAL IND-ENABLING WORK, BUT ALL APPLICANTS
9 MUST BE ABLE TO COMPLETE A CLINICAL TRIAL.

10 I THINK IT'S IMPORTANT TO POINT OUT THAT
11 THIS OBJECTIVE IS ALIGNED WITH CIRM'S FIVE-YEAR
12 STRATEGIC GOAL TO ATTRACT INDUSTRY ENGAGEMENT AND
13 INVESTMENT IN CIRM-FUNDED STEM CELL RESEARCH. AND
14 IT'S ALSO ALIGNED WITH CIRM'S FIVE-YEAR STRATEGIC
15 CLINICAL OBJECTIVE WHICH IS TO ADVANCE STEM CELL
16 SCIENCE INTO CLINICAL TRIALS TO ACHIEVE THERAPEUTIC
17 BENEFIT TO PATIENTS.

18 THESE ARE THE PRIORITIES FOR THIS RFA.
19 THEY INCLUDE PROPOSALS AIMED AT FURTHERING
20 DEVELOPMENT OF SUCCESSFULLY COMPLETED CIRM-FUNDED
21 PROJECTS, PROJECTS FROM APPLICANTS THAT HAVE SECURED
22 A DEVELOPMENT AGREEMENT WITH LARGE BIOTECH OR PHARMA
23 COMPANY, AND PROPOSALS THAT INCLUDE A CLINICAL STUDY
24 THAT COULD DEMONSTRATE CLINICAL PROOF OF CONCEPT IF
25 SUCCESSFUL.

BARRISTERS' REPORTING SERVICE

1 THIS SHOWS WHERE THIS PARTICULAR RFA FALLS
2 ALONG THE RESEARCH SPECTRUM THAT'S FUNDED BY CIRM
3 AND IN RELATION TO SOME OF OUR OTHER PROGRAMS. AND
4 AS YOU CAN SEE, SP III IS DESIGNED TO CAPTURE MATURE
5 PROGRAMS THAT ARE EITHER VERY CLOSE TO OR ALREADY AT
6 THE EARLY CLINICAL DEVELOPMENT STAGE.

7 THESE ARE THE REVIEW CRITERIA:
8 SIGNIFICANCE AND IMPACT OF THE PROPOSED THERAPY,
9 SCIENTIFIC RATIONALE AND THE POTENTIAL RISKS AND
10 BENEFITS FOR PATIENTS, THE DESIGN AND FEASIBILITY OF
11 THE PROPOSED PROJECT, AND THIS INCLUDES THE OVERALL
12 DEVELOPMENT PLAN, THE PRECLINICAL PLAN, THE
13 MANUFACTURING STRATEGY, AND, OF COURSE, VERY
14 IMPORTANT, THE DESIGN AND FEASIBILITY OF THE
15 PROPOSED CLINICAL TRIAL. FOURTH, THE PI AND TEAM.
16 AND FINALLY, THE COLLABORATIONS, ASSETS, RESOURCES,
17 AND ENVIRONMENT.

18 FOR THE REVIEW, EACH APPLICATION WAS
19 EVALUATED BY MULTIPLE REVIEWERS WITH SPECIALIZED
20 EXPERTISE IN KEY AREAS. THIS INCLUDED THERAPY
21 DEVELOPMENT, THE REGULATORY PROCESS, PRECLINICAL
22 PHARMACOLOGY AND TOXICOLOGY, MANUFACTURING, CLINICAL
23 TRIAL DESIGN, CLINICAL TRIAL OPERATIONS, AND VERY
24 IMPORTANT DISEASE EXPERTISE IN THE TARGET DISEASE
25 INDICATION.

BARRISTERS' REPORTING SERVICE

1 THE GWG REVIEW MEETING TOOK PLACE IN
2 FEBRUARY 2014.

3 JUST TO REMIND YOU AS TO HOW THE
4 SCIENTIFIC MERIT SCORING WORKS, 100 IS THE HIGHEST,
5 ONE THE LOWEST SCORE POSSIBLE, AND REVIEWERS WERE
6 INSTRUCTED THAT THEIR SCORES ARE DETERMINATIVE.
7 WHAT THAT MEANS IS A SCORE OF 75 TO 100 WOULD PLACE
8 AN APPLICATION IN TIER I, RECOMMENDED FOR FUNDING.
9 65 TO 74 WOULD PUT IT IN TIER II, AND THIS MEANS
10 EITHER THAT THE SCIENCE IS MODERATE OR THERE'S NO
11 CONSENSUS AND IT COULD BE SUITABLE FOR PROGRAMMATIC
12 CONSIDERATION BY THE BOARD. A SCORE OF 1 TO 64
13 WOULD PLACE IT IN TIER III, NOT RECOMMENDED FOR
14 FUNDING.

15 JUST TO SUMMARIZE THE OUTCOME OF THE SP
16 III REVIEW, SIX APPLICATIONS MET THE COMMERCIAL
17 VALIDATION AND OTHER ELIGIBILITY REQUIREMENTS AND
18 WERE REVIEWED. FIVE WERE FROM INDUSTRY APPLICANTS.
19 ONE WAS AN ACADEMIC WITH AN INDUSTRY PARTNER. OF
20 THE SIX, TWO RECEIVED A SCORE THAT PLACED THEM IN
21 TIER I, RECOMMENDED; THREE IN TIER II, SUITABLE FOR
22 PROGRAMMATIC, AND ONE IN TIER III.

23 AND THIS SLIDE SHOWS YOU THE APPLICATIONS
24 WITH THE SCORES. AND THE STAFF RECOMMENDATION IS IN
25 AGREEMENT WITH THE GWG RECOMMENDATIONS WHICH IS TO

BARRISTERS' REPORTING SERVICE

1 FUND THE APPLICATIONS IN TIER I AND NOT TO FUND THE
2 APPLICATIONS IN TIERS II AND III. I THINK I'LL STOP
3 THERE.

4 CHAIRMAN THOMAS: OKAY. THANK YOU, DR.
5 CARAS. MR. SHEEHY, WOULD YOU LIKE TO PROCEED WITH
6 PROGRAMMATIC REVIEW?

7 MR. SHEEHY: SURE. SO I THINK IN YOUR
8 BOOKS, AND MAYBE WE COULD HAVE JUST A QUICK NOTE ON
9 THIS, THE TOP APPLICATION IN TIER II HAS BEEN
10 DEFERRED ON THE BASIS OF MATERIAL NEW INFORMATION.
11 SO THAT ONE, WHICH IS 07526 FOR SMALL MOLECULE
12 TARGETING CSC'S FOR TRIPLE NEGATIVE BREAST CANCER,
13 SO THAT ONE --

14 DR. SAMBRANO: SO THERE'S A SHEET THAT YOU
15 SHOULD HAVE IN FRONT OF YOU THAT LOOKS BASICALLY
16 LIKE THIS. THAT'S JUST TO SHOW YOU WHAT THE SHEET
17 LOOKS LIKE, BUT IT DESCRIBES THE ACTIONS THAT HAVE
18 TAKEN PLACE FOR THOSE APPLICATIONS IN TIER II FOR
19 WHICH WE HAPPEN TO HAVE RECEIVED REQUESTS FOR
20 RECONSIDERATION. AND AS MR. SHEEHY JUST SAID, FOR
21 7526, WHICH SCORED 74, THAT ONE IS BEING DEFERRED
22 FOR FURTHER REVIEW BY A GRANTS WORKING GROUP
23 SUBCOMMITTEE. SO THAT ONE WILL NOT BE CONSIDERED AT
24 TODAY'S MEETING.

25 MR. SHEEHY: SO IN TERMS OF THE PROCESS,

BARRISTERS' REPORTING SERVICE

1 WE SHALL PROCEED LIKE WE DID THIS MORNING. IS THERE
2 ANY -- ARE THERE ANY MOTIONS TO MOVE ANY
3 APPLICATIONS OUT OF TIER I? AND ACTUALLY DR. MILLS
4 PARTICIPATED IN THIS REVIEW.

5 DR. MILLS: THIS ONE I KNOW.

6 MR. SHEEHY: THIS ONE HE KNOWS. DR.
7 LUBIN.

8 DR. LUBIN: I JUST WAS CURIOUS JUST FOR
9 GENERAL EDUCATION. ALL THESE ADVANCES WITH NEW
10 COMBINATION THERAPIES FOR HIV, IT WAS STILL FELT
11 THAT AUTOLOGOUS TRANSPLANT HAD A ROLE?

12 MR. SHEEHY: SHOULD I ANSWER THAT? WELL,
13 WHERE SHOULD I START? NO. 1 --

14 DR. LUBIN: YOU CAN SAY YES THERE IS STILL
15 A ROLE.

16 MR. SHEEHY: FIRST OF ALL, ONLY ONE IN
17 FIVE AMERICANS WITH HIV ARE SUCCESSFULLY TREATED.
18 SO 80 PERCENT OF PEOPLE LIVING WITH HIV ARE NOT
19 SUCCESSFULLY TREATED. PREDOMINANTLY THAT POPULATION
20 ARE LOW-INCOME FOLKS, PEOPLE OF COLOR. SO OUR
21 ABILITY TO DELIVER THESE MEDICATIONS TO THE
22 POPULATION THAT'S HAVING THE HARDEST TIME WITH HIV
23 HAS NOT BEEN THAT SUCCESSFUL.

24 NO. 2, HIV IS NOT -- EVEN WELL CONTROLLED
25 HIV STILL HAS ONGOING REPLICATION IN THE GUT AND IN

BARRISTERS' REPORTING SERVICE

1 THE BRAIN AND OTHER RESERVOIRS THAT HAVE LED TO MUCH
2 HIGHER RATES OF HEART DISEASE, MORTALITY IN PEOPLE
3 WITH HIV. A REALLY GOOD STUDY ACTUALLY CONDUCTED BY
4 KAISER SHOWS A MUCH HIGHER RATE OF NON-HIV RELATED
5 CANCERS, COLON, LUNG CANCERS, IN PEOPLE WITH HIV
6 BECAUSE OF REPLICATION AND INFLAMMATORY PROCESSES
7 BOTH GIVE US HIGHER RATES OF HEART DISEASE AND
8 HIGHER RATES OF CANCER.

9 AND THEN THERE REALLY IS THE BURDEN OF
10 JUST DELIVERING THESE DRUGS AND REALLY THE
11 SHORTCOMINGS OF OUR HEALTHCARE SYSTEM. SO A VERY
12 RECENT STORY TALKED ABOUT A BABY IN MISSISSIPPI WHO
13 WAS CURED OF HIV. AND THIS KIND OF HIGHLIGHTS THE
14 FAILURE OF THE CARE SYSTEM. THE BABY WAS CURED BY
15 ACCIDENT. SO THE MOTHER GOT NO PRENATAL CARE, AND
16 SO WE KNOW IF WE TREAT SOMEBODY, WE TREAT SOMEONE
17 WHO HAS HIV WHO'S DELIVERING A BABY, AT BIRTH WE
18 HAVE BETTER THAN A 95 PERCENT CHANCE OF THWARTING
19 THE HIV FROM BEING -- INFECTING THE BABY. THE
20 PRENATAL CARE WAS NOT DELIVERED. IN POSTBIRTH THE
21 INFECTED BABY, ACTUALLY THEY DIDN'T HAVE PEDIATRIC
22 DOSES OF THE ANTIRETROVIRAL, SO THEY GAVE THEM ADULT
23 DOSES. SO THIS BABY GOT MORE DRUG THAN THEY SHOULD
24 HAVE GOTTEN. THEN THE MOTHER AND THE CHILD WERE
25 LOST TO FOLLOW-UP.

BARRISTERS' REPORTING SERVICE

1 SO THEY FIND THIS BABY LIKE THREE YEARS
2 LATER WHO'S NOW A SMALL CHILD AND THERE'S NO HIV.
3 AND WE JUST HAD ANOTHER CASE OF THAT ACTUALLY IN
4 RIVERSIDE. NONE OF THESE WOULD HAVE HAPPENED IF
5 THIS BABY HAD GOTTEN THE STANDARD OF CARE. AND THIS
6 IS IN THE UNITED STATES, AND THIS IS FREQUENTLY WHAT
7 WE SEE IN TERMS OF CARE DELIVERY.

8 I HEARD ONE PHYSICIAN TALKING ABOUT THE
9 STATISTIC THAT WE'RE DOING SUCH A BAD JOB OF
10 TREATING PEOPLE WITH HIV FROM ATLANTA AT THE LAST
11 AIDS CONFERENCE, THE JOURNAL OF THE AMERICAN MEDICAL
12 ASSOCIATION PRESS CONFERENCE, SAY, LOOK, THERE'S A
13 CLINIC NOT BLOCKS FROM WHERE I TREAT MY PATIENTS IS
14 GIVING PEOPLE THIRD WORLD CARE, WHICH I THINK WE'RE
15 ALL AWARE OF THE DISPARITIES IN DELIVERY OF
16 HEALTHCARE IN THIS COUNTRY.

17 SO I THINK IT'S RATIONAL.

18 DR. LUBIN: OKAY. THANKS.

19 MR. SHEEHY: AND IT'S PROBABLY COST -- AND
20 ULTIMATELY IT'S COST-EFFECTIVE.

21 DR. LUBIN: I UNDERSTAND THAT. THANK YOU.

22 MR. SHEEHY: ANYWAY, TO GO BACK, IS THERE
23 A MOTION TO MOVE SOMETHING OUT OF TIER I? IS THERE
24 A MOTION TO MOVE ANYTHING FROM TIER II INTO TIER I?
25 IS THERE A MOTION TO MOVE THE APPLICATION IN TIER

BARRISTERS' REPORTING SERVICE

1 III TO TIER I? IS THERE A MOTION TO FUND THE
2 APPLICATIONS IN TIER I, NOT FUND THE APPLICATIONS IN
3 TIER II AND III?

4 DR. JUELSGAARD: SO MOVED.

5 DR. PRIETO: SECOND.

6 MR. SHEEHY: IS THERE -- ARE THERE ANY
7 PUBLIC COMMENTS? I THINK WE CAN CALL THE ROLL. AND
8 I THINK OUR FORM FOR -- OUR FORMULA FOR DOING THIS
9 IS THE SAME AS BEFORE.

10 MR. HARRISON: CORRECT. YES OR NO EXCEPT
11 WITH RESPECT TO THOSE APPLICATIONS WITH WHICH YOU
12 HAVE A CONFLICT AND OBVIOUSLY EXCEPT FOR THE
13 APPLICATION FOR WHICH THE REVIEW HAS BEEN DEFERRED.

14 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

15 DR. DULIEGE: YES, EXCEPT FOR THE
16 APPLICATION FOR WHICH I HAVE A CONFLICT.

17 MS. BONNEVILLE: STEVE JUELSGAARD.

18 DR. JUELSGAARD: YES.

19 MS. BONNEVILLE: SHERRY LANSING.

20 MS. LANSING: YES, EXCEPT FOR THOSE FROM
21 WHICH I'M RECUSED.

22 MS. BONNEVILLE: JOE PANETTA.

23 MR. PANETTA: YES.

24 MR. HARRISON: JOE, EXCEPT FOR THOSE --
25 THE APPLICATION WITH WHICH YOU HAVE A CONFLICT.

BARRISTERS' REPORTING SERVICE

1 THERE'S ONE.

2 MR. PANETTA: EXCEPT FOR THE APPLICATION
3 FOR WHICH I HAVE A CONFLICT.

4 MS. BONNEVILLE: FRANCISCO PRIETO.

5 DR. PRIETO: YES, EXCEPT FOR THOSE WITH
6 WHICH I HAVE A CONFLICT.

7 MS. BONNEVILLE: JEFF SHEEHY.

8 MR. SHEEHY: YES, EXCEPT FOR THOSE WITH
9 WHICH I HAVE A CONFLICT.

10 MS. BONNEVILLE: OS STEWARD.

11 DR. STEWARD: YES, EXCEPT FOR THOSE WITH
12 WHICH I HAVE A CONFLICT.

13 MS. BONNEVILLE: JONATHAN THOMAS.

14 CHAIRMAN THOMAS: YES.

15 MS. BONNEVILLE: ART TORRES.

16 MR. TORRES: AYE. I NEVER HAVE A
17 CONFLICT.

18 MS. BONNEVILLE: DIANE WINOKUR.

19 MS. WINOKUR: YES.

20 MR. HARRISON: THAT MOTION CARRIES.

21 CHAIRMAN THOMAS: OKAY. THANK YOU,
22 MR. SHEEHY. WE ARE NOW ON TO ITEM NO. 10,
23 CONSIDERATION OF APPLICATION FOR THE RFA REGARDING
24 EXTRAORDINARY SUPPLEMENT AWARD OF THE MAJOR VARIETY
25 FOR EARLY TRANSLATIONAL III PROJECT, DR. BLAU. DR.

BARRISTERS' REPORTING SERVICE

1 OLSON WILL LEAD THIS DISCUSSION.

2 DR. OLSON: THANK YOU, MR. CHAIRMAN.

3 OKAY. I'D LIKE TO JUST TAKE A FEW MINUTES TO REMIND
4 YOU ABOUT THIS PROGRAM. IN DECEMBER OF 2012, THE
5 ICOC APPROVED A TOTAL OF \$16 MILLION FOR
6 EXTRAORDINARY SUPPLEMENTAL AWARDS. TWELVE MILLION
7 WAS ALLOCATED FOR MAJOR SUPPLEMENTS, AND I WILL
8 DESCRIBE WHAT THAT MEANS IN JUST ANOTHER MINUTE, AND
9 FOUR MILLION WAS ALLOCATED FOR MINOR SUPPLEMENTS.

10 THE PROGRAM GOAL WAS TO PROVIDE
11 SUPPLEMENTAL FUNDING TO EXISTING CIRM-FUNDED
12 RESEARCH PROJECTS THAT COULD ALLOW ACHIEVEMENT OF
13 VERY SIGNIFICANT TRANSFORMATIONAL OR TRANSLATIONAL
14 RESULTS THAT COULD NOT BE ACCOMPLISHED WITH THE
15 EXISTING FUNDING.

16 THE PROJECT ELIGIBILITY AND SCOPE WAS IT
17 WAS OPEN TO MOST ACTIVE CIRM AWARDS. YOU CAN SEE
18 THE EXCLUSION IN THE FOOTNOTE, THAT WERE AT LEAST
19 ONE YEAR INTO THE PROJECT PERIOD, WERE SHOWING GOOD
20 PROGRESS ON THE PROJECT, AND THEN THE SCOPE AND
21 OTHER REQUIREMENTS WERE COMPARABLE TO THAT OF THE
22 PARENT RFA.

23 WHETHER SOMETHING WAS A MINOR SUPPLEMENT
24 OR A MAJOR SUPPLEMENT WAS DEFINED BY THE REQUESTED
25 LEVEL OF FUNDING; WHEREAS, A MINOR SUPPLEMENT WAS

BARRISTERS' REPORTING SERVICE

1 THE LESSER OF 10 PERCENT OF THE EXISTING AWARD OR UP
2 TO A MAXIMUM OF 500,000. A MAJOR SUPPLEMENT WAS
3 DEFINED AS THE LESSER OF EITHER 50 PERCENT OF THE
4 EXISTING AWARD OR UP TO \$3 MILLION.

5 I JUST WANT TO REMIND YOU ABOUT THE
6 PROCESS FOR A MAJOR SUPPLEMENT APPLICATION AND
7 REVIEW PROCESS. THE PROCESSES DO DIFFER A BIT
8 DEPENDING ON WHETHER IT IS A MAJOR SUPPLEMENT
9 REQUEST OR A MINOR SUPPLEMENT REQUEST. SO I'D LIKE
10 TO REMIND YOU OF THOSE.

11 THE PI SUBMITS A BRIEF PROPOSAL THAT
12 SUMMARIZES THE PROPOSED RESEARCH AND ADDRESSES HOW
13 IT MEETS THE GOAL OF THE PROGRAM. THAT PROPOSAL IS
14 ASSESSED INTERNALLY BY STAFF FOR ELIGIBILITY AND
15 RESPONSIVENESS, AND THEN THE CIRM PRESIDENT MAKES
16 THE DECISION AS TO WHETHER TO INVITE SUBMISSION OF A
17 FULL APPLICATION UPON REVIEW OF THE PROPOSAL AND
18 WITH STAFF INPUT. IF INVITED, THE PI SUBMITS A FULL
19 APPLICATION.

20 FOR A MAJOR SUPPLEMENT THE FULL
21 APPLICATION IS REVIEWED BY THE GRANTS WORKING GROUP
22 WHO MAKE THE FUNDING RECOMMENDATION. I DO WANT TO
23 POINT OUT THAT IN THOSE CASES WHERE THE SUPPLEMENT
24 IS REQUESTING FUNDING FOR FDA-MANDATED ADDITIONAL
25 STUDIES, THEN THE CDAP CAN MAKE THE -- CAN GIVE

BARRISTERS' REPORTING SERVICE

1 ADVICE TO THE PRESIDENT. AND, AGAIN, THAT WILL COME
2 TO THE BOARD FOR DECISION. SO THAT'S TRUE FOR THE
3 DISEASE TEAM, THE DISEASE TEAM THERAPY DEVELOPMENT,
4 OR THE SP AWARDS. AND THEN IN BOTH THOSE CASES, THE
5 ICOC MAKES THE FUNDING DECISION.

6 A MINOR SUPPLEMENT, THE PROCESS IS
7 IDENTICAL TO INVITATION TO SUBMIT A FULL
8 APPLICATION, BUT IN THIS CASE THIS DOES NOT REQUIRE
9 A FULL GRANTS WORKING GROUP REVIEW. IT MUST BE
10 REVIEWED BY AT LEAST TWO MEMBERS OF THE GRANTS
11 WORKING GROUP WHO MAKE A FUNDING RECOMMENDATION TO
12 THE PRESIDENT, AND THEN THE PRESIDENT MAKES THE
13 FUNDING DECISION WITH STAFF INPUT, AND THE ICOC IS
14 THEN INFORMED OF THAT DECISION AND OF THAT FUNDING.

15 THE REVIEW CRITERIA IS BASICALLY SOMEWHAT
16 OF OUR STANDARD REVIEW CRITERIA. IT'S VIEWED ON THE
17 BASIS OF OBJECTIVE, RATIONALE, AND RESPONSIVENESS.
18 ARE THE OUTCOMES POTENTIALLY TRANSFORMATIONAL OR
19 ACHIEVE SIGNIFICANT TRANSLATIONAL RESULTS AND NOT
20 ACHIEVABLE WITH EXISTING FUNDING.

21 TO LOOK AT FEASIBILITY AND DESIGN, THE
22 REVIEWERS WHO ARE ASKED TO EVALUATE IS EXISTING
23 PROJECT PROGRESS, ANY PRELIMINARY DATA THAT'S
24 DIRECTLY RELEVANT TO THE PROPOSED SUPPLEMENT, THE
25 RESEARCH PLAN, AND THE BUDGET. AND THE REVIEWERS

BARRISTERS' REPORTING SERVICE

1 ARE ALSO ASKED TO LOOK AT THE TEAM, THE ASSETS, THE
2 COLLABORATION, THE RESOURCES, AND ENVIRONMENT.

3 I DO WANT TO TAKE THIS OPPORTUNITY TO LET
4 YOU KNOW THAT AN EXTRAORDINARY SUPPLEMENT HAS BEEN
5 MADE TO EARLY TRANSLATIONAL AWARD DR 1249, A MINOR
6 SUPPLEMENT. IT WAS TO CONDUCT STUDIES TO ASSESS
7 PROCESS SCALABILITY OF THE PROPOSED THERAPEUTIC
8 CANDIDATE AS WELL AS PRECLINICAL STUDIES IN THE
9 TARGET INDICATION OF OSTEONECROSIS. THE REQUESTED
10 FUNDING WAS FOR ESSENTIALLY \$500,000. IT WAS
11 REVIEWED BY THREE MEMBERS OF THE GRANTS WORKING
12 GROUP, ALL OF WHOM STRONGLY RECOMMENDED FUNDING.
13 SCORES WERE ABOVE 80 IN ALL INSTANCES, AND IT WAS A
14 APPROVED BY THE PRESIDENT WITH STAFF INPUT.

15 I NOW WANT TO MOVE ON TO THE SPECIFIC
16 ACTION ITEM THAT YOU ARE BEING ASKED TO CONSIDER
17 TODAY, WHICH IS THE REQUEST FOR MAJOR SUPPLEMENTAL
18 FUNDING TO DR 305501 TO EVALUATE HUMAN SKELETAL
19 MUSCLE STEM CELLS IN AN ADDITIONAL INDICATION, WHICH
20 IS STRESS URINARY INCONTINENCE THAT COULD OFFER A
21 POTENTIALLY FASTER PATH FOR CLINICAL DEVELOPMENT AND
22 BE POTENTIALLY TRANSFORMATIVE. THE REQUESTED
23 FUNDING IS FOR \$900,000. IT WAS REVIEWED BY THE
24 GRANTS WORKING GROUP. THE AVERAGE SCORE WAS 73
25 WHICH PLACES IT IN TIER II. BUT I WILL LET YOU KNOW

BARRISTERS' REPORTING SERVICE

1 THE MEDIAN SCORE WAS 75. THE RANGE WAS 60 TO 80
2 WITH A STANDARD DEVIATION OF 5.4.

3 WE DID MAKE A STAFF RECOMMENDATION ON THIS
4 ONE, AND I WILL JUST SUMMARIZE THE POINTS FOR
5 CONSIDERATION THAT I'D LIKE THE BOARD TO TAKE INTO
6 CONSIDERATION IN THEIR PROGRAMMATIC DISCUSSION. I
7 WOULD ALSO NOTE THAT DR. LISA KADYK IS HERE TO GO
8 OVER THE REVIEWS -- THE GRANTS WORKING GROUP REVIEW
9 SUMMARY IF YOU HAVE ANY FURTHER QUESTIONS.

10 BUT BASICALLY THE STAFF RECOMMENDATION
11 INDICATES THAT IT DOES LEVERAGE TEAM EXPERTISE AND
12 KNOW-HOW TO ADDRESS A SECOND DISEASE TARGET
13 WHERE -- THE REASON WHY WE THINK THIS HAS A FASTER
14 PATH TO THE CLINIC IS THERE ARE NOT VERY MANY CELLS
15 REQUIRED. THERE WOULDN'T BE THAT MANY CELLS
16 REQUIREMENT FOR DISEASE MODIFICATION. AND IT'S ALSO
17 A COMPLEMENTARY APPROACH IN THE PORTFOLIO.

18 CIRM IS CURRENTLY FUNDING ONE OTHER
19 PROJECT TARGETING THIS INDICATION, BUT IT USES AN
20 APPROACH TARGETING SMOOTH MUSCLE CELLS RATHER THAN
21 SKELETAL MUSCLE CELLS. AS BOTH MUSCLE TYPES ARE
22 IMPACTED IN STRESS URINARY CONTINENCE, AND THE
23 CONTRIBUTION OF EACH TO DISEASE PATHOPHYSIOLOGY IS
24 NOT TOTALLY CLEAR, THIS WOULD BE A COMPLEMENTARY
25 APPROACH.

BARRISTERS' REPORTING SERVICE

1 AS I SAY, DR. KADYK CAN TALK ABOUT IMPACT
2 AND THE NUMBER OF PATIENT POPULATIONS. SO THAT IS
3 THE STAFF RECOMMENDATION. AND WITH THAT, I'M HAPPY
4 TO TAKE ANY QUESTIONS. OTHERWISE I'M TURNING IT
5 BACK TO MR. SHEEHY. THANK YOU.

6 MR. SHEEHY: WELL, I DO HAVE A COUPLE OF
7 QUESTIONS. ONE OF THE THINGS I FIND REALLY
8 CHALLENGING WITH THIS IS, UNLIKE OTHER REVIEWS, THE
9 PATIENT ADVOCATE MEMBERS OF THE WORKING GROUP WERE
10 NOT PROVIDED WITH THE APPLICATION, NOR WERE WE
11 PROVIDED WITH THE CRITIQUES. SO A THIRD OF THE
12 WORKING GROUP ARE BASICALLY BLINDED.

13 DR. OLSON: I'M JUST ADDRESSING THE FACT
14 THAT IN THE CONCEPT THAT THE BOARD APPROVED -- I BEG
15 YOUR PARDON. THEY'RE NOT PROVIDED WITH IT?

16 MR. SHEEHY: I'VE NEVER SEEN AN
17 APPLICATION OR --

18 DR. OLSON: OH, SORRY. THIS WAS A MAJOR
19 SUPPLEMENT. WELL, THAT IS SOMETHING THAT OBVIOUSLY
20 SHOULD HAVE BEEN CORRECTED BECAUSE IT DID COME
21 BEFORE THE GRANTS WORKING GROUP. AND SO INSOFAR AS
22 MEMBERS OF THE WORKING GROUP HAVE ACCESS TO
23 APPLICATIONS, I WAS NOT AWARE OF THAT.

24 MR. SHEEHY: AND IT KIND OF CAUSES A
25 BREAKDOWN BETWEEN -- BECAUSE USUALLY I REFER TO

BARRISTERS' REPORTING SERVICE

1 THOSE --

2 DR. OLSON: OF COURSE.

3 MR. SHEEHY: -- IN ORDER TO -- AND SO I
4 HAVE A FEW NOTES. AND SO IT'S JUST REALLY
5 CHALLENGING IN TRYING TO FIGURE OUT HOW TO MOVE
6 FORWARD ON THIS WHEN --

7 DR. OLSON: I WOULD HAVE BEEN HAPPY TO
8 MAKE IT AVAILABLE TO YOU IF YOU HAD REQUESTED
9 EARLIER.

10 MR. SHEEHY: I NEVER KNOW WHETHER THINGS
11 ARE DONE INTENTIONALLY OR ACCIDENTALLY. MY
12 ASSUMPTION IS GOING FORWARD, BUT IT'S HARD BECAUSE I
13 HAVEN'T -- I COULDN'T REVIEW ANYTHING. I DID IN MY
14 NOTES HAVE PEOPLE MAKE SEVERAL NEGATIVE COMMENTS.
15 ONE WAS THIS GRANT HAS ONLY GONE ON FOR A YEAR.
16 THEY HAVEN'T FINISHED AIM 1 OR 2. SO THAT WAS A
17 PROBLEM THAT THEY IDENTIFIED. SO THEY WOULD HAVE
18 LIKED TO HAVE SEEN SOME -- IT'S NOT LIKE CUT OFF OR
19 GO. THEY STILL HAVE TWO MORE YEARS OF FUNDING ON A
20 THREE-YEAR GRANT.

21 DR. OLSON: RIGHT. BUT IT'S IN ANOTHER
22 INDICATION. AND SO, AS I SAY, I'D BE HAPPY TO
23 HAVE -- DR. KADYK WOULD BE HAPPY TO SUMMARIZE THE
24 REVIEW AT WHICH YOU WERE PRESENT, THE REVIEW
25 SUMMARY, FOR YOU AND OTHER MEMBERS OF THE BOARD.

BARRISTERS' REPORTING SERVICE

1 THAT WAS ONE COMMENT. AS I INDICATED, THE SCORE WAS
2 73, THE MEDIAN SCORE WAS 75, WHICH WOULD HAVE PUT IT
3 IN TIER I, BUT WE GO ON THE AVERAGE. AND I
4 APPRECIATE AND REGRET THAT YOU DID NOT HAVE AN
5 OPPORTUNITY TO SEE THE APPLICATION.

6 MR. SHEEHY: OTHER COMMENTS WERE THE DATA
7 ON THE CELLS WERE MISSING, THE MODEL ON WHICH THE
8 STUDY -- ON WHICH THIS NEXT STUDY IS GOING TO BE
9 BASED. MY NOTES ARE HARD TO READ. MAY NOT BE THAT
10 USEFUL. I MEAN ONE DIRECT QUOTE, WHY ARE THEY DOING
11 AIM 3 NOW? WHY NOT FINISH AIM 1 OR 2? THE OTHER
12 ONE, HOW MUCH OF THIS CONDITION IS DUE TO NERVE
13 DAMAGE WHICH THESE CELLS MIGHT NOT HAVE AN IMPACT
14 ON?

15 IT'S JUST I DON'T KNOW WHAT TO DO WITH
16 THIS BECAUSE THE PROCESS IS NOT THE SAME AS OTHER
17 GRANTS GO THROUGH, AND THIS WAS SUPPOSED TO BE THE
18 SAME PROCESS. IT'S JUST VERY CONFUSING FOR ME
19 ESPECIALLY WHEN THE WORKING GROUP DIDN'T APPROVE IT.
20 SO THE WORKING GROUP KNEW THAT THE 75 WAS THE SCORE.
21 LOTS OF FOLKS WERE NOT THAT ENTHUSIASTIC OR SOME
22 FOLKS WERE NOT THAT ENTHUSIASTIC WITH IT OR THEY
23 WOULD HAVE SCORED IT IN A FUNDABLE RANGE.

24 DR. OLSON: I WOULD -- AGAIN, I NOTE THAT
25 THE SCORE WAS 73, THE MEDIAN SCORE WAS 75. IT PUTS

BARRISTERS' REPORTING SERVICE

1 IT FIRMLY AT THE TOP OF TIER II, WHICH OBVIOUSLY
2 MAKES IT OBVIOUSLY SUBJECT TO PROGRAMMATIC
3 DISCUSSION.

4 MR. SHEEHY: BUT THE SENSE TO ME THESE
5 KIND OF AWARDS, THEY'RE KIND OF LIKE T BALL, RIGHT?
6 IT'S NOT -- YOU DON'T HAVE KERSHAW THROWING THE
7 PITCH. THIS IS NOT COMPETED AGAINST ANY OTHER
8 APPLICATIONS. THIS IS FURTHER FUNDING FOR A GRANT
9 THAT'S ALREADY BEEN WELL REVIEWED, AND WE HAVE A
10 PROGRESS REPORT ON IT THAT I'M LOOKING AT. IT'S
11 JUST -- I'M JUST IN A STATE OF TOTAL CONFUSION ON
12 THIS BECAUSE I HAVE NO INFORMATION, AND I FEEL
13 UNCOMFORTABLE MAKING A JUDGMENT ON THIS IN THE
14 ABSENCE OF ANY INFORMATION.

15 AND FURTHER, NOT HAVING THAT INFORMATION
16 AT THE WORKING GROUP REALLY DOESN'T FACILITATE
17 ADEQUATE PARTICIPATION BY THE PATIENT ADVOCATES WHO
18 ARE THERE. I DON'T KNOW WHAT OTHER PEOPLE THINK,
19 BUT USUALLY WE HAVE A NICE, CLEAN, WE GET TO READ
20 THE APPLICATION, WE GET TO READ THE CRITIQUES, WE
21 BRING IT FORWARD TO THE BOARD, AND THEN WE HAVE A
22 DISCUSSION.

23 MS. LANSING: AM I ALLOWED TO TALK ON THIS
24 ONE?

25 MR. SHEEHY: SURE. I THINK SO.

BARRISTERS' REPORTING SERVICE

1 MS. LANSING: I GUESS MY QUESTION IS,
2 GIVEN WHAT YOU'VE RAISED, WHICH IS A REALLY
3 LEGITIMATE CONCERN, CAN WE POSTPONE THIS? AND HOW
4 WOULD THAT AFFECT US IF WE POSTPONE IT? CAN WE
5 POSTPONE IT TILL JEFF AND ANYBODY ELSE WHO NEEDS TO
6 HAS THE CHANCE TO LOOK OVER THE MATERIAL? CAN WE
7 HAVE TEN DAYS? CAN WE VOTE ON THIS ON A PHONE CALL?
8 I MEAN THERE'S A LOT OF OPTIONS THAT WE HAVE BEFORE
9 HAVING TO ACT WITHOUT YOU AND PERHAPS MANY OTHER
10 PEOPLE HAVING THE INFORMATION THAT THEY NEEDED.

11 MR. SHEEHY: WELL, THE OTHER POINT IS THAT
12 GRANT IS GOING -- THEY'VE GOT TWO MORE YEARS OF
13 FUNDING ANYWAY.

14 MS. LANSING: I WOULD REALLY URGE US TO
15 ALLOW YOU AND OTHER PEOPLE WHO DID NOT HAVE THE
16 NECESSARY INFORMATION TO REVIEW IT.

17 DR. MILLS: I THINK WHERE IT GOES, THOUGH,
18 IS JEFF'S SAYING AT THE GRANTS WORKING GROUP REVIEW,
19 THE PEOPLE, HALF OR A THIRD OF THE PEOPLE REVIEWING
20 IT DIDN'T HAVE IT. SO POSTPONING IT SO JEFF SEES IT
21 I DON'T THINK IS REALLY HIS POINT. I THINK IT'S WE
22 WOULD HAVE TO RE-REVIEW IT.

23 MS. LANSING: OKAY.

24 DR. MILLS: THE REVIEW WAS FLAWED. AM I
25 GETTING --

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: THAT'S KIND OF --

2 MS. LANSING: OKAY. WELL, THAT'S EVEN
3 MORE CONCERN -- LET ME JUST SAY AND THEN I'LL TURN
4 IT OVER TO. THAT'S EVEN MORE CONCERNING TO ME. SO
5 THAT WASN'T CLEAR FROM WHAT YOU SAID, AND I
6 APPRECIATE THE CLARITY. AND SO THEN I THINK IT
7 SHOULD BE RE-REVIEWED. I THINK WE DON'T WANT TO
8 HAVE A PROCESS THAT IS NOT FULLY TRANSPARENT.

9 DR. OLSON: I WOULD POINT OUT THAT THE
10 GRANTS WORKING GROUP REVIEW AND THE SCORE IS A
11 SCIENTIFIC REVIEW. I REALIZE THAT THE PATIENT
12 ADVOCATES OFTEN COMMENT DURING THE SCIENTIFIC
13 REVIEW, BUT IT IS THE SCIENTISTS WHO ACTUALLY DID
14 THE SCORE. AND THEY DID PARTICIPATE.

15 NOW, I APPRECIATE THE COMMENT THAT THE
16 APPLICATION MATERIALS APPARENTLY WERE NOT MADE
17 AVAILABLE AND CERTAINLY REGRET THAT. BUT I DO WANT
18 TO POINT OUT THAT IT WAS A GRANTS WORKING GROUP
19 REVIEW WITH A SCIENTIFIC SCORE.

20 MR. SHEEHY: BUT IF YOU LOOK AT PROP 71,
21 THE PATIENT ADVOCATES ARE DESCRIBED AS BEING FULL
22 PARTICIPANTS IN THE REVIEW.

23 DR. STEWARD AND THEN MR. JUELSGAARD.

24 DR. STEWARD: I'D LIKE TO ACTUALLY JUST
25 MAKE A MOTION TO SEND THIS BACK TO THE GRANTS

BARRISTERS' REPORTING SERVICE

1 WORKING GROUP BECAUSE THE REVIEW WAS TECHNICALLY
2 FLAWED. I JUST HAVE TO REINFORCE YOUR POINT. THE
3 INTERACTIONS AND EXCHANGES AT THE LEVEL OF THE
4 WORKING GROUP OFTEN INVOLVE QUESTIONS FROM THE
5 PATIENT ADVOCATES THAT ARE REALLY PART OF THE
6 SCIENTIFIC REVIEW. WE DON'T VOTE ON IT, BUT IT'S
7 PART OF THAT SCIENTIFIC REVIEW. SO FROM THE
8 TECHNICAL STANDPOINT, I THINK IT MAKES THE MOST
9 SENSE TO SEND THIS BACK AND GET IT DONE IN THE
10 TECHNICALLY PROPER WAY AND COME BACK. THERE'S NO
11 HURRY ON THIS, AS YOU POINT OUT TO US. THEY HAVE
12 TWO YEARS OF FUNDING LEFT, AND SO IT CAN WAIT.

13 MS. LANSING: I'D LIKE TO SECOND THAT WITH
14 NO REFLECTION AT ALL ON THE SCIENTIFIC REVIEW.
15 WE'RE NOT QUESTIONING THE VALIDITY OF WHAT THEY DID
16 OR ANYTHING, BUT WE ARE WANTING TO HAVE A FULL AND
17 TRANSPARENT PROCESS AS WE WERE ASKED TO DO THROUGH
18 PROP 71. AND ANYTHING THAT QUESTIONS THAT, WE MUST
19 CORRECT. I'M SURE IT WAS UNINTENTIONAL AND WE ALL
20 AGREE WITH THAT. SO LET'S JUST DO THE RIGHT THING,
21 AND THEY'VE GOT THEIR FUNDING ANYWAY. SO I THINK
22 THERE'S NO HARM IN DOING THAT. SO I SECOND THE
23 MOTION.

24 MR. TORRES: CALL FOR THE QUESTION.

25 MR. SHEEHY: YEAH. MR. JUELSGAARD.

BARRISTERS' REPORTING SERVICE

1 DR. JUELSGAARD: JUST ONE ADDITIONAL
2 THING, AND WHETHER IT'S PART -- IF THIS MOTION
3 PASSES PART OF THE GRANTS WORKING GROUP REVIEW OR
4 SEPARATELY A POSTPROGRAMMATIC REVIEW, BUT THERE'S A
5 COMMENT MADE. AND THIS IS NOT ABOUT SCIENCE. THIS
6 IS ABOUT SPENDING MONEY. SO THE COMMENT WAS MADE
7 THAT THIS IS A FOLLOW-ON INDICATION TO A PRIMARY
8 INDICATION. I DON'T KNOW WHAT THE PRIMARY
9 INDICATION IS THAT'S BEING STUDIED, BUT NOW THEY'VE
10 DECIDED TO LAUNCH INTO STRESS URINARY INCONTINENCE
11 AS A SECOND INDICATION. AND IN THE DESCRIPTION THAT
12 WAS PROVIDED TO US, SOME REVIEWERS, I DON'T KNOW HOW
13 MANY, BUT I THOUGHT IT WAS A VERY VALID POINT OF
14 VIEW SUGGESTED THAT PERHAPS YOU SUB OUT. BASICALLY
15 NOW THIS BECOMES THE PRIMARY INDICATION, AND YOU
16 STOP WORK ON THE OTHER INDICATION. IN OTHER WORDS,
17 JUST DO ONE INDICATION AT A TIME.

18 NOW, THERE'S NOT ANY MORE EXPLANATION
19 ABOUT THAT IN HERE, BUT I KNOW THAT THAT OFTENTIMES
20 HAPPENS, AT LEAST IN OTHER FORUMS WHERE CLINICAL
21 TRIAL WORK GOES ON. SO WHETHER THAT'S SOMETHING
22 THAT CAN BE ADDRESSED AT ANOTHER REVIEW OF THE
23 GRANTS WORKING GROUP, IF IT'S DONE THERE, OR
24 SUBSEQUENTLY IN HERE, BUT I'D LIKE TO KNOW A LITTLE
25 BIT MORE ABOUT THE OPPORTUNITY JUST TO SIMPLY TAKE

BARRISTERS' REPORTING SERVICE

1 THE MONEY THAT'S BEING -- THAT'S ALREADY BEEN
2 APPROVED AND INSTEAD FOCUSING ON THIS NEW INDICATION
3 AND PUTTING THE ORIGINAL INDICATION OFF TO THE SIDE.

4 MR. SHEEHY: SO IN ANY EVENT, I THINK THE
5 MOTION IS TO SEND THIS DOWN THE ROAD. DO WE HAVE
6 ANY FURTHER BOARD COMMENT? DO WE HAVE ANY PUBLIC
7 COMMENT ON THIS?

8 DR. COMMONER: THANK YOU FOR GIVING ME
9 THIS OPPORTUNITY TO SPEAK. MY NAME IS CRAIG
10 COMMONER. I'M A PROFESSOR OF UROLOGY, AND I AM
11 WORKING WITH HELEN BLAU, AND I AM SPEAKING ON HER
12 BEHALF. APPROXIMATELY A THIRD OF WOMEN WILL DEVELOP
13 STRESS INCONTINENCE AFTER THEIR FIRST CHILDBIRTH,
14 AND HALF OF WOMEN OVER THE AGE OF 60 WHO HAVE BORNE
15 CHILDREN WILL HAVE STRESS INCONTINENCE. IN
16 ADDITION, 10 PERCENT OF MEN WHO HAVE PROSTATE CANCER
17 SURGERY WILL DEVELOP STRESS INCONTINENCE, HALF OF
18 WHOM ELECT SURGERY.

19 CURRENT TREATMENTS INCLUDE PELVIC FLOOR
20 EXERCISES WHICH HELP ONLY A MINORITY OF PATIENTS.
21 ABDOMINAL SURGERY HAS A SUCCESS RATE OF ABOUT 60
22 PERCENT, BUT AT THE PRICE OF AN ABDOMINAL APPROACH,
23 A HOSPITALIZATION, AND A THREE-MONTH RECOVERY.
24 SLING SURGERY HAS EMERGED AS THE NO. 1 OPTION FOR
25 PATIENTS; HOWEVER, THE RECENT FDA WARNING ABOUT THE

BARRISTERS' REPORTING SERVICE

1 SURGICAL MESH COMPLICATIONS HAS MADE PATIENTS AND
2 SURGEONS MIGRATE AWAY FROM THIS TREATMENT.
3 PARAURETHRAL INJECTIONS OF BULKING AGENTS WORK ONLY
4 30 TO 50 PERCENT OF THE TIME AND ONLY TEMPORARILY,
5 AND THIS IS NOW RESERVED FOR A MINORITY OF PATIENTS
6 WHO ARE EITHER TOO SICK FOR SURGERY OR AVERSE TO
7 SURGERY.

8 THE GOAL OF THIS PROJECT IS TO DEVELOP
9 MUSCLE STEM CELL THERAPY FOR TREATING STRIATED
10 URETHRAL SPHINCTER MUSCLE ATROPHY AND STRESS
11 INCONTINENCE. THERE'S A COLLABORATION AMONG BASIC
12 SCIENTISTS, BIOENGINEERS, AND UROLOGISTS. THE
13 PROPOSAL IS TO PURIFY THESE MUSCLE STEM CELLS FROM
14 LIMB MUSCLE BIOPSY TRANSPLANTED INTO THE EXTERNAL
15 URETHRAL SPHINCTER OF THE SAME PATIENT WHO SUFFERS
16 FROM STRESS INCONTINENCE. THE CURRENT PROJECT
17 EVALUATES THESE HUMAN MUSCLE SATELLITE CELLS THAT
18 ARE TRANSPLANTED INTO STRESS INCONTINENT MICE USING
19 A WELL-ESTABLISHED MODEL OF STRESS INCONTINENCE.
20 AND THE METHOD OF EVALUATING FUNCTION AND STRENGTH
21 OF THE NEW SPHINCTER IS ALSO VALIDATED.

22 WHY MUSCLE STEM CELLS? THE CURRENT
23 INJECTIONS WITH BULKING AGENTS ARE MERELY BULKING
24 RATHER THAN FUNCTIONAL. AND EFFICACY IS TEMPORARY
25 AT BEST.

BARRISTERS' REPORTING SERVICE

1 WHAT MAKES THIS AN ATTRACTIVE TREATMENT
2 OPTION IS THAT THE SOURCE IS AUTOLOGOUS. THE
3 EXTERNAL SPHINCTER IS READILY AVAILABLE WITH A
4 MINIMALLY INVASIVE INJECTION. AND AS WE SAID UP ON
5 THE BOARD, THE EXTERNAL SPHINCTER IS SMALL, SO A
6 SMALL VOLUME OF STEM CELLS IS NECESSARY. THESE
7 SATELLITE CELLS EXPAND AND SELF-RENEW IN VIVO TO
8 MAKE MORE MUSCLE STEM CELLS, AND THEY SHOULD RESTORE
9 THE CONTRACTILE FUNCTION TO THE ATROPHIED MUSCLES IN
10 THE EXTERNAL URETHRAL SPHINCTER THAT RESULT IN
11 NORMALIZATION OF FUNCTION AND ACTUALLY REVERSES THE
12 EFFECTS OF AGING, MENOPAUSE, AND CHILDBIRTH.

13 THESE MUSCLE STEM CELLS HAVE ADVANTAGES
14 OVER OTHER STEM CELLS IN THAT THEY ARE UNIPOTENT
15 HUMAN MYOGENIC STEM CELL, A POPULATION THAT'S
16 DEDICATED TO REGENERATING MUSCLE. THEY'RE NOT
17 TUMOROGENIC, AND THEY HAVE BEEN SHOWN TO BE HIGHLY
18 EFFECTIVE IN INCREASING STRENGTH.

19 I CAME HERE TODAY, I GAVE UP A BUSY DAY IN
20 MY CLINIC WHERE I WOULD SEE 25 PATIENTS, MOST OF
21 WHOM HAVE STRESS INCONTINENCE, AND I CAME HERE
22 BECAUSE I'M DEDICATED TO THIS FIELD AND TO THIS
23 PROJECT AND TO THIS TEAM OF SCIENTISTS, ENGINEERS,
24 AND NOW UROLOGISTS. THE MESH LITIGATION MESS HAS
25 CHANGED THE WAY I CAN TREAT MY PATIENTS. AND NOW TO

BARRISTERS' REPORTING SERVICE

1 HAVE A MINIMALLY INVASIVE TECHNIQUE THAT'S LOW RISK,
2 HIGH EFFICACY, THAT CAN BE DONE WITH A SIMPLE
3 INJECTION THERAPY THAT RESTORES FUNCTION RATHER THAN
4 JUST BULKING WOULD ALTER THE WAY THAT WE TREAT OUR
5 PATIENTS AND THE WAY THAT I PERFORM MY PRACTICE. IT
6 WOULD DRAMATICALLY IMPROVE PATIENT CARE. THANK YOU.

7 MR. SHEEHY: ANY OTHER PUBLIC COMMENT? I
8 THINK WE CAN VOTE NOW.

9 MR. HARRISON: SO AS A REMINDER, THE
10 MOTION IS TO REFER APPLICATION FOR EXTRAORDINARY
11 SUPPLEMENT 05501 TO THE GWG FOR A NEW REVIEW.

12 MS. BONNEVILLE: STEVE JUELSGAARD.

13 DR. JUELSGAARD: AYE.

14 MS. BONNEVILLE: SHERRY LANSING.

15 MS. LANSING: YES.

16 MS. BONNEVILLE: JOE PANETTA.

17 MR. PANETTA: YES.

18 MS. BONNEVILLE: FRANCISCO PRIETO.

19 DR. PRIETO: AYE.

20 MS. BONNEVILLE: JEFF SHEEHY.

21 MR. SHEEHY: YES.

22 MS. BONNEVILLE: OS STEWARD.

23 DR. STEWARD: YES.

24 MS. BONNEVILLE: JONATHAN THOMAS.

25 CHAIRMAN THOMAS: YES.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: ART TORRES.

2 MR. TORRES: AYE.

3 MS. BONNEVILLE: DIANE WINOKUR.

4 MS. WINOKUR: YES.

5 MR. HARRISON: MOTION CARRIES.

6 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
7 MUCH, MR. SHEEHY AND ALL PARTICIPANTS IN THAT
8 DISCUSSION. THAT, UNLESS I'M MISSING SOMETHING,
9 SEEMS TO CONCLUDE THE -- OH, NO, NO. WE DO HAVE ONE
10 MORE THING. THE GAP, RIGHT. ITEM 12, CONSIDERATION
11 OF INITIATING RULEMAKING FOR AMENDMENTS TO THE
12 GRANTS ADMINISTRATION POLICY, FONDLY KNOWN IN INSIDE
13 CIRCLES AS THE GAP. MR. TOCHER.

14 MR. TOCHER: THANK YOU, CHAIRMAN THOMAS.
15 AND GOOD MORNING, CHAIRMAN AND FELLOW BOARD MEMBERS.
16 THE GOAL OF THIS ITEM IS TO SEEK THE BOARD'S
17 APPROVAL TO INITIATE A RULEMAKING PROCESS TO AMEND
18 OUR GRANTS ADMINISTRATION POLICY KNOWN AS THE GAP.
19 THIS IS THE DOCUMENT THAT IS EMBODIED IN A
20 REGULATION THAT DETAILS THE RULES FOR MANAGEMENT OF
21 CIRM GRANTS THAT HAVE BEEN AWARDED. AND
22 PERIODICALLY WE HAVE BROUGHT THE POLICY BACK TO THE
23 BOARD FOR CALIBRATION AND ADJUSTMENT TO IMPROVE THE
24 POLICY AND CLARIFY ITS REQUIREMENTS AND ALIGN THE
25 DOCUMENT WITH BEST PRACTICES.

BARRISTERS' REPORTING SERVICE

1 IN THIS RELENTLESS PURSUIT OF PERFECTION,
2 WE HAVE BROUGHT THIS PRETTY MUCH ON A BIENNIAL BASIS
3 FOR REVIEW AND --

4 MR. TORRES: LIKE I SAID, I MOVE TO
5 APPROVE.

6 MR. TOCHER: I HAVE JUST ONE NOTE, ONE
7 NOTE, SENATOR. THIS IS BEING LED BY GABE THOMPSON.
8 HE'S OUR GRANTS MANAGEMENT OFFICER. AND THE
9 ATTACHMENT THAT YOU HAVE IS A DESCRIPTION OF THE
10 AMENDMENTS THAT WE'RE PROPOSING TO INITIATE THE
11 RULEMAKING PROCESS REGARDING. ALSO ATTACHED TO THAT
12 IS AN EXHIBIT THAT DETAILS THE PROPOSED LANGUAGE.
13 WE SEEK TO ALIGN OUR POLICY WITH THE NIH IN THE
14 CONTEXT OF SOME RESEARCH, PATIENT CARE COSTS, AND
15 HOW WE ALLOCATE DIRECT PROJECT COSTS. THERE'S ALSO
16 AN ATTEMPT TO CAP COSTS ON SERVICE CONTRACTS. AND
17 WE ALSO WANT TO ADDRESS A COUPLE OF SITUATIONS WHERE
18 PRIORITY APPROVAL IS REQUIRED TO CHANGE SOME ASPECT
19 OF THE GRANT; FOR INSTANCE IN THE CONTEXT OF
20 SABBATICALS BY OUR PI'S AND ALSO NO COST EXTENSIONS.

21 WE DO NOT, HOWEVER, AT THIS POINT HAVE A
22 SPECIFIC PROPOSAL WITH RESPECT TO NO COST EXTENSIONS
23 AT THIS TIME. WE HAD AN OPPORTUNITY TO SPEAK WITH
24 DR. MILLS, AND WE WOULD LIKE TO CONTINUE OUR
25 OUTREACH TO INTERESTED MEMBERS OF THE BOARD AND THE

BARRISTERS' REPORTING SERVICE

1 COMMUNITY, REGULATED COMMUNITY, TO FINE-TUNE THAT
2 LANGUAGE, AND WILL USE THE ONGOING PROCESS, ONCE
3 IT'S INITIATED, TO COME UP WITH A PROPOSAL TO
4 ADDRESS THAT ISSUE.

5 SO I'M HAPPY TO ENTERTAIN SPECIFIC
6 QUESTIONS AS WELL. I HAVE GABE THOMPSON HERE AS
7 WELL TO ANSWER QUESTIONS, BUT OTHERWISE WE'RE
8 SEEKING APPROVAL TO BEGIN THE PROCESS TO AMEND THE
9 GAP.

10 CHAIRMAN THOMAS: IT WAS IN ADVANCE
11 SHOWING GREAT FORESIGHT MOVED AND SECONDED.
12 MR. SHEEHY.

13 MR. SHEEHY: I JUST WOULD LIKE TO MAKE ONE
14 COMMENT FOR CONSIDERATION. I THINK ON THE NO COST
15 EXTENSIONS, PAGE 33. IT'S IN YOUR NOTES. IT'S ON
16 PAGE -- SO ON THIS MEMORANDUM IT'S ON PAGE 3. SO NO
17 COST EXTENSIONS ARE ALREADY ALLOWED FOR A YEAR, AND
18 I WOULD JUST LIKE TO -- WHEN WE EXPLORE GETTING THE
19 LANGUAGE DOWN, THAT I THINK IF WE'RE GOING TO EXTEND
20 GREATER THAN 12 MONTHS, AND THESE ARE FOR AWARDS
21 THAT FUND CLINICAL TRIALS AND PIVOTAL IND-ENABLING
22 ACTIVITIES, WHICH ARE OUR MOST EXPENSIVE AWARDS, I
23 ACTUALLY THINK THAT SHOULD COME BACK TO THE BOARD.
24 I MEAN IF PEOPLE HAVEN'T -- THOSE ARE
25 MILESTONE-DRIVEN GRANTS. IF THEY HAVEN'T DONE THEIR

BARRISTERS' REPORTING SERVICE

1 WORK WITHIN A YEAR, NOT ONLY WITHIN THE TERM OF THE
2 GRANT, BUT WITHIN THE TERM OF AN ADDITIONAL YEAR, I
3 THINK WE SHOULD PROBABLY HEAR ABOUT THAT. AND IF
4 THERE'S A RATIONAL REASON TO CONTINUE GIVING THEM
5 FUNDING, WE SHOULD, BUT I DON'T THINK IT SHOULD BE
6 SOMETHING THAT WE ARE NOT MADE AWARE OF AND DON'T
7 HAVE AN OPPORTUNITY TO COMMENT ON.

8 CHAIRMAN THOMAS: THANK YOU, MR. SHEEHY.
9 ANY OTHER DISCUSSION BY MEMBERS OF THE BOARD?

10 MR. HARRISON: COULD I CLARIFY WHO THE
11 SECOND WAS? I BELIEVE SENATOR TORRES WAS THE MAKER
12 OF THE MOTION.

13 CHAIRMAN THOMAS: I THINK IT WAS
14 DR. BRENNER IF I WASN'T MISTAKEN.

15 MR. TORRES: DR. BRENNER ALWAYS SUPPORTS
16 ME ON MY MOTIONS.

17 CHAIRMAN THOMAS: ANY PUBLIC COMMENT?
18 HEARING NONE, WE'LL TAKE A VOICE VOTE ON THIS ONE.
19 ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED? DEAN
20 HAWGOOD.

21 DR. HAWGOOD: AYE.

22 CHAIRMAN THOMAS: THANK YOU. IT'S
23 UNANIMOUS. THAT DOES CONCLUDE THE ACTION ITEMS PART
24 OF THE AGENDA. WE HAVE WHAT APPEARS TO BE ONE
25 PRESENTATION REMAINING, WHICH WOULD BE MR. MCCORMACK

BARRISTERS' REPORTING SERVICE

1 GIVING US A COMMUNICATIONS UPDATE. THE ALWAYS
2 SARTORIAL MR. MCCORMACK IS PUTTING ON HIS COAT AS HE
3 APPROACHES THE PODIUM.

4 MR. MC CORMACK: SHOULD ALWAYS BE
5 RESPECTFUL, MY MOTHER TOLD ME.

6 CHAIRMAN THOMAS, MEMBERS OF THE BOARD,
7 MEMBERS OF THE PUBLIC, AND ESTEEMED COLLEAGUES, IT'S
8 ALWAYS A DELIGHT TO TALK TO YOU. A GOOD FRIEND OF
9 MINE WHO COACHES PROFESSIONAL SPEAKERS ONCE TOLD ME
10 THAT THE KEY TO A GOOD PRESENTATION IS TO ALWAYS
11 STOP TALKING BEFORE THEY STOP LISTENING. SHE SAID
12 THE MIND CANNOT ABSORB WHAT THE BEHIND CANNOT
13 ENDURE. AND SO --

14 MR. TORRES: SO MOVED.

15 MR. MC CORMACK: AND SO WITH YOUR BEHINDS
16 IN MIND, IN A PROFESSIONAL WAY, OF COURSE, I'D LIKE
17 TO KEEP THIS QUITE SHORT. WE HAD A LOT OF COVERAGE
18 IN THE LAST MONTH AFTER THE APPOINTMENT OF DR. MILLS
19 AS OUR NEW PRESIDENT. ALL THE MAJOR NEWSPAPERS
20 AROUND THE STATE FROM THE *SAN DIEGO UNION TRIBUNE*,
21 THANK YOU, BRETT, TO THE *L.A. TIMES* AND THE *SAN*
22 *FRANCISCO CHRONICLE* DID LONG PIECES ABOUT THAT. WE
23 ALSO GOT EXCELLENT COVERAGE IN ALL THE BUSINESS
24 JOURNALS AROUND THE STATE AND ALSO A FINE PIECE IN
25 THE *BALTIMORE SUN*, AS DR. MILLS IS A SON OF

BARRISTERS' REPORTING SERVICE

1 BALTIMORE, KIND OF.

2 CHAIRMAN THOMAS: HOW LONG HAVE YOU BEEN
3 WORKING ON THAT LINE, MR. MCCORMACK?

4 MR. MC CORMACK: KQED RADIO ALSO DID A
5 REALLY NICE PIECE FOR THE "CALIFORNIA REPORT", AND,
6 AGAIN, THAT GOT STATEWIDE COVERAGE.

7 IT WASN'T ONLY THE MEDIA, HOWEVER, WHO
8 WERE VERY INTERESTED IN THE APPOINTMENT. OBVIOUSLY
9 WE HAD A LOT OF INTEREST FROM BOTH THE RESEARCHERS,
10 THE GRANTEES, AND OUR PATIENT ADVOCATES. AND SO
11 WITH THAT IN MIND, WE DECIDED TO SET UP A SERIES OF
12 MEETINGS, EVENTS AROUND THE STATE SO THAT PEOPLE
13 COULD COME AND GET A CHANCE TO HEAR FROM DR. MILLS
14 HIMSELF SO THEY COULD HEAR WHAT HIS VIEWS, HIS
15 GOALS, HIS VISION FOR THE AGENCY IS, AND THEN ALSO
16 TO ASK HIM SOME QUESTIONS.

17 AND WE'RE GOING TO HAVE THREE EVENTS. THE
18 FIRST IS IN SAN FRANCISCO AT OUR OFFICES. THAT'S
19 MONDAY, JUNE THE 9TH. NEXT DAY IN L.A. WE'LL BE AT
20 USC. AND THEN TOWARDS THE END OF THE MONTH, WE'RE
21 GOING TO BE IN SAN DIEGO, BACK HERE IN SAN DIEGO,
22 JUST DOWN THE ROAD, IN FACT, AT THE MANCHESTER GRAND
23 HYATT. BIO 2014 IS BEING HELD THERE. IT'S A BIG
24 CONFERENCE, AND SO WE THOUGHT WE'D USE THAT
25 OPPORTUNITY TO HOLD A MEETING WHERE AS MANY PEOPLE

BARRISTERS' REPORTING SERVICE

1 AS WANT TO COULD COME ALONG AND TALK TO DR. MILLS.

2 IN OTHER MEDIA NEWS, WE ACTUALLY GOT A
3 REAL NICE FEATURE IN THE ROB REPORT, WHICH, IF YOU
4 HAVEN'T READ IT, IS A VERY -- I SAY A VERY BOUTIQUE,
5 SHALL WE SAY, JOURNAL, BUT IT HAS A VERY KIND OF
6 INFLUENTIAL AUDIENCE. SO IT'S A GREAT AUDIENCE FOR
7 US TO BE ABLE TO REACH OUT TO AND SHARE OUR MESSAGE
8 WITH THEM. THEY DID A GREAT PIECE THAT FEATURED THE
9 WORK OF TWO OF OUR GRANTEES, VIACYTE AND DR. EDUARDO
10 MARBAN AND CAPRICOR AND THE WORK THAT THEY'RE DOING,
11 AND ALSO A VERY LONG INTERVIEW WITH DR. FEIGAL. SO
12 THERE WAS A GREAT PIECE AND A GREAT AUDIENCE FOR US
13 TO BE ABLE TO REACH OUT TO.

14 IN ADDITION TO THE MEDIA, WE LIKE TO TRY
15 AND GET OUT TO THE PUBLIC AS OFTEN AS WE CAN. AND
16 WE DO A LOT OF ROTARY CLUB SPEECHES, SPEECHES TO ANY
17 ORGANIZATION THAT WILL HAVE US, QUITE FRANKLY. IN
18 APRIL MY COLLEAGUE, DON GIBBONS, AND I WENT TO
19 WASHINGTON, D.C. WE PARTNERED WITH THE ALLIANCE FOR
20 REGENERATIVE MEDICINE AND THE INTERNATIONAL VOTE FOR
21 STEM CELL RESEARCH AT A BIG EVENT BEING HELD AT THE
22 CONVENTION CENTER IN WASHINGTON, THE U.S.A. SCIENCE
23 AND ENGINEERING FESTIVAL.

24 AND OVER THE COURSE OF A COUPLE DAYS,
25 AROUND 350,000 PEOPLE CAME THROUGH THIS FESTIVAL.

BARRISTERS' REPORTING SERVICE

1 IT WAS AN EXTRAORDINARY EVENT. AND THIS IS JUST ONE
2 OF THE PARTS OF ONE OF THE HALLS. THERE WERE THREE
3 OTHER HALLS. SO YOU CAN SEE THE SHEAR MASS OF
4 PEOPLE THERE. MOST OF THEM WERE CHILDREN AND THEIR
5 PARENTS. AND IT WAS A GREAT OPPORTUNITY FOR US TO
6 TALK TO THEM AND REACH OUT TO THEM AND TALK TO THEM
7 ABOUT STEM CELL SCIENCE TO EDUCATE THE PARENTS ABOUT
8 THE PROGRESS THAT'S BEING MADE.

9 PERSONALLY I FOUND IT JUST KIND OF A
10 WONDERFULLY REASSURING TIME. I THINK WE HEAR SO
11 MUCH THESE DAYS ABOUT CHILDREN AND EDUCATION AND HOW
12 THIS NEXT GENERATION OF KIDS DON'T CARE ABOUT
13 SCIENCE, BUT I THINK ANYONE WHO WAS THERE WOULD TALK
14 TO YOU ABOUT HOW AMAZING IT WAS. THESE KIDS FROM
15 THE AGES OF FIVE UP TO ABOUT FIFTEEN WERE SO ENGAGED
16 AND SO ENTHUSIASTIC AND EXCITED ABOUT THE SCIENCE,
17 ABOUT ALL ASPECTS OF SCIENCE, THAT YOU COULDN'T HELP
18 BUT COME AWAY FEELING REASSURED THAT THE FUTURE WAS
19 IN GOOD HANDS. IT WAS A GREAT EVENT TO BE AT.

20 DR. THOMAS MENTIONED A LITTLE EARLIER THAT
21 WE DID THE MILKEN GLOBAL CONFERENCE AS WELL. THIS
22 REACHES SOME 3500 ENTREPRENEURS, FINANCIAL EXPERTS,
23 AND BUSINESS AND POLITICAL LEADERS AROUND THE WORLD.
24 WE HAD KIND OF AN ALL STAR PANEL THERE OF OUR
25 GRANTEES. YOU CAN SEE EUGENE BRANDON FROM VIACYTE,

BARRISTERS' REPORTING SERVICE

1 DR. PAULA CANNON FROM USC, OUR ESTEEMED CHAIR, JILL
2 HELMS FROM STANFORD, AND THEN ALYSSON MUOTRI FROM UC
3 SAN DIEGO. ALYSSON, YOU REMEMBER, CAME AT THE LAST
4 BOARD MEETING AND TALKED ABOUT HIS WORK RESEARCHING
5 INTO AUTISM. AS DR. THOMAS MENTIONED, THE ROOM WAS
6 PACKED. THE OVERFLOW ROOM WAS PACKED. EVERYWHERE
7 WAS PACKED. BUT THE RECEPTION WAS GREAT.

8 THE FIRST PERSON WHO CAME UP TO DR. HELMS,
9 JILL HELMS, AFTER THE EVENT ACTUALLY WAS THE FIRST
10 LADY OF ICELAND. AND SHE WAS REALLY ENTHUSIASTIC.
11 SO I'M TRYING TO KIND OF WORK A TRIP TO ICELAND TO
12 SEE HOW WE CAN EXPLORE THAT.

13 A NUMBER OF PEOPLE WHO ALSO SPOKE AT THE
14 EVENT BUT COULDN'T GET INTO OURS INCLUDED THE UK'S
15 FORMER FIRST COUPLE, TONY AND CHERIE BLAIR;
16 BASKETBALL LEGEND, WELL, LEGEND IN SO MANY OTHER
17 WAYS, MAGIC JOHNSON, STEVE CASE FROM AOL. REMEMBER
18 AOL? SINGER MUSICIAN WILLAM AND MATT DAMON WHO,
19 BESIDES BEING OBVIOUSLY A VERY WELL KNOWN ACTOR, IS
20 PHILANTHROPIST AND ACTIVIST. HE'S DEVELOPED A
21 PROJECT TO HELP FOR CLEAN WATER IN AFRICA. AND WORD
22 HAS IT THAT THE SPEECHES WEREN'T QUITE AS WELL
23 ATTENDED AS OURS.

24 AND FINALLY, HERE'S A FACE THAT YOU DON'T
25 KNOW YET, BUT HOPEFULLY SOON WILL. THIS IS DR. ANN

BARRISTERS' REPORTING SERVICE

1 HOLDEN. ANN, COULD YOU STAND UP, PLEASE? SHE
2 DOESN'T HAVE THE RAIN FOREST BEHIND HER TODAY. BUT
3 ANN IS THE NEWEST MEMBER OF OUR COMMUNICATIONS TEAM.
4 SHE'S WEB MANAGER AND SOCIAL MEDIA GURU, AND SHE'S
5 ALREADY BEEN KIND OF MAKING A BIG IMPACT ON WHAT
6 WE'VE BEEN DOING. SHE'S BEEN LOOKING AT OUR BLOG
7 AND A NUMBER OF THE OTHER THINGS THAT WE DO AND IS
8 WORKING ON DOING A LOT OF REDESIGN AND RELAUNCHING.
9 AND WE'LL BE TALKING ABOUT THAT AT AN UPCOMING
10 MEETING IF IT'S OKAY WITH MARIA AND HER SCHEDULE.

11 AND WITH THAT, I'M HAPPY TO TAKE ANY
12 QUESTIONS. MS. WINOKUR.

13 MS. WINOKUR: I JUST WANTED TO ADD TO
14 THOSE WHO DON'T KNOW, JEANNIE FONTANA, WHO USED TO
15 BE A FREQUENT MEMBER OF THIS GROUP, HAS JUST TAKEN
16 THE JOB WITH THE ROB REPORT, WHICH THE ROB REPORT
17 HAS LAUNCHED A NEW DEPARTMENT HAVING TO DO WITH
18 HEALTH, HEALTH ISSUES, MEDICAL RESEARCH ISSUES, THAT
19 WHOLE AREA. AND JEANNIE IS THE PRESIDENT OF THAT
20 NEW DEPARTMENT.

21 MR. MC CORMACK: WONDERFUL.

22 CHAIRMAN THOMAS: THANK YOU, MR.
23 MCCORMACK. LADIES AND GENTLEMEN, THAT CONCLUDES
24 TODAY'S AGENDA. WE THANK EVERYBODY FOR COMING.
25 THIS IS A RECORD. WE'RE OUT OF HERE 1:30-ISH, AND

BARRISTERS' REPORTING SERVICE

1 WE LOOK FORWARD TO SEEING EVERYBODY IN JULY IN SAN
2 FRANCISCO.

3 ONE LAST THING. SORRY, SORRY, SORRY,
4 SORRY, SORRY. ONE LAST THING, VERY IMPORTANT LAST
5 THING. THIS SHOULD BE ON THE AGENDA, THE PUBLIC
6 COMMENT SECTION. WE HEARD FROM ALL OF OUR FRIENDS
7 EARLIER, BUT I DID HAVE ONE LAST THING TO GIVE YOU
8 ON THE TOPIC OF PUBLIC COMMENT. AND IT DRIVES HOME
9 THE IMPORTANCE OF OUR WORK AND OF THE EARLIER
10 DECISION TO APPROVE THE STRATEGIC PARTNERSHIP
11 AWARDS. THIS SPECIFICALLY REFERS TO THE AWARD TO
12 ASTERIAS, A COMMENT FROM DON REED WHO WAS NOT ABLE
13 TO BE HERE IN PERSON, BUT DID SEND THIS. AND I
14 WOULD LIKE TO READ IT INTO THE RECORD IN CONCLUSION
15 FOR THIS MEETING.

16 "DEAR CHAIRMAN THOMAS AND MEMBERS OF THE
17 BOARD, AS YOU MAY KNOW, I AM UNDERGOING RADIATION
18 THERAPY FOR CANCER AND CANNOT TRAVEL RIGHT NOW.
19 OTHERWISE I WOULD VERY MUCH WANT TO OFFER PUBLIC
20 COMMENT FOR SP IIIA -- 07552, 14 MILLION FOR SPINAL
21 CORD INJURY TRIALS. I AM DELIGHTED THAT IT RECEIVED
22 SUCH A HIGH SCORE OF 76 AND IS RECOMMENDED FOR
23 FUNDING IN TIER I.

24 "THIS IS, OF COURSE, THE PROCEDURE
25 ORIGINALLY FUNDED BY THE ROMAN REED SPINAL CORD

BARRISTERS' REPORTING SERVICE

1 INJURY RESEARCH ACT. IT BEGAN WITH THE FAMOUS
2 PARALYZED RATS THAT WALKED AGAIN FEATURED ON "60
3 MINUTES" WHICH MADE CHRISTOPHER REEVE SAY, "OH, TO
4 BE A RAT TODAY."

5 TODAY THE DREAM HE EMBODIED IS A GIANT
6 LEAP CLOSER. IT HAS GONE THROUGH MANY YEARS OF FDA
7 INVESTIGATION AND TEST AFTER TEST AFTER TEST, MORE
8 THAN 22,000 PAGES OF CORRESPONDENCE BEFORE BEING
9 ALLOWED TO GO FORWARD. THE INITIAL SAFETY TRIALS ON
10 HUMANS, THE FIRST IN THE WORLD, SHOWED NO PROBLEMS.
11 THEN THE BLOW WHEN GERON CLOSED DOWN ITS STEM CELL
12 DEPARTMENT. BUT ALL THE SCIENTISTS THERE STILL
13 BELIEVED IN IT. STRONG PEOPLE LIKE JANE LEBKOWSKI
14 AND FRED WORTH. NOW AT LEAST IT WILL HAVE ITS FULL
15 CHANCE.

16 THANKS ARE DUE TO HANS KIERSTEAD'S GENIUS,
17 TOM OCARMA'S TENACITY, AND THE VISION OF PIONEERING
18 GIANT MICHAEL WEST, AND THE MAGNIFICENT CALIFORNIA
19 STEM CELL PROGRAM WHICH BOB KLEIN BEGAN AND YOU AND
20 THE ICOC BOARD CONTINUED TO BRING FORWARD. ON
21 BEHALF OF MYSELF, MY SON ROMAN REED, AND AMERICA'S
22 5.6 MILLION PARALYZED CITIZENS, THANK YOU VERY MUCH.
23 SINCERELY, DON REED."

24 AND IF ANYTHING MORE THAN THAT EMBODIES
25 WHAT WE'RE ALL ABOUT, I'D LIKE TO HEAR IT. ON THAT

BARRISTERS' REPORTING SERVICE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

NOTE, WE STAND ADJOURNED.
(THE MEETING WAS THEN CONCLUDED AT
1:33 P.M.)

BARRISTERS' REPORTING SERVICE

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

SAN DIEGO MARRIOTT LA JOLLA
4240 LA JOLLA VILLAGE DRIVE
LA JOLLA, CALIFORNIA
ON
MAY 29, 2014

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152
BARRISTERS' REPORTING SERVICE
160 S. OLD SPRINGS ROAD
SUITE 270
ANAHEIM, CALIFORNIA
(714) 444-4100